var title_f20_30_20960="Diffuse macular edema";
var content_f20_30_20960=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F57041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F57041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Diffuse macular edema: Appearance on fundus photograph and fluorescein angiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 229px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Color fundus photograph and B) fluorescein angiogram showing diffuse, as opposed to circinate, diabetic macular edema which is difficult to visualize on the color photo.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_30_20960=[""].join("\n");
var outline_f20_30_20960=null;
var title_f20_30_20961="Lichen planus - oral Wickham striae";
var content_f20_30_20961=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oral lichen planus - Wickham's striae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lacy white plaques (Wickham's striae) are present on the buccal mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_30_20961=[""].join("\n");
var outline_f20_30_20961=null;
var title_f20_30_20962="Nevus homogeneous pattern";
var content_f20_30_20962=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermoscopic images of nevi with homogeneous patterns",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 443px; height: 548px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Homogeneous brown pattern.",
"    <br>",
"     (B) Homogeneous pink pattern. It is not uncommon to see vessels in this variant (melanoma may enter in the differential diagnosis).",
"     <br>",
"      (C) Homogeneous blue pattern in a blue nevus.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_30_20962=[""].join("\n");
var outline_f20_30_20962=null;
var title_f20_30_20963="Hemodynamic changes in normal pregnancy";
var content_f20_30_20963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F54685%7EOBGYN%2F61948%7EOBGYN%2F55985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F54685%7EOBGYN%2F61948%7EOBGYN%2F55985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hemodynamic changes in normal pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 259px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal pregnancy is characterized by an increase in cardiac output, a reduction in systemic vascular resistance, and a modest decline in mean blood pressure. These changes are associated with a 10 to 15 beat/min increase in heart rate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Total blood volume, plasma volume and red cell volume in normal pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 425px; background-image: url(data:image/gif;base64,R0lGODlhtgGpAeYAAP///4CAgAAAAABmMwAzmf8AAEBAQICZzMDAwP+AgP/AwEBms/8gIP+goBAQEDAwMMjczliWa3BwcP9AQP8QEJC5nLCwsODg4ICzmSBNptDQ0MDN5vDz+aCgoCAgIP/w8JCQkFBQUBBAn/9gYECMZv/g4MDZzfDw8CBzOVCWc+Dm8xBwQGBgYGCAv6Cz2VBzuZCm03CNxv9wcP9QULDA39DZ7P/Q0PD28/+wsGCggNDj2eDs5jBZrDCDWXCpjf8wMCB5Tf+QkKDGs7DQwJC8pvL384KwkOTu5y58RUqNXmafd7rUwqzLtZ7CqTyFUtbl23SohAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAC2AakBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8uAICPP3+NgBAfn9mw0N/MnaJ7AgpQ8MGHww6Iogw4eNEhQokADiKocWMxYqQWEihRIaT2HMZ0OBSZM2JNmYEHBQgwkpXcKU9DLmo5q6RkycOCKkqZH4JuycOOGQAoqIjlYcJFEBoaaSoEKSeuvo0AJOfY4Ceq+kzhEKUuKYMSGIIJ0TKr6cMAMHAKVP/wsEmTEjJdQPMiaMiGljxAQZCwHYICs0q+AEThUkEEvWLICmJRADiOy0QQIcfz/4jamALGBQDRhcLfDDsNZPXPFJXIqjwAwZBWQA+FGAQdHXCUSXgMu0QFoKFB5jnU0hwY+PHH8koPBjMvAEhQeVcA1gRoESrV/HFm4SKVyhCQtQAA8gO+wZnkKPHjrB9OlNqe+tFmR94fG3SCdDF919qSCosCmGlQ3btRZEEAW4BZsNCAZEFQBCfTBedQXYF1xTcH1XAH4VCUVhArlt+E9CDeAgA4goJiCDZRSMANJ78PFT0HwQiughXMk1oFN/cTnVFIbeUQTVj8M92EABOgXkYf+N3GWI1I1PbihUipqExkBLi+CF5IswXhLfPDQieBl1R7VVpgKF8fafXDgAxx0AFDDQWQE2EDiDAgwEd2Z0g3zg0UJiZscdgcVNyaSGACB4Jw49XWIllo6UoNNnXVbypTw0AiBDRzMEJlRwOjGHlZrCdcSAXcPZQNuVgqj3Q0ywiereV4Ns6tpCANamU4cbIvqYaNRV8mglkhYXWKWRXIosOcNigqaxyz6ibLTfNLsJmqxSu8i02mpjrSd4ZtutIdyOW823oVjp3rjlmhsNuqSE1p67ALRLLzPwmvLBcvOyK+O91uSbyr4tchmtvQAXIzArWrpILcIJ3wIQIgu/Imn/bMcOgoNbIUEcMS0IKVRIxbIUm8CxCDXX8b8fCyNRfgCQXMuzJws3nEYetwwLRx6VIDMu2AbREZIr6yyMTkOJW4wCQ09k8EM5G82KVUOtOwzVE/kHUdRSqyLUVUUh8/VOwWXEddenHLkepMOofRXbBp2N9ijFnpiiihwXY+Ldklkk99yfNJwx4LX8TbgmBM/w9OG0GM64JfJa/fhALE+OCg4JSW55LI5v3gi2cHueSD2kC3JCBwF0cMIgFgQAwgWsuw67tJWL/kkJM0BreyMC9N67IA8IYIAADwgiAfEOOAD78Q8kP3sjne9OyMU1S8+7AKVbIEAIAIQggAUnCOAA/wAgCCBB+OOXLwHt1nNCsMPtX29ACPYEIAA/9geAgPAA7G+A//3jnyAQsI8CGlB/0dud0GYSP0eEIAAsEN8F8lev+wHQfxcUYP8OeEAC1q6BkIgcCCUxPASoDwDHA4EGiAcA7YVghcVzIftGGAkF/EBpNFQEAh4AQfGd4AIC8AACPCAA2BHRAt7rAACOmMQZ5pARzwrdEw9xgeARTwOC6AARPaBEAGggeA5YnxfBKEZHJPBwJhvcFBv3wTUKbo26OGPX3rc4OBaujTRswHg0Z8dZyLFlmJNTH3vxx4SBbpC+KCS9SjCB4iDyF4ocF/XU+MhcRJJadKwkMC65LH7VUf+TccTj5EQIymBw8j3hylspNylKwEVxlcQ4pUbSCMtYttJomsFYLYshS4Zkcpe8vGXE9NgvYAaTcKEpjTGR0ct8HHKZzBSmJBupNWgao5nxoKU1k4FNd+xrS9tcRjfXkbhPhtOWCSPlOcUpTVQmRJXrVMY4uTExQzwzns2YpzZCljHc6Q6f+WynQF62lFxSCqDO0Cc2eCYeGywHfgh9hkKvgbSdMDCi0JhoNbA2ET5iNJrvGZtFPxoNjUoDd+spgBRJegyTPmNOI7BbimQAT5ZyU6DwaMBxqmfTarg0GR8IAol6mo2fGqMEmyomUa9h1Kt9xZxLlUZTgfGSf0a1qDj/HUdQSUTJq1pjqrqIzHhq6lWswqMvSLJJWbsB1lpgpjhQXStTs5qNDzyqq3LVRlstxq+V5nUbe2UFWsHy13IENhXPkkFcCwtYukLDSkHAK2O9cdhREIwlk01HZUFxMcJmVrOORcazIPpZdGx2RAzgaWlBe419MeAHfl0tOU5LrBFQ4E6yfQdtJdGZguUWHru9yU4l+9tzBDdLucFhcd1xXEQUS6nLBW5oZ/bU6OKjuTKxqnXl0dytKne73J1uK5C6R/AKhLYK+IpazZuPzb41AYtlr27FWwq7clW+DGmrWCdAVvz2Y6qDXa9/C2LUtyp2wGaj7ybsy4DIIhhnCsbE/2Vj+2B/6LOzHq1wNDSAgNmdLnWrE0TrXhc7EjsRNFJMbHw1/AwNOOB+wBMeC1GIPOXRuHk2NmOEEcHPkSXEwSzmhhX5IUPvgU985DMf+pJcRkYUkqCCIBhsg0zZMMKYgvnL4P/4B8ABctCAHgwFQymQXtdkmMrSWGHrrsxm/XFZeFoehAe/jMAdG6Ki4iEtmgHru965znw0ViELXQjDFm7vxJzg6M323I0L1COCLLgAEIVIRCN+r4lMFEAXoWdnQoiUKIwOBwUBoMUgdvGL4hMjqsMIiTO67W2hhtEZ93Y3msb6Pdi9tWk7rWt/9RoAGziAsIct7A0QLterPAABlv/N7GUf4Ni8lq2ym83sZwMO2aWcNrUJYO25YVuTHGjBtp0N7VgHmwcEEMG4uV1uKqsABi8QQQZaQAMOaJvaC+DAtaPtVQ7QoAUZEMELYKACQty72QF3gbf5XY4NONzYglhADGARgwXo4twE4MEBIG6Ig1d7AxlYQMGl9u1dNFsENQAAASz+igUQwBbvjve8672IYBN72MbmQAxEAAOSM5wcywYADAjwApVbXAUtWIDE9a1zpT/bBQegwdKTnnIAVHwBLai6IGhwgIJDXd8wWMALaBDxlwe74GcHwAGgvgAX1OAFL9A3AFyg9J5nwt8AFzjBOQFykeus5LoI+gZWbnT/YC/gAOJuAQACfoAYZAAALs9ABtIdeUFkoPHyJoQLCNDzzMeAADF4AQHI7nK1E8DYyjb2snmg7gygW/GfDz3nLYFxjXPcEzrnecsAnwtno1vhhJ970gkvAhG0oOuQNzu7Sw/siqubEBwQAQ9qwG7pA4ADRE++6VF/+sKnvvDyFnbwB2Hzm298EDGXN73lToq+jxxgvMfFspWu8MLHfvAWf/vkRaCC0g/+2aVHA0RHA+hWCIlHAAUXfIRXet/3fYTngBZHAJcnbPU3CB63bDHwbwE3cO+HCrlnd/cSf7cQdISwgKO3eRbXdhvgcjXgf8v3csoWdZNXCAIYfKLHdbNX/3pDp3GTp3oWB4EAIHobB3WFcIGrd36wUAM8sABaZy4iaAskOAiEVwPq5nIWJ3oSqHAuCIAvxwHoJnkvVwiTV38cIHoiMHHaxwEuxwOi54PbV3jhpm4i0G2CYIR0KAsxSC9PqC12eAtKOH1O+HOD1H/rdoe0kIfdsofIYm8SWIi68IdNiCyK2CUwIAIi14e7gIjLMomnQQOuB3GYuAstCIiSKIg0tIIZUIHAZn7F9guVGAPsh2um2EBIN4exuAz9lwG3pxWcCBGM2AK36AyvGIwJBlAuYIkdKA25uIvFuE4gp4vaMIyryIrMGF7n1IIioIrZsIyheF2zaDm1eADEmP8Nxzh542aI1rhM9mZ8yegNauiI//WNh3OMTGgO3XgPvRgPG8AD0HgO9zgP+egO/ad76fCP6QhK4cZt4zgOBhkPAZkO69gC7eiP8Nhe8vgxLhBy1YgO5XdzGyldj7SPGUB22/WQ46AC8QaCJXmR5qJzoLeQv2WS33AAAjeR1iWT3JCRC/CRN8mSy4KK2thHEtBkt4CT14CSc1hKBmAAu2CU1MCIsLhKS9mUPnkaleh3j9QBS7mVDsCUoWQ9nsgDPDlF9tNnGoQLTukMQLlKjkY69YBFX+k54QiTFZaWyfCLdIlIIPBiveOVllSVBkGPNllK4rOVRGkLdlkMzziWoOT/AYA5CYkpDNgYlMY0RAW0aWj5mPMwl+tkRX1JlWgTkYNpTNtDOnD5l11Dj5F4ThLAApCkme0gkoy5TMPjO36ZmS0zkCqJUBKwlQZwmHcUMQkpjr+GaOMimsXZarBZDjo5m8lJCJF5Ch1JbA7HjyT5nMrZJUZYfLt5VSEGmjBihHH3V5b5nUW5nNjQkFF1AcPjABaAmuFZkYVVD/D5Hp93jnJ1Ar2pASHwnnHpExwAA+aIn2vlPdjDAtzznxlBA6I3duppUwIAAv8TALd5nhmhAo6XATAgdw/KUt/zP/MTCRoAAiBmOqijOiX2PCP2PJz2EBxAd8YXidOJc3LFAslD/0SYeT2fCQDBMzzFc2POA6Q51qIFUQMtYIkukJeTdQLew2qRoERAJACGxj1GtmTqY6WApmP+EKCSFwOjyWgIcDz402ZaFmdeRmd1lg8MOoD+hQAhYJiSoJWAhmUW9GZbxpRdtkFoGmbygKGSt6EIxpc7SkLYc0IpVGiENmiHpqXv8KILEKMa5qSSsEMBcDxFNGlDVERLdGmatqlI1KmMyg5GiqRKul1aaZqQUEW94wH+WWpcJAirpmpklJ3qwKUZ4KV7FkG2CZ7nsKZjF2vEc5m8epIZCqi39puvOQ6OCqm/ZqNwqqDdMKptV6osVpuDipvdYKu4ip3CYJS+ep3c6v9Fbnma2HqUxUqtsWatZ2mh1bCsWReuiIA6+xChwwoN0pqk8NoIBuCa0MoM2vql+cphCGABXVmvyvCt+eoI6oqeigB4fqqh6Jqv8po6vIBt7rqaCRtQx3CvEZuxZnmt7CoM/5qxlOCbz1qfv4CwJKsPDNsID2usK4sJEtqfFduyiXCxMbsJlto7/omytsCxOcsJMMakFYqYNjsIIxu0nfA9xlO0wUkLKqu0nuA9BhA8IGCwrPCyHSu1j8CkqVazr4CzXAsKGsCihBRtM9qKgwC0YxsK9mMAOdqvmdCHSdu2ouCmveMALECu5coJ4tmg4Gq3pHABIGBF/OqzmmCEECv/uKtQak7LRp/QoYzrCQhgo3l7tXKLCZI7ufDhOyEQtyHrt/LJuaIQAI5ptpl7CZtLuphgnokUbavLumblCWmLhLI7W0d7u7Oru5uYu7z7Vb77u9QQncKLCsRbvD8RvMibUcq7vAnVvM7LDMcbvW4LvdR7U9frE9ObvZ2wvdwbI9/bjOELNdY7vt1avubLSumbX+i7vmfrvgTWvvCbuvM7X/Ubj/drkfnrjfuLj/Lbv370vwDMOQI8wK/gvQacCAicwIewwAxcCA78wIMQwRJcLwX8wITrOiH2YSgqYrKTorRawb9grT/aozPGPEGKwkPqZBfMwOBzAkQ0sIdWpUh2/6U1nKVEKsLBUGl06mZ4Cmd2KmdomqY6DAwn1MNlGsRnSmd8WsS9cDz8aqgRiqjbQ8UJmsNOrAve45j6g6mV5qmYxqmgiwgUbLdmyQ+uemqzOkZfa5xZDA5l/MBxzMBznMB1bMB3PMB5DMB73L99vL9/nL+BfL+DXL95bAKIbAI30Agk4AOEIAQkoAOPHMmSAMmS/Ag6QAJCAACNLAk+QAJylccDMMqjPASMMACgPAgYMAAmQAir3MqR8MqQYAIDgAEAgMqSQAIDEMot3AqjDABCgMsAYAIp0MiLDAAYQAI5IMyCsMpEkAIpIMmyfAOfnAOXTM3KfMk6UMy6DMuDIP8ExewDN3ADyZwCpkzLtszMAKADGNDKJoABkjwExUwEgqDLALAD7XzP+YwBQpDMQrDNKXDMxGzMyyTKu0wEA5ADADAEA5ACPtDQAPDQKbDKqdzMqIwBK7ACyMzKANADK4ABHr0DHf3RIb0DGZ3MHK3KDY0BQGACHg3SA6AD6HzLFX3PEJ0CA7ADDO3QA+DI9jzTMz3KHj0AQNADCb3QDS3RBd3LrEDKA9ADi4zTGMDSu7wCQCAI6izLD/3OrKwDPY3URODVjszQRIDQmyzLg2DVgnADtEwCGLDM7VzLNF0IunwDKwDKOL3IHs3JuwzUco3LsozLUk3VSy0Po/zQQLD/yLo81VM9145t0a38yq/s13Fty+gsy2iN1RXd1oyNyH9d08Cc0AOwyfbM16ZN2XMd2KC82Ixd2PHwy7qcAgCA0ClgAkOg0Lo8BMFc0848BBm90a1s1cQc0wAg3Dgt0w1tAt1MCDhNBMRsAhktBCZABNL92YVwA6O8AouM0Biw06bt1R+92KnN0bhM27at0MZk0Pe8AqONzEAwyrKtA++ty7w9AOwNBNLM0Tpg1ECwyevM3/790Ctg1N4MADeQA/e9A9s8ykAwBEEN2gCwzOgd0ewd0KYd0UQN1+PdysJM1RCd3kz9xp5QyPNL4vBr4u6L4lO04PAt0nET4p+lA+zt/9Qr4OLnBeOZhdNODd8v3mss3tA2zglFAAE77tQ9fmsyvuM1DglDDgEQ0AQVUAFGEAFUjgQocOURUOSkfOSxpuM7LtsA0ORPHuVTXuVXjgJUHgFQEOUV4OQQcASEoOW/HL+39gRyPgBnnuZrHuVuDueR4OVODeY3XlYHPuMrkAPHPAlH4ORRrgQRkARX7gR3DgomreRBjr9XdQNGveNQrQhNDuVQQOVXjgRUbgQV0AROPgiTTulengKXjulRtcxartBOzgRSbuZoruZ8DgFFwAiATsqC3m42JeZ3judJEAFKEOVL8OaWUOk0/upoo+KMUOjZjei14Oa1zua3nuYRYP/lZ57rWb7qnrADrQ7t0Y7jvaDpRd7pnfAE2L4E2l4B3B4BTvDtKHDsaZ7s2r7sfY4IxR5O0q4Isl7kE14Ii47t8e7oaQ7p3+4E8x7vTIDtT+AJA7/jBe/aIeHmxZ7m9k7q3G7qbI7q2E4L6s7piQ5Nc+zubm7rbF7mHP/t+F7sbt7ryUDt9m3tAM9wP+7qsnDwTg7v2j7v9u7w+R7v2M7rh/DvnCtHSf7sQn708T7v3j7qD7/v2E7zmlDxTn3xditHv87jhwD12q7wVF7v3z7vIK/s2O7nr1DyTs3ukytHd07lDH/m+F7q2h7xbj7xxmDzh37yjCv3cu7mIt63nCD/7oUfupzw9R+e+Iq/Cc5Oykvu+I8P+eVO+YaP+XqF7poPmZzf+cny+aDvxqM/vKJf+iyM+rur+j51+qxPxq7/+uQS+7IPnbRf+4IQ8OOr++HL+9/r+9wL/Nkr/NdL/NRr/NGL/M6r/MvL/KGGAKfJwd+5oiBM+rgfChrwtoNgwj+qwstTY6irwLdvvrXplUX2PVh6PjdcRnP2ZQRkAEMc//I///Rf//Z///if//q///wPCAGCg4SFhoeIiYqLjI2Oj5CDCACUlZaXmJmam5QIAgaUAQIBAKIBnqCoqACrnYoICJGQBgays7W2jbS5jru8i76/icHChsTFhcfIhMrI/5Oc0NHSraalo6uqn6za0t3emILf4qWk493h5ufl6dDo7Jzu75nx8uDr9fP3+Pv1rSACEgBIEABCg4AHACwICGEQocIQ/N7Ri0iOoqWJETHu04iPozyPH/VRBGmxJCYN/x4gOHFBgAcEHgRcABDTQggBHWgKsInTpDiSEkXyA8qOqDmj45B+U7pU6FCnPqNWMiCgqoBJHWJ6yAlAwwMBDgJ2/RpWqjemTX2iPQu13lppb9u1DRk1rtm7eIvOpWvSrly1e/X2DZzOLzzCeRMrLoz4aOOfjyEDnlzSsCbLlyMv3sw5X13N6j5Trgw6GmZ7ojurXs02NWnXFk9fkl2Jdv/t0nBxs94t1fbt0a8HA8+o+zBs3sh3+w5VfNPyisKjx26e+Xjy65xhRdVuknv3ZyW9WxQfkXx58OHRY1/Pvr379/Djy59Pv779+/jz69/Pv7///wAGKOCABBZo4IEIJqggRSd0EAAIJ9SHgAaWNPgcPheA8GCElWiAwEzroRRABxxmuGF8HoJoIYkLwnfCV1Q5wCF8GogCCiUaOPCJB+9RVRVCOOpInUVWcePjQTQKSQmMSLbonicIUaVeez7eqBOF8FlwwgkxPfPVKOzl1JIAlGjJ5VXvfUnKQwDcZIGT7b14kAcs0NeKQR7EBFF8Mc0UQFhgsofAQPr06d6fhFr/Q0o1cK53AgsOxPTAjPC1AiUCX3Hl3j8BGWQBo+t1QJVYlHDqnqfVpBpoo9f9Q8pNQ5p1pzagsjdQndYUGatFUlJy63ui6GrqQCCwil0HB2HaE4opraSTBV9NmdxNHgjyISwsCMACiMlhGsBAMrXpkrXtXYCtthe09JKhxl4ngY7Vznckml6BpSl7Ra5aK3IXfOnBmwDku2tlgWbl0r3tJqzwwgw37PDDEEcs8cQUV2zxxRhnrPHGHHfs8ccghyzyyCSXbPLJKKes8sost+zyyzDHLPPMNNds880456zzzjxn4mGEJ3zYibSZSGDlUbT0rHSjiSILEZTdUMWO0wMv/211ewqBkq0D1gR0QgAGhADwBSwYwAKFUn9drAZlh4CwTQYUewFVLKA3Igi1AHDBKRaIWfbZZZodTiwWlP0m2bRIEKGDNjHUyd+xiBkAwFdXng5YADjwlQa9PuBAAJtfoPmfXEttgAMatPRAACzsWeZCA0mggaT3giXBTSB4oqMBoq/uANcKrR6TNQ74aG4t2dZJlQdf8Qgl2AF4wPU/CFtuvTRUIasQCDp29Qnro/zDAthXUSVKTnhKAKElN0XouTXqaXPCJ56IJT75CFA1k9SiTDIQVmXThtQA8BVxgWhvO3nf9RbYjX8M7wF62gYuTiGK8Qlibi4JlAVO1yRKDOmQf2iyBDfoF6gKDgKDHiRT/+AXu1V8kEwDpITqAMLAGkLDIAvJVbEy54AOIAAEHWiIBQbFOZnExEMsGOLvLOEqNq1QhCrJVu4CJUQiEsoCw1th/6jSNwGSCQBSE18sSOEjLNnwjJjQ0dqqgiUN3MQlb4LWj1DoCQ/U6yBm9JWOQhChJ1YCLDoKiCfWIceDXOAEy8simvqXo094MYWhiIkD3oQsIKHxku3hRjcu4MMOaI4iA6keJke5G01Ko5ELySM+fkcpUrrylbCMpSxnScta2vKWuMylLnfJy1768pfADKYwh0nMYvInEAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Shnider, SM, Levinson, G. Anesthesia for Obstetrics, 3rd ed, Williams &amp; Wilkins, Baltimore, p. 8.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 491px\">",
"   <div class=\"ttl\">",
"    Systemic hemodynamics during normal pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 471px; height: 518px; background-image: url(data:image/gif;base64,R0lGODlh1wEGAvcAAP///4CAgAAAAMDAwEBAQP+AgICZzAAzmf8AAP/AwMDN5jAwMKCz2RAQECAgIKCgoNDQ0FBQUHBwcLCwsMjczpCQkODg4JC5nGBgYPDw8OaZmf+goP9AQEBms6zLtfDz+fLNzRBAnyBNpv8QEDBZrGCAv/+wsC58RdlmZtDZ7LDA31BzueDm8+yzs89AQHCNxvzz8/8wMO/AwGafd//w8PL387rUwv8gIMwzM//g4JCm09xzcyBzOf9wcP9gYNJNTTyFUp7Cqdbl23SohP9QUFiWa//Q0EqNXvnm5uTu59+AgIKwkP+QkPbZ2WYZGdZZWeKNjemmpnZTNu8DCbOMjJ8TORA5HJ9Tec8JHJkmJl8fX3NNTb98lrupm2AwcO+Tma12aJ9jiTspG68PL9DJ3L+Mpt8GE4BJfCA8lcecjr9NZtC5zLx/dKBzmV8/f5mGhoCJvEBGU88ZLKFDNDVrOL88Vk8jad8WIzBDabCwzy8pfA8vj0tjN0A1gl85TF9fn896jSAyWb8cNZ6CacyTk78vL3VAbM9wcHlmZn85bH8fH2VvRj9Gk59DaY+WwmBbNjpUQQAfX3AsZYBAQIyDg6uLdW8yOWwyMq8wMK8wT+8wMK9QbzBGc0dcToBmkmkmJlBiqXJ3czMzf3NTXyUxG7+Pj9eRjZ+TuYAwMFAzeaCjyb+ZrINbQgAshV8AAM+pvFBAgK9gf4wjI1AhGsE3M49WgzBJnGYzZkNGKb8sRn8ZTHBzet+2w8+JnKWxm5JkTrZzhh8shUUlGoOGaa9wj1F8UY8WQgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADXAQYCAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3rt27ePNqpEBBr9+/ZGdcAEy48EcTBQqYgMihB0e+B2vwGGy4suWJNGIg4KC5wMMCGzjOmHHQw+TLqFMvLIDAMQAjJnIUSABANm3QTDh4BgAaQALFPjgs9k2kMY2DkAmeAHJwyAnKqqNL34BgcwEjvhF4TqAdAIIRPYgg/2DinQPv7xyq5zCBgEiP9geLkB4oBMiJJAZPDIEuvT/qAiNUh8AG3G3X3WYA0IAggqzR9l4C4iV2AwIGJcEDcwNdMEQRHhRkwxEa+ieiZce99h4HBWbnGYLltdjgeQmkl1hiBgUxw30DcRgiQUMsQUERIwZJWAEcEOiDdkZ8R+SBMSRwJHkMInCblEy0l4AJPhh0hA0cDsRDDRQcUdAJQlgo5Jl6xVjdDbu9d8ORK44QoGtRTnnbhPARJMQJAFywhEAfCvQlfRjygB+aiF7GIkZLDAFAmAIt8ScARdgwkKQCFdFXopwWtuhFQGw66JaRTgpAqALt16lEFlQQQAUZCP+UwQMBPBDrRQMMIJAFA1iwqlYUYAjAERRINhCXAu05kI2/QkSAANAuINACAjwr7UXQChSAAAFMNAC3ET3b7Es9XnqBB0AKZGyfjibL57gNTZBBBg4IMMAEAkQAQAQCTDDQAAEELPDAuh6ULQDbdptBAARE4C8AEhBAAAYQAAAwBA8MgEG13f4bAMa5RiBxBRbXG4CuA4gswa3wjkTmsUWoOhCxw1o60MstN1SvBQkjDK5AAA88MAEdGwRtwM92u0ADAVBbsQMBSNCAAz43wC21DhBA0LZWB4wBwwI88IDVBDyAbwQS5JuzSIEOZCEQQvB4QRLvDjRDEGsvVIEAEvj/3G3PDAWMELSEcwsBxxt3O0DEVvv88LdFa9uvrBVEQG234u7LbQD15g3S3QXZVxC6QbS77HyeG5Q2BgLt3XfaJAceOUEHJ/wt0QHfm+8E1PpcMOQFbVvw0hXsjbkAAiUtcOodSXboQEOgLhDdR3SoZ93MC8Qv1CdbIIADA+zckOAGI+83AA00kHEFtHI7QefCA7371vYK9P3i4D47AQR7R3Av69HZwIwGSMACGvCACERgJdJFkOQQBAiDGlPcsme/wnXrAfVywAMcQj6jma9nEODX9+SFNfjVL3kCaAD9CvYAaCUNABOwGsk4By19oUY2I4hBAnfIwx4SMA2bYsho/w4COgpupING7AiEEOAD2gzFgQQpnZAgQK3wxQ4lSEwiRmiwgRuwqURNgVSQltaAxWktJVnUIkVy0IMRFGkqPBBSvwgAsDNicXZqjIgJODACH2CnKTKQQUFoNqIGVIAA7wPgHfMoERowwYtMACMgXQADHuFtRNsiXMEWyUiHGMEHbhxOUECgAUESBAQgOMgOdhBF04nokA5bSRo7aZAN8LEHOSgKCJTwg4LsIAqnTCUMXGDKR4mJlhKZJTJpUAAvbkCSRflBCwjigiYQ5JcCCSRB4jiiZxUuAiwriTIZ6SQrSUQBBkinOtepAIGgc53wbKcCdNDOjWhTIE1wAQBQKf+QaiKEkP4hwAIk1oDLcZKWCfhNDEZQgFxO5J3wVGc9IRpRA8izBCQ4AAlKQE+K3JMgUWBlC1iZz4QM4ZL+AZ9AJIABDNhRnHj0nBESwIQCFKc6MWhMaGoyT4xqtAT1dIg0DcJPGOAABiElSAumKRApikgArMuAyBh2UHjRIAECDM6EbsABH4AmAdCkiApUUJJ5TtQADFBAUAvSgl4O5KMC2UEL+DmQFuCAqWL0z8YIFwAM2NAk4wwSTXvAmepwgAgFYEIC/uiRF4SArClBZwc6IIIDHEAEk7UoAIZa1x+kciB0ZetdBTWihY0MABDw1UkCq5qr2nRCMfBqQk3CAhL/kIAFMlErAyzaVoP8QAMOWapAANofCORqABVDY0xviBgOTEinTkyJCkLwgpzAVSAagIJETiqitBHupYBdLmGMIEA+uhE0jGWJYyELlNA+xKn9SaHANqjcymCVsAjgqmIcCpPa3vYqeZUO1FzCWrlswAeauQFiwWqT6Va3KnTlZn8idtzkeiRoQkOaeOPiSEhGNydjvYoGgDusIEbHmy4ECYYzTDS84BBFOwmxVkacKpRGh1bzVUmB1ZKDI/mRJwx47FZoDAB0IfMhOz4LhPrIX52UIAQp0IhaQ5KCDjCAI0kFgPP6M7bv6njDaLElQ8N6kw+sgAQf2IhlF3KADlBE/wEHMABHSlrj/jigXgRogCJXC+aydPEGO+3JB0iwgjSr+QAEYcBkV0BWBlzWALhVdAd0IBC0pkDOkmY0AOAsZ474EwA2EJZq+oU8ln65Lcx0Y6B7koIQlMAjax7ICl5ggMqy4AUHCEEHUoDrF6zgAJTO9ZpnXesDsIDTHcGmQHA26gEsIAAiOzWPQUmED/dkuleGNaIHwgIDUPYA7WyzQEIggnSKW6Pc9nZl1RrnjhAZAJiKzgK+Bq2+1Rctn2Rik38iY21zOwQkYEAJwA0AcRe83Om8ssFZAHCBgxvZHAmtsvxTPFn2eSsxYui+xWJZiR5gBQroAMEvqwAW/Nqiu/8tuJs3/fGQP7zdIgGCzVKTAVcFjL5V9cpVEQNJMu8kBR0diWWHDoCBA5zgBrBsCj7w5FzL2eBFz3VG2d3pkMAXNSiulrSxkgOsFiA4mtmMblbNkw+owNuXBSpaQmuhGox6ARXe+lMSWtPiBMiNiFWstX2igBJUtgMGUIGh0/JuSlkPNc8m8MV/sgHCpgcBOfUqgTYOFKBPVAdRfkt2CWLkywQsAtyrldyPkqQemIDBSDE72kWgdrqAAAUE2bJlCufleyPFCCMgO1HQ6fc2B37wdWmCW6Fn48Ic9/gW5nNScK/7n5jVnQbAPGFw4CFRVwbaALAAIkc/FOYHpacZ3ej/Wg3zA2sqZ4KWUZ9AXMr9oHgfJx9Iqzt9utGgqwYFn72UqSpzQqravvu5NxBTtmkVJVHQV4CaRYAIeFbslAJPRgKXN37SoQQkRh/YYxgLsAATEEP2lnNAkQN9RBC0doAFyIAlSIIVZYLeFgKulnmJ0luhM3OGgS/Q0gCqBRHINRCzUivhpBBJZhOZkSUDEWTs5RIKwADAxymctSyuZBg8UwE36BAQsC12RC3WwkGLVxNBSBBP5oJH1hHX1Xbj4k1ndDaa8zAL8YMzsYUCYWZo9oUo0SXjcjuS8zc/YzEZJjAtBhRsCACDVmhwiBIeYH2dQofnAzh4mIcMk4Ux0Yet//ZqgRgSwlUQRVB8f5FaAoGJOKh1AOA6ECMAV+SDjPgSmWEeAoFtkSgSdsVUA0EBJ+B2hbGH/ieFewN3GeA94CM+svMTRBADYNRvqQgSUfAEBlEE/KEXEJBnWZNn4LUQWacrGPQ9OJeGo9gSCHYcwBiMITFMSFAQdPM8evEthdMAaKh8PHGNABBk2aaNI0GBBjEETagXEjCN7VcT6OhYXsiOIQECw+c2OAIYNZdj/3cT6IhR+aiPIeFZBnEBDOQXWdeMJKGGKnGNg/aGCFkSGqAEBlEDJ2BieSEAcJcryRdeOdFGRlBbJZCEFxkSSEBJNdKQeZF4LSGRJ7EBI2AEj/+4kiiBAqz4QIeXFxIQevQIUzdhk0aAijp5Eu41EIP4Fw9Zjy5hlACgAuuYlC9RiX5hXHE3kDAhlVZJE64Ii3kxAQHAMyNJlDNhlAxQlV95EteVKcdYF96VMntGko1YJQngaGzZliUBg974j3ehZ3A3i+boEp+UQxugl3y5EkvII/E4F/ZCR+zHlSfRYTeAS+h0AHu5mH3Zj/4IjnQhUA7AL6FolylhAuJBBFxAfyuwmZxZEo2ZITA5FxBgNSDZg2hpEmzUc5tmf6/JEjLwA5VUEBzpkXLBK8eFmxFZjZghZj7AC/L3mzOBAhUYRbMZFwugL/RSl7kJEofJAYAABxn/BXLSORNIgAPdaBBAYIlw0X8QORI06RCWmQl/IAKsV4TlKRMaAHsGYQPMJheGpD1/VZgbgZoIkAt2oFEGcJD5KRMw8APFxHn/CRcbk4FhA5USsZtVEAs0cIS41aA68ZaRAgRiCRcZsDEN0IEXpoiLmBEbsFBVEAwigJ8gShRDcAQl6hYQcJYrqoh7aBHUsQloIAKuWaPWFaEEUQTXuRYSo3gXQR2JEAJFaqTW9WnEeQSPqRa846QVsQFTYAckwKBUyhMt4JIbCQT7xxZPSZkOsQFYoAeAOKZDoQRPMJwFsSc/uRYRIzEEoKKmGREbMAZ7UHVyOhSrhBB46jnxSR3E/0CjhQoUMPAEGlkaJ5CnaEFF9uIApdmdDsEAVdB8jxoUw9ST15OmZ0FGZoShB6GYoYoU+YSkhJKlYzFHdaSqBcGqrYoUm4cQNXAERZCjZGFIiOQA3LmcD4GruXoUS0mcRYCjaJFJ0LJJBKoQyJqsSSGiqQI3aAFL5TitCFGt1ooUMuAC2oUQSzChYZGDM9ln4BquSIEET/AE6WkQHnAC7MkVGUAtnGhxC9Gu7poUUEBMCBFqmhIWLWShQ/mntVQFU/qvRxGcKDCvBREEJ1AEoKkVTTMtzJkR40QdoOqwSgEDGoADGmCnsXcB+nGxV8E5AZM1osemnvqxILsUSIACEP+KEEngHBcArFUBrbXngemomTNrFdg6PUVgr1qxYjfHff46tFEBAqTaQEUABB7As5aRRU3rtFABAk/wWybLeTPAAzNQtaqBRFmrtU+7Ay6gBBIbex4QtmNrtX7RQWeLtlKBBErgAjuQfxv5tmJLtmyxg7aChQJRt3Y7FSL7A0/At30LtxdAAej3EEgAAjKgASAAJjbwuE1hhSBJuIZ7uFUxVwJBSjIAAm2rZR6wBFN7IUWwBBfwurD7ul2wnyjgAjhAC3MwB1LABzzgqz7CFGbIL2iotENDNHiAByyavMq7vMzbvM77vNAbvdI7vdRbvdZ7vdibvcq7BU6QBVlQCDj/4AIoQJ0aQAUBQwUjxgZgIAXs2764YAVWIAZOIAxiQArwawWQ0AmhoIjSShQ9g4jEq4e4U70Sc70FTMADPL0HTL0LrMAJHL0N7MDWG8EQ/MDSS8Hae71vQAWlMGLmGwDoO2IiPMIfLL39OxT/e4eiiBHxGTwbOxAtDMMvrC0zjDAzHMMyfBE4bMMsXMOd4omwMz4+vMM8bBE7fMQ1jMNEjMQ6PMQ+zCm4GD4CEIUJscRO3MRYbMRJfMNXrMVZ7MXIFI0aRLhfXBFMDMZmvMVonMZlPBFWvJhv3MbJpMZr7MZc3MNyHBFx3JZ7zMZ1PMd5DBFK3MV+XMiGbJV9TBFn/3zIgPzHgkzIikzHjrySiWzHgYxkkhzJk/zIl0zGm4yQldzIjKzHmWzJo0zKnSzEeMyXoYzKn6zKr7yLp8zJsUyNq9yWuYIRuYwrJxwRu1wRv0wRwewtvfwQw0zMvJzMygy6zNzMzvzM0BzN0jzN1FzN1nzN2GwSxqVagquc2eywtfkznHst3+y0+totwTs55TyzAZCi4JLCT7zOi3k4ZPnO9hzP8szHtPcqfPOJm5rPrYqcG4MBFhDFugjQ/wo4YpywCN3QDv3QEB3REj3RFF3RFn3RGJ3RGr3RHN3RHv3RIB3SIj3SJF3SJn3SKJ3SKl0Y2ywrtDK4K32R4dwx4/8c0xd5zjCkNsJr0+zYzmljh0DtMSxazDAUMN3aEBHDEQ9AADzK01xBz/B8PkDDoj9KEPlaLQa1r85oPhoRP04dFj7LLUAMirAcPP2MWhPQQlDDKx+TMTAkMrEjLgtDMqYVSwMxhSjzMW9NALEjPDyjK38NALQyAX16okwNNCrjzV8dFAINVQV9Pwe9wgbRQhxTMWnTAEzNNe6TL2nTN+KSZxWzNE0jABbmPfrCLxZwNp3tO8ADPM9yZyn02jmNNmqz2Eqh0BnE0AahTO1MOBvEidvyMPwSK0sDAElzoYdDNIlDEM+SAZitOcStQsLT2vmDPK6NPPzSslxt218xS7f/AgFpozXAfUKZ89nfAy63IzDS2kIbs0HljTzTjd7VbTHzrTxEzN1JMUsMkzHLfT88c0LGY4bPYgH1UjHpsz7TmAE1GCsBrjbCczhM80Lict2dmC//g99gMUsD4E0D5jOk7dUQYzXgZNzW/T0ZEELQ4gDdOtADITX5EivxkzbEOt8UjjD1UttkMVve+UblfN9aVB0L8SkQkSKcialWZKvBCOQDYUuHtRjUwSa5xOTkwRsbYASeweREsBhEvpiomtRsipBKLhDu0UwIwEboYQTvER7j4R0BQiFjPiFd1x2cSauEqbA6Gea1QSQTQhssMgJswhrmAXkDIRvOJSVbzpfC/5pISJ6KYQ6CMXBgUtIi3vHnvcEijg7pCSXnIQFF4+KzRB0SPp5E1TEj3FFt6cHnN5AAORAhXifppa4mmb4bGMHpAlFEDaS5nMKt/NqWAgLkR5JDkc4aCGAENABKSiLpAPDrmhHrGjG2nI6uNxKXfIzPzSwZNcAsFvjsgsEpWffiQNvQbwsAE9dUdyM9e/K63D5QeWZQ3toWCSVATvQbBLJ3eJEczMYX4w4ANoLuiaJSENNS7wkSob4UMzUbAvEbHFDo+ZXwBu8bRKLwXKUb9E4Xtn4z6McX/I4oUAUAUkU0Af8RA08UXERYW9UY8f5VE48Q797wNJXybUHrFd8n0v8+Int1NH717VaxRAuWXh/hJJoRW4rFFjYgg624KZweb4hiWnyNWlQMn9QuFFjlcyNBUwgGeU2EFlRLRJYIGaZhqUGileqK81JhAqIUEy1/8Iqh6mDRlA3UF9B+SR7g9d1VOB8v8E/PEznAR2VfEwjPR+gh8Wg/71OR9VE0A/kOGeiKJvK1tB8RwBqGFQDSA1J/E12HGCef8HgS8Q2fFGx/PdguEG+b75zS4SLh+C1aFQkQA00CFSt/8oI/FEN/EPZqYpJxAahD6yNCYSK56EZBA20k6zn/8JnP8CdfQC4fEzEPADMwBEGU8WeypmKfFCbgRpSnFa2P9gTE8Cwf9DL/QetQ5PxCgmOMH/1IQfZx8RuJEe9VD/THnxG4/xDh/pohLxPmXxhU//NX7/AD1P4LARAzggAgWNDgQYQAkpxI2NDhQ4gRJU6kWNHixAcNBGwkcNHjwQABPo4kSbHACBMlVa5k2bJhAiYJCCYoULMABw42C8i0eEJIySMUXA4lWrSlAwcCCDTAYPRhSKdRHdIgEsOIVKxZsdLUyZPmhgQ8GwphWHLJEq1p1boUMEEAAAlN10Jd69RIDCI0pLJQ0LevCgOBGbCoW5gkTZw3ECC4gXPnzEGLxH6kcMTwZcwPBQxYECBCx7kiM7M0MaLARxY6Ahvo0Np1iAOxY4dw7Xr1/4oDJHSkGN17YtgNjwEkSJNm8scTSXwvL7wAQ4CNEurSZX6RKkqLLBiUEBFixWoVfvsSpvhBRYkQIl4oqN4e6wwP7uVjrVChMPX5EEvnnWj+hYgDVtjNKAX+C6EEFT7Ib0GSLriAQQhLyqCCkAJ4YDrRIkzIhJQiUuEFEg7owAD2tEpBhxBXGExDFh2iQKgWY4yIgI04wlBGihRgLbcXVMBMO9x04w1HIos0UoAFBlASghtl5LChE3FTL0HmzENPvRKN1HLL/DrDDD8NN8DOIBU6SK+EFRcssDsEFeSSuRffjDGkCByo8MLQYvRhhKsK+uCFEHQgr8UTU1xNPAWGlP8zLQ9mWJTFGiMFTS0wF6QqBr0KSoGEDgYlUrvAXqitAwBlO0CEUV8QzM1HR6qBhxpahVBJWpdsEkIa8MqUIAZCMEDWh1JA9LbcBAX2IviOZdAzACwgYIJbFzRiBB8M+mCFELJUtjwGgjR2W4g8sAxc+RrAE4NJ06rUvdI2MCgFEVZglVyLzkvvBUXpNegEGPVdbjOCAkhXq3Xbe7IgAw7QwV+S7FUvX3ovGILh5RZYYIIJGpCOIgsorCADgjJ4wEKQJSp4vg86IAFiij1KwUAE9U2CB+VazsytjRqwoCIaN1qAoAWUQnKik3s7mCAFDpzXZpJeZtNHcId4kGnMLAj/oIKdK5oggwySGsCtCACIoC2TM2xPTHcJApQBqodKLUUGll6UgrLaljEpqwUQCboMB6jw75AIMJu5HvgkiAUSSPDU7pbeDpDExbk8Ij7GWaxAAOn4BkBzgvwGvELB3fPBKl5DeKHyqD7YzkwRSzBABZZljBN1CCUQQK7LpbPdvoiKLixXTAH4AD1taU9dAR1EBZCE7xgo3njaIcha+orGtjOAASwQwIEB8C6buRxi8EGvTTuQG3qtFGCAtRBRNUAHBc5vb3b0jQp984EhilRvAB5IygE89W5wmJlWtQCggwP8qn69SQFgVtCBA9CmR/MR1wKJAoGlOIAAS8kfVnyX/5Z2CW8FIoidBUfDF0CVsDf8MmFLBrC/BkArT0ZzV9Lk1cL5GIAE8huNxHDYEgkE8D4DXEtYEBYCtv1wPitYgXxmVjMlkmRCd4pWYXrQAwCwQGUqjOJoPiACBbZHal0kSc9sNEPDbAABG+jVC3hIxtGkIARQqw7d4PgRJNGKSWisixo3oIADJPGO8ulV5HpzhIEMsiJeuswHjeJHOQpSke4B0RsN4wEeUG6SEZHA9SxURa1AEombzE8HSuAeTGqSlA0xo1JAiRVRSnKV1fniwtrjAVXO8iAQqNUeKUXEqMRSl/OR4/OiIgMNgGCYI5lAAKzmS3UB85FrjOQy51NIrf/A4AdP0IA1L2K7zURALr9UywY2IMcwerM9lcwKFFCggW5GxAY2UCcAmJIkgb0ydQeq53xIcEqpNMEFSICnRDwAhHpuhgADQJc+iWLOD/yznygLlFTeCYAW7GAiQMilLgmwAAeMjXfkhCUCviDRiRLzAFykiAxkgJAo/IAgMMABDCRiA594EwIaQVLJSBpMk6I0pdcMgSUjAgMXoOAgSFUmQXbQgokEAQixWqYFauXTaEpFjScF6FDzUwISlGQHOxioQZSgBINklCJDGNcwFxC2ro0zq07ZqlC9mh+7WkQGLoCBEuIJABDw1SA0telEjjCxYQIMfw5VSV07cFcIfWD/lBdB6ktBIFOC/CAKCHkqRWoAhETOsgG8i0DYiuK5zwlMmiXxo8qMClkGrvQiYy3ID5SpAaUiRK0UIQs9Z4kBJAVNiC5B7efuNxQ/gvW1sO2NDopakb0WFgAaUAISXNCEhBC2IvPUZQaAq7EhFsWcymVuvQJDR4l04HQlAStFKmsQ66IACg7pbHkBAAFoMpYk5LWvRCIqohClEyIGkKVHIrreiND2ICj4gXQRslckWIS7pNzgl1brEQ7xt78RSdh6G8gCEmUxxATWwYgIQmAA6Og8HYCaAh7oRoiwYLIPie6DX/oQKDxBwifoKBwn8LNGXtgi09LCDjc8EQbEZkS8/wHkr5oMgAi+ADcLExEAEkab2LBABQF6QYAikjQuvvcjT5hvRciCWEW2soNSceREcjACLTz3yBMxAGxi47wEpjjPVf5AlaucMPZ02cUJNACAJKIDEfBQwR+xLlQrUoMjzICqd5TABje4sZ+WJFdVCAFL5+wngrxMRE9+cpWh/Ng/H4A9gIbgagTskBI8NiE1JokMcOBoz87gCJP+dEXaHJEYcNrTvbZyB5xXggSmIII7+lVuFIBsKj8W0FZWNQJXoIDz9IcECC6ImEvSgltfZAg5hSMEgta9kc61JD7AAhqGTWwFQPBUCuyyCJDd7BDAZr2pXrWqrVyqJk5ExrJctP9KwI1rinjgBBfolxIX0IAGDKDS+pVID9r9bmJTxNRSUUGnC0Jrlhz8IjZYQsN/2JaF5pOPHtnAFPqA8YxPZONSKbSCvN2SvZZ5oqN9lgPkSjAhP8QELod5zNvDRAAU3CVIeMITIjzyHtcPOjUaAMUfEgYtGNPoGoqoJwTrFCi4AOETsQEQOPrDChAgAjJc+UQ2UAYRiKDAWycULFaBFRn84AdjN6jZo466AeS37Q+hQQFugAU3zJ3uMVIBeqPSAr3zPSIHBYJvjZeBoLnSMG3OwZ7GkPjFwxHye3ewQU8gaeM9ILgCGK66HZIAIkyhCoxQfOh/2AIUuEAJTZ1IDWb/cALLMy4AQGYkYxMQAzPowha1t30UCap3DTz9pvSkgAd4bbMAXE+Dn2z7BjrUBi3IvfnDBIESktqC0j+kMicYwk+YNnVJRSsBHLiBCRgQd+aPX5EwyCgOnpr+sRg3RDI5eimukGg9DxKNHCAC07g/8dO/fuK/HfA/9JOIGvAAtuKBwyLAKBIZkiGaAKCBHkCAHlAF/IPAu5JA/9OAFgABEADAg6CAIICR6ru+FgoaGgGy3sGEESCCUzhBFGQu/tOAHUABFMABJDTCHYCnKHBB3isICpgBHpgBB6lCB+HAgkgCCmA4gthCK7zCVgEbsSEb/bgBTWgDIAzCXoMBF2wB/3hSAiN8AiTEgScwQr8yhV+QAj3cQykAA3jqAiscgiLgAR7gg0fwQw0AAz6UgmHgwkfRHM4BAAOskElwhUhohUBILU3cRE7sRE/8RFAMRVEcRVIsRVM8RVRMRVVcRVXcAlf8BCeIRVmcRVkUAyu4xVsUg1mgRV50gi3QxKozEkjkn87ZRAKIA1TcoFRUxmUUnGR0xlNkxmiERlOUxmqkRlK0xmtcRW1kRW/8xk8MxiLJHbgQgHRziF9LiHRUx6CDiHVEiHcEiXZEx3lsiHg0iHsMmHq0x33kRzVsCO3hHu8RIJLIR31UCYPcnH6Ux5JISIdcyIJISIVcCYkkNv/ZHv8EZMeChMiI5MiObEiPnMiNBEmSHAmJrMiK/MeDNMmQPMmWfMmSZMmY9AiXpMiQVMmPlMmRnEmahMmd1Emg7EmEvEmRxEmetIiHHMqjREqfDEqhdMqnXEqjZMqf/IiarMqotMqm1EqszEqonEqq/Epfu8mk7MqwFEuKMMirlEqwBEGzHEulfMu03EqvvAi1JEuiTEmVvEu2nMu+/B65dMvAJMi/FMy29AglIYnEVExxHInFdMzGRMzIvIjH/IjKlEzGVInLtMzJPEzP/EzQDE3RHE3SLE3TPE3UTE3VXE3WbE3XhAheyhoPfACsek3bfJOdIkYcHJrb7E0uyTyREMP/sWE73yzOOdEY/hlGojRO5kwLCGgL5dwcYmxO6swP+NuIq8GccjzH6uzO5bAqhrodCwjI7hGArPFO9KwOzrlIAEpP93xP+IxP+ZxP+qxP+7xP/MxP/dxP/uxP//xPAA1QAR1QAi1QAz1QBE1QBV1QBm1QB31QCI1QCZ1QCq1QC73QxTMiozACDkgbDE3NxYAIBOCAj0gABDiNDwVRBDCIDcAJIkgJNbqBAsgBAGhRDmACgiiADTCC07DRFx2OE01RFTUIIugBw0OAHBjBEeAAIxjBHiACBMBRBBiBEC3SI80BE0XRkpiw/eyYD6SIByAA/CKAjIy5EC2IHLgJxZCJ/xEliBGQ0QJoUwSIATRVUwQIiyBVCSCYGoigH9OcxL/pzP6Jv7TcDKsR1JKgEYvQvPo5UwB4sxjYAB+4UwBo00qFUx2tVBJ91BGI1EnFUy0diYPqFy49CAdJTUANHCLSnoi7L5EIU7WDlkOdgAuBgM+gkezBnv7ZoLUjCAuotF4tiAyoNAzYI+6zkPLEHr8ZgNJiEr/ZmWdVPTs5T+NZDJswUSKYP0pljARYwBNNgODQ1JlAgGzlgDvNUpXg0hoAvoY41d5cF3I0iAiQgOwzzxfSCAKwAIgTmM14IZGY13q1gAzY14YqiIcbPp0BAM1TioxgWOgQHIiTzqqDDokTgP8GENNGXYwQndROpdQ4RQAjoIE9mdLTsFQA4NgYONc8bYkZcJR2RYt3JaJI9FWB8ZoX2pjLuRCK9ddmqdnNyFlfLYjnlA63sI+F7QhFldhy9BuAoViFXTMUjBOcqgE/LYizi9mEUL1JGc8GWIAHAC4lIUan3Vm90VevBVunPQie5dmjBYCkHdvNgNuqY1Q15K5GAQDuCgKXNYiDKs6CSQrB+YwXioABwFWelUQBIFzD1ZvBLdzNeM4keQDTIogG4J6xYRKNiAtXopEJgADoqICMaQAAuJzO8BqF5R5q1b91padXmTSyMIgXWQI+vc2CsYCx2R77+K5zO9xy7Np+5R//3QWYH8NOgzA3jCSIjEDOjsgYc4SO/2GSDMjBsZnYjRC85mvZgkiWgiA3AIAPd8XaIklb0Zzagvje7k2k1jVf29TLzVOs8Q0+P52du1Xf12RfCY0T+nVN+6XQqq3f5RTQ/k2IUmXO/fVPgeg7LKTd/w1Q7oWIPYXCBF7NAi6SDTBSnagJr7jgCz6OkTCnmdDgrvhgEMZgEQbhDN5gzHjdibgAmAWA/G3NCXaSG8BUFB6OESZhG77hE9bgEUwbrhjhHTbhEtbgIL6JnMDhHxbiHAbiISZivaUI+nlh1ozhGDEBDy2JJCbiJraJHrhizEjiIq7hLBbjG96JAJYIKZbg/wXGEe/7zDRWTSpmkPmrPzee3fVdYw1ZQNMIzTdOzTh2DxEkwV35zCf2zT+ujpMgAhodTRUGX3Axgcbg4NBsYP+lFytOzQN2ZGA5mtQ8YxSMzZAZGdo0TFkpnA4R0gXKTdHYTR10RzxejvCJgUVGZWUxXnSzCOAEAOEkQ1eWldLAohgBFVcbZmIuZhSjGk++q4eLuIlLS+Tcm+SczlRVrVYxZUJBkccxZm0m5jSkmD5OKZTzG6hFiOdspmiG5r4xxlfGjFieZQZZkwOhkpVgAFLRgeValG/eubSbAJ8r1EjJTt0xR8DcEpoYAWBeECu5F61TiXjzlXvmEhaes+tEVP+EAE/gwoDx3J7yTF1/5JIE6IFTlg8gKZai+4iGNoCHNhIbKIJPS7tgRUpiZM8yZciJKpQASRO1eDbTMaRHqQxDXue14GTmgOc2yQwWQLYS4Ok3eZU5a6XErU02A+q0eLOQ9iKHWY/qOOoDSOpjgZUj+6gN8l2phsexzooYOOgf0RFvKWm1YAFAKYGFNpKgODLuIYi4KFigM5IeoNPC4AsDiDUlQxOlbo8PqLMOiGscKYLgK6/bAYAM+AyVy2siKQ13jgq/BuzWgZwiKWzaQOwWkd0jA64aCQAMmNysOGSjoGqnuGx5MyXNXpQPQDRj45JkHqoMEBgCsA/qcb0WOev/oVAdzHZtBRjsRXHA/JNPXrKVwYOQvW4J1cGN7xhuqjFu/QSnM8o0DaFslXjum07pbaFu2YngobJYKlruBRFqi+BuFfFufQFvFsnnerITC9MX9Y6bH3JvCPEAlt6wStMjq2MO9I6I+mZvu8HvzHBBFymGJ2QuNftv31Dt/uiW7t4kA8cKBF8wtGoICqCDvyqvkSlv7F4Q3xZwCV/vYapwpyDCg0ACHMithuCBDofhsm6J5n6IAa8nFCcKDXCBg4CCCXQIGYDxDWvY6+bt+dDuhiiTCR+qHG8JDcAB7KotgZK+wfoBOuiCDUMKpWAKB2fnMUGIa0EiAqfwbh4K89ss/4LIOwBAgRs7CNwqAizvr7Z4i7jo8ssYcYSwoTGfpSYnCRRYtB3YrIJacRcAgSLwhQ3bjM74DDu3Ir4+iD+ZI2Lrc49AgSjgcQDQrt0yK7SCb29yjqnDNCOvDiQ3CAVAFeIuL0qvCBQILOyKAo0CLB0ziMCKsC6I8yOrD6eY5uOSD6GOdFuiOwd0vI9o9UAHgB9ocxxYsHgadPuaogM0Cl6fcZeAl04ZPwMIuJJodVhvAswiiCfgPcgrLGcvrwY3b/eos2BvPhY4gD0niFYXKCXQuaRzNG3CtUQU737KI+UOcd/g5E1ZmSAkAWK/iB/ALhcoq4IYdNwyCA1gBTRjrv/iC6/2oIEvT5hXGz8d6KqRWPakc/E0VyrrekINYAOEYi468aSZNgrUtoge2NSAZ+tPkyOV8PgLLwjrAoCzcnMN8GrY2p8il2zmSIARoFHnyngUFAHPhgiPbwgcgDCeV2zmqhX/RnfDiIEC0CISAssX4DaPaPqEyL0Yny4o8PRhYhZnIU6h940CiAHngjGwPPWSAHuEUIIGQwgQQIGVti9zIQi8HvXLeLNUUPrP9LiOp7E2NwhvZ2rGDsbIBnzD4ABjgHvPLIF1t4ic/3oAAAL3gy2LwRjwsvq0+IAwGAEyEE0VCKuPyPuPOPghCC3IwhmL5egE7I1eCYOq9sw+S/X/hmD9SgcBs9clq8EaiscMyTruqVSR1Qf5ioACDajt0Wx5h+CCMzjNbln+j9AAep9iancIMpiC3A/Ndmdv378IGcgt6AdN6U+IOtjU0yR4jyh/iwCBWS/ku9rt3fb3tCiDogcIAAIHEixo8CDChAoXMmzo8CHEiBIb6igxscWOiQBg4BAo5ITGkCJHkixJkEAAgQEImIQYIGXLiCzuFIhp8ybOnDoFpggxUYOGkDhgCDwhZCfSpDghEGjggEBTlkoJvpx6UE0Mq1q3ci0pQoFEoCGfgBA4I0jXtGoJDhDg1m2DCVyrdl0zJcHavHrXvngRNqhGFDIEBpmx97BVCQ/W/9Ld+kFOD8SSJ+dUIOJvSCiAP1LubDNDhZcBFj+0ELpCBoEZHoxO3bCxVi4jaHiubVtiiBQRxWqMomSg0dvCJRJ4K0Cqw+JuFwhccFwA89cwtSrwYmI49uwES+jYDXhikx8Di6DVbv4g9AHqIUCckCGDAwEDJgiIACCCALkMYU8lYeA8gLapQEJESkQh0lACeQBEgA0uMJ1G8VkQgAApUTjdAKJp+BJKWxlAYIMhSvbBASxAhEJZIQk2EBAeiGieBA6IRhpEFQggAQAX5ljhQBluKFqHVpngBVgvGpnXCgycmKJGvAFggw1HYqecW8g5JIEAGAhkI45YViCdVTSMwP+FlGV2xcAKS4okAwpmageBeutBhJ+MAQxggQAODCAhmFP1IMcHbgqqFAsHBOoQiiJxNCh2EwQwIXsPGcfjA/E5QONC/OmUwBRrMPqpTiSo8FCiIv3QxEBQgioZlvJFoOVWmuYUgxqr2hpTRaQyqZGBAy14614NYLBAhlZOJetNBdxhIrDNhtTTQ6eO1EKbLLrobFryETAABsYqhWxMOYxQBrblSvSVQx2NBIMLSPjKoLlbEbCAA/h9GSuEOXFQR7z9NtRXuiUp8R0ALfo7FQQNLOeaVuCaZMIUZBw88UGWBUwSCOK9SzFSFsQ5AMNWOVzSGWRyfLJAuTWkLkk/7Gr/MMo3LWAffLA2nK9NKoRwaMwUc7eySRr85msRPdskn0reJjWySEOOajTFAwJdEhIuECVQDTzUALVJDdwbgX345iRmLVxTTCKzCVXdEgotEDTDtWaLhAF0zmF6LM4mESFI2nL3m+RCIFRbUgtPEEQBBX6LlAHdDeA4V94kQeyI4gejGfjgJblceUkQRJoW0xKJeQbn/hbK80GCx6RBRgSpWvpDUDEWuUhEjFEk7OaKqpDqLbHrbqpAbJ07QxNEBzrtGkEMB/Hx5ppQ7y0pMfR4FzS/EJXHQR6TmF6gfj2w0EKfOdVWE5QED0mAj5AEUEH1+M0x2f70+s6iixBGN+1A/zAAFxRd/2RC5xCIgQKA2AIYQpzUkowVpAYwMyAAIOCcPd0rfibphRf6BsFVWSyB/DPJE9xGEA/wIG4AXEADGjCA9m3PJP7ZoLNUdhAFtkQG5hthCSGYn22tpIUjMUEYQARDYP1shh80CQqgYBASmhB8XiPABBxgM5El7yE30ALuhmgrqRkxJ1XblYKaeD0KvWUAOfHRj1ZSxYYwwQx+0SKw0NbFnGjAcHDcEgEioB+coPFHQQoJE6Ygie/d8VOAM0ivdPKEIxpwAJ/rigAR4gMz6EFJhbzV5QxSqpyAoF1LFGPpMuAc7SFPIzSIARb2YMlL2up0mgTjTaBAPgAw8f96D6ibAO5GxYkY4QZVOMAqWWmr3RVkkzlh12AKUkviBSA6DyplREwwgkYAU5jNeh5BjJkTG14Nh6D0WwDq9JTR+PAhQKymNcPnk2LCEieyPMgyS0dG4ygNKZEcCAPQmU5g3W8g2jzmEw60xByWro8v0eXS1jiQDWwgn8Hcp60QOBBpKaUJOEDVQL8J0YgIcAMIuII+N6oUFRjAAPRrSAfeSJIODoRlSonCE7rpTZGKJHQeBelDaZqTD5DgAB3o6X8cYoCchkSGAnGpUpKIEA9oVKeZWuNNQ+rUnBjgAG9MgQpYYACwaBUsQ9VBB4I6VAAowKQl6MDTFLCClBLyIEX/POpW2CXCpTZ1qgUZWVSJateY5NOnBtCNAg7wn8D+5wAheMEKDtAdnwKgqiHowAFKpIIDrOAFlG0IF+G6lU7ONaN73U/y8vpZpBggBJEFJmHJKlgAMJZEHWDta6sKFsuqVbAGEMEBGiJHzW6lCS6g3kDLM9qDgEu0w90pTyzbgdSmlrGwfa5sG3sABUC2pCV1yCEBgFSrwOAJO5DpCI9wgguo77gDQZZxzXsTA3SAAQoogWBTYFj2rvYAJHivYqE7XekqQAeUVYAKLNKQTK4tLTDYQUwTQoEh8GAIiTMvenGq3spA9gAiCKplRQDfwobAtG9kbHRDjNvLNsSV0UuL/xJcgFGEJOECJzjCg0eLLIdOOC/O3cnuTpyWFrigs0uN8Wc1ZQIuSLXGXLmxTnKl47TI4Af/hGdd08kfI4xAC3o1spmgtWS1aMAFOwBeQkgYhPI6FTbisjKWb/WVLasFBlDAARTAq8wivHgJQIZoY05ZhSun2Ux9YfNakLADFzDycEsQbxGiLLfVtMYhjYnBnvt8K8vkrzOC+0ELwJyQJCwICFECAOJg55ziHO+pAvEBFvIgaWCFABiF3gtGcLDIFYf50/67AK5znesHUwDXdzYXfeyDnz0qpCo9SPWqiWiIVyNGBkr4wQ+UkMyF9FrX1ua1ryemIx2BdgNTeEWygf+lglswezJNqCMO9tcCEIBAzgiBAbtBEAUNtDNe2+aRQAyqIQKgYgp+SCPAAy7wgRO84AY/OMITrvCFM7zhDk/4LkQxiodTnOGIuIQTZJGFLOCg4yhAwf40IMuPu6DjONh4FhThhC1U/CVmFBGXAOClHgWcAJY4xMOhQnGdO5znDff5z1HSc6EzHOgLN/rRid5wTsSh4khvOcIpQQUqEAIoGpg6Fd4AdSAp/eUhwpOe+ARaktwTIWU3yNnvqlBT13TtZnf728kO97jL3Vlpv02l8oRQ4s6d73Vv+0juTpW+qx3whj98SAQ/eLsT3k2KV0njF4/4iTw+R5GH/OQlUvn/zV/+vJ0/T+WNxPm/J77zo8+8S0z/+dMH/vPmCf2LWF/61tO+9rO/Pe5zr5HQwz47vQ+R7HevetvrXvOXf3zwKe/63w+H+QFKvvGJr3zSCx/1qad+9bG/KucDCPocHb71rx/+PhU/+tLPPrC4D/rVs//839f++8sv/vE7evmu1476X99+988f/fJ/iOIh3/7RX/0x3sSoB0kg4EgoYEgwoEY44AN6XQSKBARKRAVaoAROYAJm4KpcYLh9IAiGoAiOIAmWoAmeIApCkMdECpykoAs2DxmxR3HoBJxYwFo40kCYRgCgxlToIA8CAKM9QMjshA+6BqP9oFJAQGgI4UAw/9r9veDuVQkAzGAEdYsEpMaETED79F3C4BtXQACFIAeVlNpOjGFzPAcZ6oQZitJzNMAQ6gQ9CUQXEoADpBMY2gmjhKEAVMAMWkADPMgfAkBbHIfC7F1CjNITRoRyIId7wAfSJEUjxsd81Md95IdSRKJ8tAVzFAcH5sRi4IkACER8PBIr0c045aF8OMAfhqKNyAWWwAmP0MdLlFGmOI4XckVbeIvYTYWE3FsiMoSEsCG9TFFSrBCPQECexEfYXNItLSMqqsdb7IgZUQg0pkRbPEqcvCFBIKOj3OJW5GJBxJxVxJwvjuONACEGOAV0aKMnFgeOaOIA2A0r4UdxqNAzTv+hW0RQfexJAwgij1wjAE7KLz4EOA4ElhAjUhzklpzjzCmFQgKAjaQEfgwk9sgHMrIEtxVScVSAjdThoFAjAICiQOTdArAHQAKkQ3gMt2SJDX6hjRBLatCJyymFTNoJ2O2JALQkUtTkANwSschjMT5Iq9hgfBjPIxYSfphRPq5PRsqLcSilcVCkQQgkAOTdpUwFVUqAwshID46SA+iHBAlAAxjiBjWjjdQTFKYl1GjlcbCjWr4lXMalXM4lXdalXd5lIWXIAICNSQYABDyAGT0AVNwL4whdJ+KlTniMTh4EC3HMCqqGBzJEY4pIGAZACu2IwgQAlkiAvQCAc0gA3Uj/JWISlzcWBBVSYJwoBFMsBgHATwCJpUDQTShKilScJvAhDZZkiCUCgFPM4rZkiT+K5mjelRdaQLe0ZmoUxwQQAAa4Bh/qkUo8ABgihHGMJUIAJDl1BhkJYTRWIXIKYgBMQLfIxS3JiAUoJ18CYfv8kXCAJDWCJADkyYycZGkOJ05k5ACgBN1oSXFgAJbYx2YOW3wqzGxOZShawAQB4UpAJ3YuRmioxJdkwILKxYTMxwM4ig2yhlsmXp4sQAXEx4H+oWUyB4U0gHJYAJaYKFN0aJ4AgCpqpkc23x5OwGXC50T2ZABkQJ4YY0rYpn3aRFM+QLdoDxU6B28yh47aB3Qo/8RSNqNnNkAzCQAspoT20I3nACcKRSksKgwB3NKXOMV97qFY2ggrWuIrgmRuxmdtzqaRphAGPIrv5UmesAd8Mo7CQGlVcimP+OiPtkRGbiY4UuEMkpL2kBJ1zmYuXmQAhCZAak9bSICNONJxLGqFPKpq/CF9VFBMUKNz6Ggouqd8gKpSrqlAzCAEREB8NMBi2gZ8OgRg7uVu9mlOVKadKOctsQQn2oiw5QeFfImhosds3hIG5KJoVKOaiuIC0Is/Ep2xxiZ0CMCGcuidsEc+ImME8KM0ZuuOnudszmCX5qeUYkerNoRscuV5wElqZMCd5NthGsRkUp7sTMW7vl5Uzv8hkYplWwIhfjiOQPyqgfZkCtlgCgFmBQAmj5BSq8DEwA5AwaKkP1JimHpdk8ZHSWYrqEqpoIYifuhdjWFJSjipJiZHgUpEM3aew06lVLCG3BhHBLDgxn5lo0oFKLbkqboFzN5iUcoqTtAHSzTOjuCIhOaRfhgnc8pgKErol0BAt0TA3UxABBDAl3DrsBJEYc4k0WJApPBhaxrnpFYlVEBneT6KynrnFYKneEKRMOlojOrs0fTjKq6oGWWpc0CAHwJiP3prA9AtdCyqMwbbZkIAxWLKZ4Zm3VpmP9KNBDRTPOYJS0RA4kpIihLAioakiAZiiZ4oK0Uk2+JEcdxSpir/jD7qZ4XYyJtyYnFQyGIgowNAasjgR2qgULb2CHBeI+muhKvUBx6i5ITQIdKQ0gy2osxJKZoe5eZ+YEeGIr1QIrG6HIW86Utwa3zAxHIqTKllbOzm2z9WSPOKhgUwzihNAEDWrZD2LqmKqqi+5cccRPqWIDJSIhndy8IWLDIuAPhKwIpawChyC/he5kBEZLBdLxDuqMfOb/0qbQUY4wHXB/juIyfGp55wqz5eqypaLPGaCZ9iS3WSYgaXoMIkrVu4rM3KhVFCBwS3hQOEJXSQIltGQGqMa54+R0qM8AJMyJ0+Tj0CQOMkaAxSIUnSKdK48GE4LdTmW3iOJx5trSA+ze0V4iQexks+6mpBPDHEFq9IvKqAcozfnuPlugXXJi6xZDHTcilZrko+FuRAlLG/UrFElKtwAojrPmm25iZ+RAAeTmQ4heIFO4tbROnd7DFQqjEMWa+oeq9bLKf2VkUeN0uVdKmBQsUYA3Lz+K/7/rB8YMABe4muzgd/5gcp6vHIausnJzIk584KtzAlZ0gNqwSI2geN7mG/LOV59W4of/Io17It3zIu57Iu7zIv97Iv/zIwB7MwDzMxF7MxHzMyJ7MyLzMzN7MzP/NeBAQAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bonica, JJ, McDonald, JS. Principles and Practice of Obstetric Analgesia and Anesthesia, 2nd ed, Williams &amp; Wilkins, Baltimore, 1994. p. 60.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_30_20963=[""].join("\n");
var outline_f20_30_20963=null;
var title_f20_30_20964="Rasburicase: Patient drug information";
var content_f20_30_20964=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Rasburicase: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     see \"Rasburicase: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/5/23636?source=see_link\">",
"     see \"Rasburicase: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F217416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Elitek&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F854900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fasturtec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10024009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700218",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may happen. Tell your doctor about any fever, rash, feeling tired, upset stomach, throwing up, loose stools, belly pain, flu-like signs, sore throat, cough, or trouble breathing. Do not restart this drug if you have had an allergic reaction.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe red blood cell problems may happen. People with more chance of getting these problems may have an enzyme deficiency called G6PD deficiency.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691510",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat high uric acid levels during chemo.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702858",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to rasburicase or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703739",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have G6PD deficiency.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703759",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had red blood cell problems in the past.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11023 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-2522EA1FE6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_30_20964=[""].join("\n");
var outline_f20_30_20964=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217416\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854900\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024009\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024011\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024010\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024015\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024016\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024018\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024013\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024014\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024019\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024020\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=related_link\">",
"      Rasburicase: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/5/23636?source=related_link\">",
"      Rasburicase: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_30_20965="Example of SCIT prescription form in use";
var content_f20_30_20965=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F78830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F78830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 655px\">",
"   <div class=\"ttl\">",
"    Example of SCIT prescription form in use",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 635px; height: 791px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Maintenance concentration and subsequent dilutions reported as volume/volume (v/v) dilutions with maintenance concentration 1:1 v/v.",
"    <div class=\"footnotes\">",
"     AU: allergy unit; BAU: bioequivalent allergy unit; W/V: weight per volume ratio; PNU: protein nitrogen unit; G: 50 percent glycerinated; Aq: aqueous; Ly: lyophilized; AP: alum precipitated; AcP: acetone precipitated; HSA: normal saline with 0.03 percent human serum albumin.",
"     <br>",
"      * Volume to add = (maintenance concentration/concentration of manufacturer's extract) x total volume.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Target maintenance dose volume is 0.5 mL per injection.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Cox L, Nelson H, Lockey R. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol 2011; 127(1 Supp):S1. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_30_20965=[""].join("\n");
var outline_f20_30_20965=null;
var title_f20_30_20966="B anthracis Gram stain";
var content_f20_30_20966=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Bacillus anthracis Gram stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A Gram stain of Bacillus anthracis, the cause of anthrax, demonstrating gram-positive rods.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention and Dr. William A Clark.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_30_20966=[""].join("\n");
var outline_f20_30_20966=null;
var title_f20_30_20967="Influenza vaccination in individuals with egg allergy";
var content_f20_30_20967=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Influenza vaccination in individuals with egg allergy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/30/20967/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/30/20967/contributors\">",
"     John M Kelso, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/30/20967/contributors\">",
"     Julie Wang, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/30/20967/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/30/20967/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/30/20967/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/30/20967/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/30/20967/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of the intramuscular inactivated influenza vaccines and the intranasal live-attenuated influenza vaccine are cultured on fluid from chicken embryos. As a result, there is a small amount of egg protein in these vaccines. Thus, there is a potential risk of inducing an allergic reaction when administering the influenza vaccine to an individual with egg allergy. However, many of these same patients are also at higher risk of an adverse outcome due to influenza infection (eg, age &lt;2 years, history of asthma) and would therefore benefit from vaccination.",
"   </p>",
"   <p>",
"    This topic reviews the risks and benefits of administration of the influenza vaccine in patients with egg allergy. Other issues related to egg allergy (including prevalence) and allergic reactions to vaccines are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33944?source=see_link\">",
"     \"Egg allergy: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=see_link\">",
"     \"Allergic reactions to vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The measles, mumps, and rubella (MMR) vaccine is not contraindicated in patients with egg allergy. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=see_link&amp;anchor=H22#H22\">",
"     \"Allergic reactions to vaccines\", section on 'Measles, mumps, and rubella'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13223?source=see_link&amp;anchor=H3#H3\">",
"     \"Egg allergy: Management\", section on 'Egg-containing vaccines and lipid emulsions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28638413\">",
"    <span class=\"h1\">",
"     RISKS ASSOCIATED WITH INFLUENZA INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both seasonal and pandemic influenza infection can lead to severe infection and death, particularly in certain high-risk groups. Seasonal influenza results in higher mortality rates among patients with certain chronic medical conditions (eg, asthma), pregnant women, and those at the extremes of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations of seasonal influenza in adults\", section on 'Complications of influenza'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35224?source=see_link&amp;anchor=H5795631#H5795631\">",
"     \"Influenza and pregnancy\", section on 'Clinical course in pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Influenza vaccination is recommended for all individuals six months of age and older and is particularly important in those at increased risk of complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"     \"Seasonal influenza vaccination in children\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK OF ANAPHYLAXIS TO VACCINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic reactions to a vaccine may be caused by the immunizing agent itself or to other",
"    <span class=\"nowrap\">",
"     proteins/haptens",
"    </span>",
"    that are introduced into the vaccine during the production process. These may include residual animal proteins, antibiotics, preservatives, stabilizers, virus-inactivating compounds, and latex [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, not all episodes of anaphylaxis caused by the influenza vaccine are due to egg allergy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=see_link\">",
"     \"Allergic reactions to vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overall, anaphylaxis induced by influenza vaccine is a rare event [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A survey of children and adolescents enrolled at four health maintenance organizations from 1991 to 1997 revealed no episodes of anaphylaxis to influenza vaccine out of 197,964 doses administered during this time period [",
"      <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The rate of confirmed anaphylaxis to two versions of H1N1 pandemic vaccines was approximately 2 per million doses administered (97 cases) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/2\">",
"       2",
"      </a>",
"      ]. Insufficient information was available to confirm anaphylaxis in an additional 117 cases. Anaphylaxis was excluded in 181 cases of reported anaphylaxis to the vaccines. The rate of anaphylaxis was within the range expected for vaccines in general (1 to 10 per million doses of vaccine).",
"     </li>",
"     <li>",
"      Several cases of anaphylaxis to the intranasal influenza vaccine have been reported, although these cases were not directly linked to egg allergy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/3\">",
"       3",
"      </a>",
"      ]. No studies have directly compared the rate of anaphylactic reactions between the intranasal live-attenuated vaccine and the injectable trivalent inactivated vaccine. It is not possible to compare the two forms of the influenza vaccine with regard to the risk of anaphylaxis, because it is such a rare event.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fatal anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of reports to the Vaccine Adverse Event Reporting System over a 15-year period from 1990 to 2005, during which 747 million doses of influenza vaccine were administered in the United States, revealed four reports of death shortly after influenza vaccination that identified anaphylaxis as the cause [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/4\">",
"     4",
"    </a>",
"    ]. No information on egg allergy was provided nor was any evaluation performed to determine whether these were allergic reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     VACCINE EGG PROTEIN CONTENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, influenza vaccine manufacturers did not state the egg protein content of the vaccines. Now most manufacturers of these vaccines provide this information in the package inserts. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"     \"Influenza virus vaccine (inactivated): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/21/20824?source=see_link\">",
"     \"Influenza virus vaccine (inactivated): Pediatric drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The vaccine ovalbumin content is typically expressed in micrograms per 0.5 mL dose (",
"    <a class=\"graphic graphic_table graphicRef79474 \" href=\"UTD.htm?41/31/42494\">",
"     table 1",
"    </a>",
"    ). All current vaccines are reported to contain &le;1 mcg per 0.5 mL dose.",
"   </p>",
"   <p>",
"    Independent investigators assayed several brands and lots of the 2009-2010 seasonal and H1N1 influenza vaccines and found that the actual ovalbumin content of the vaccines was one or two orders of magnitude lower than the manufacturers' claimed maximum levels [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. All lots tested of the seasonal influenza vaccines approved for use in the United States for 2010-2011 contained less than 0.17 mcg of ovalbumin per 0.5 mL dose [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/7\">",
"     7",
"    </a>",
"    ], although it is possible that untested lots had higher levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SAFETY OF VACCINES IN PATIENTS WITH EGG ALLERGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Safe administration of injectable influenza vaccine (containing up to 0.7 mcg ovalbumin per 0.5 mL dose) to over 4000 individuals with egg allergy has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/8-17\">",
"     8-17",
"    </a>",
"    ]. These studies included more than 500 patients with a history of anaphylaxis to egg ingestion who were vaccinated with trivalent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    (TIV), all without serious reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ALTERNATIVE TO VACCINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to vaccination is chemoprophylaxis after exposure to the influenza virus. However, there is increasing emergence of resistance of the influenza virus to the available antiviral agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=see_link\">",
"     \"Prevention of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link&amp;anchor=H14#H14\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\", section on 'Chemoprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ALTERNATIVE METHODS OF VACCINE PRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most influenza vaccines are produced in fluid from embryonated eggs. Alternative methods of influenza virus propagation are under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/18-25\">",
"     18-25",
"    </a>",
"    ]. These methods do not use embryonated hen's eggs, and therefore do not pose an increased risk to patients with egg allergy.",
"   </p>",
"   <p>",
"    A trivalent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    (Optaflu) produced using cultured mammalian cells was approved for use in adults in the European Union (EU), Iceland, and Norway in 2007, although it was not available in all EU countries during the 2007-2008 influenza season. This same vaccine (called Flucelvax) was approved by the US Food and Drug Administration in November 2012 for individuals &ge;18 years of age (",
"    <a class=\"graphic graphic_table graphicRef79474 \" href=\"UTD.htm?41/31/42494\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. This egg-free vaccine has been evaluated in 6281 adults in seven randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/27\">",
"     27",
"    </a>",
"    ]. The efficacy of Flucelvax was 84 percent in one of the trials, which is comparable to that reported for standard available influenza vaccines. In addition, rates of serious adverse events in the cell-based vaccine groups were similar to that seen in the egg-based vaccine groups and placebo groups.",
"   </p>",
"   <p>",
"    A second trivalent egg-free influenza vaccine (Flublok) was approved by the FDA in January 2013 for patients aged 18 to 49 years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/28\">",
"     28",
"    </a>",
"    ]. This vaccine contains three full-length recombinant hemagglutinin influenza virus proteins (two influenza strain type A proteins and one type B protein) that are made using an insect virus (baculovirus) expression system and recombinant DNA technology. Significant antigenic mismatch between the vaccine antigens and circulating viruses in one randomized trial of 4648 healthy adults made efficacy against antigenically matched strains difficult to confirm [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/29\">",
"     29",
"    </a>",
"    ]. However, vaccine efficacy against all strains was 44.8 percent, similar to that seen with traditional influenza vaccines. Adverse events were similar to those that occur with conventional egg-based inactivated influenza vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. A randomized trial in 156 children 6 to 59 months found that Flublok was less immunogenic than standard TIV, particularly in children &lt;3 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OPTIONS FOR TESTING AND ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For adults with egg allergy, we recommend a trivalent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    that was not produced in eggs, if readily available, instead of an egg-based inactivated influenza vaccine (",
"    <a class=\"graphic graphic_table graphicRef79474 \" href=\"UTD.htm?41/31/42494\">",
"     table 1",
"    </a>",
"    ). For individuals aged 18 to 49 years, either a vaccine produced in cultured mammalian cells",
"    <span class=\"nowrap\">",
"     (Flucelvax/Optaflu)",
"    </span>",
"    or a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/11/39093?source=see_link\">",
"     recombinant hemagglutinin influenza vaccine",
"    </a>",
"    (Flublok) may be used. For individuals &gt;49 years of age, Flucelvax should be used. However, the opportunity to immunize an adult with egg allergy should not be missed if the cell culture-based or",
"    <span class=\"nowrap\">",
"     baculovirus/recombinant",
"    </span>",
"    DNA-based vaccines are not readily available. In such cases, patients should receive the egg-based inactivated vaccine with the precautions noted below.",
"   </p>",
"   <p>",
"    We would not use either egg-free influenza vaccine in patients under 18 years of age for several reasons. In certain age groups, some influenza vaccines are less immunogenic and others have higher rates of adverse reactions. The",
"    <span class=\"nowrap\">",
"     baculovirus/recombinant",
"    </span>",
"    DNA-based vaccine has been shown to be less immunogenic in children under 5 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/31\">",
"     31",
"    </a>",
"    ]. Immunogenicity and safety data are not available for the mammalian cell culture-base vaccine in children and for the",
"    <span class=\"nowrap\">",
"     baculovirus/recombinant",
"    </span>",
"    DNA-based vaccine in children 5 to 18 years of age. In addition, the risk of the egg-based vaccines in patients with egg allergy is minimal.",
"   </p>",
"   <p>",
"    The following section outlines options for patients with egg allergy under 18 years of age or patients 18 years of age and older for whom the egg-free influenza vaccine is not readily available. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Alternative methods of vaccine production'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Risk of anaphylaxis to vaccine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A history of allergy to the ingestion of egg, raw or cooked, should be sought prior to the administration of any egg-containing vaccine. People who react to raw egg, but tolerate cooked egg, may still experience allergic reactions to egg-containing vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/32\">",
"     32",
"    </a>",
"    ]. Such patients may not be easily detected, since they may not think of themselves as \"egg-allergic.\"",
"   </p>",
"   <p>",
"    Data suggest that the trivalent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    (TIV) is safe in individuals with egg allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/8-16\">",
"     8-16",
"    </a>",
"    ]. Thus, the American Academy of Pediatrics (AAP), the United States Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP), and the National Institute of Allergy and Infectious Diseases (NIAID) in the United States have removed the relative contraindication to administration of the inactivated influenza vaccine in patients with egg allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Many of the vaccine package inserts still contain the contraindication, although some list only severe egg allergy as a contraindication to receiving the influenza vaccine. (See",
"    <a class=\"local\" href=\"#H28638413\">",
"     'Risks associated with influenza infection'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Risk of anaphylaxis to vaccine'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"     \"Seasonal influenza vaccination in children\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin testing (prick or intradermal) with influenza vaccine prior to administration is no longer recommended for patients with egg allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. In studies of patients with egg allergy, the presence of a positive skin test to influenza vaccine is not predictive of a subsequent reaction. Skin testing with the vaccine is still appropriate when evaluating a patient with a history of a reaction to the influenza vaccine itself as opposed to a history of reaction to egg. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=see_link\">",
"     \"Allergic reactions to vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Administration protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beginning with the 2011-2012 season, the AAP,",
"    <span class=\"nowrap\">",
"     CDC/ACIP,",
"    </span>",
"    and NIAID specifically recommend that patients with egg allergy receive the trivalent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    (TIV) with some precautions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Individuals with a history of a reaction no more severe than hives after egg ingestion can receive TIV at their primary care provider&rsquo;s office. The vaccine is given as a single dose. Prior skin testing and two-step graded challenges are no longer recommended. Individuals with a history of more severe reactions suggesting anaphylaxis (including angioedema or cardiovascular, respiratory, or gastrointestinal symptoms) after egg ingestion should be referred to an allergy specialist to receive TIV. Any provider who administers TIV to an individual with egg allergy must have the personnel, medications, and resuscitative equipment available to treat potential anaphylaxis. In addition, the patient must be observed for 30 minutes after the vaccination to monitor for signs or symptoms of such a reaction.",
"   </p>",
"   <p>",
"    The live-attenuated influenza vaccine (LAIV) is",
"    <strong>",
"     not",
"    </strong>",
"    recommended in patients with egg allergy because the safety of LAIV in such patients has not been evaluated.",
"   </p>",
"   <p>",
"    Our approach to the administration of influenza vaccine to recipients with egg allergy is based upon observational studies and extensive clinical experience (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Safety of vaccines in patients with egg allergy'",
"    </a>",
"    above). It is consistent with the AAP and ACIP recommendations, the American Academy of Allergy, Asthma, and Immunology",
"    <span class=\"nowrap\">",
"     (AAAAI)/American",
"    </span>",
"    College of Allergy, Asthma, and Immunology (ACAAI) Joint Task Force Adverse reactions to vaccines Practice Parameter 2012 update [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/34-36\">",
"     34-36",
"    </a>",
"    ], and the British Society for Allergy and Clinical Immunology (BSACI) &ldquo;Guidelines for the management of egg allergy&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a history of egg allergy who are currently ingesting egg directly (eg, scrambled egg) are no longer considered egg-allergic and, therefore, may receive the vaccine in the usual manner.",
"      <br/>",
"      <br/>",
"      Patients who are only tolerant of smaller amounts of extensively heated egg (eg, egg in baked goods), but not egg directly (eg, scrambled egg), are considered allergic to egg in relation to receiving the influenza vaccine.",
"      <br/>",
"      <br/>",
"      Persons with a history of suspected egg allergy who have not had a previous allergy evaluation should be evaluated by an allergy specialist to determine the status of their egg allergy, but this should not delay their influenza vaccination. Patients who have a previously confirmed egg allergy who have not had a recent reaction or evaluation should also have the status of their egg allergy determined.",
"     </li>",
"     <li>",
"      We no longer suggest skin testing with influenza vaccine prior to administration in patients with egg allergy.",
"     </li>",
"     <li>",
"      We suggest administration of an age-appropriate, approved influenza vaccine (",
"      <a class=\"graphic graphic_table graphicRef79474 \" href=\"UTD.htm?41/31/42494\">",
"       table 1",
"      </a>",
"      ) as a single dose in all patients with egg allergy, including those with a history of anaphylaxis to egg. We recommend a 30 minute post-vaccination observation period in a facility prepared to recognize and treat anaphylaxis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Persons with a history of reactions no more severe than hives after egg ingestion can receive influenza vaccine in a primary care provider&rsquo;s office, provided the appropriate personnel and equipment are available.",
"     </li>",
"     <li>",
"      Individuals with a history of more severe reactions after egg ingestion, or who are sensitized (have a positive test) to egg but have had no known exposures or reactions to egg, should receive their vaccine in an allergy specialist&rsquo;s office where additional expertise is available should it be required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the intranasal vaccine contains one of the lowest absolute amounts of ovalbumin per dose, there are no data on its administration to patients with egg allergy. Thus, TIV rather than LAIV should be used for vaccine recipients with egg allergy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/30/20967/abstract/34-36\">",
"       34-36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many patients with egg allergy are at increased risk of influenza complications, including young children and those with a history of asthma or wheezing, and therefore would benefit from vaccination. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most intramuscular trivalent inactivated vaccines (TIV) contain a small amount of egg protein. The amount of egg protein in the vaccines has decreased significantly over the years, and all egg-based vaccines now have low ovalbumin levels (",
"      <a class=\"graphic graphic_table graphicRef79474 \" href=\"UTD.htm?41/31/42494\">",
"       table 1",
"      </a>",
"      ). No serious reactions have been reported after administration of egg-based TIV containing up to 0.7 mcg ovalbumin per 0.5 mL dose in recipients with egg allergy, including in those with a history of anaphylaxis. Beginning with the 2011-2012 season, the American Academy of Pediatrics (AAP), the United States Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP), and the National Institute of Allergy and Infectious Diseases (NIAID) in the United States specifically recommend that patients with egg allergy receive egg-based TIV with some precautions. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Vaccine egg protein content'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin testing with influenza vaccine prior to administration in patients with egg allergy is no longer suggested. Skin testing with the vaccine is still appropriate when evaluating a patient with a history of a reaction to the influenza vaccine itself, as opposed to a history of reaction to egg. Patients with a history of an allergic reaction to the influenza vaccine should be referred to an allergy specialist for evaluation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=see_link\">",
"       \"Allergic reactions to vaccines\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For adults with egg allergy, we recommend administration of an egg-free, trivalent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"       inactivated influenza vaccine",
"      </a>",
"      (TIV) made using cultured mammalian cells (in patients &ge;18 years of age) or an insect virus (baculovirus) expression system and recombinant DNA technology (in patients 18 to 49 years of age) rather than an egg-based inactivated vaccine (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). However, if an egg-free vaccine is not readily available, immunization should proceed with egg-based vaccination with appropriate precautions noted below. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Alternative methods of vaccine production'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Options for testing and administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all other patients six months of age or older with known egg allergy of",
"      <strong>",
"       any",
"      </strong>",
"      severity, we suggest administration of an age-appropriate, approved egg-based, trivalent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"       inactivated influenza vaccine",
"      </a>",
"      (TIV) in a single dose followed by a 30-minute observation period in a facility prepared to recognize and treat anaphylaxis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Administration protocols'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link\">",
"       \"Seasonal influenza vaccination in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"       \"Seasonal influenza vaccination in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Persons with a history of mild reactions to egg can receive TIV in a primary care provider&rsquo;s office.",
"     </li>",
"     <li>",
"      Individuals with a history of reactions more severe than only hives after egg ingestion, or who are sensitized (have a positive skin test) to egg but have had no known exposures or reactions to egg, should be referred to an allergy specialist to receive TIV.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The live-attenuated influenza vaccine (LAIV) also contains a low amount of egg protein, but is",
"      <strong>",
"       not",
"      </strong>",
"      recommended in patients with egg allergy because the safety of LAIV in such patients has not been evaluated. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Administration protocols'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link\">",
"       \"Seasonal influenza vaccination in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"       \"Seasonal influenza vaccination in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/1\">",
"      Bohlke K, Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003; 112:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/2\">",
"      Tavares F, Delaigle A, Slavin D, et al. Anaphylaxis following H1N1 pandemic vaccines: safety data in perspective. Vaccine 2011; 29:6402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/3\">",
"      Vasu N, Ghaffari G, Craig ET, Craig TJ. Adverse events associated with intranasal influenza vaccine in the United States. Ther Adv Respir Dis 2008; 2:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/4\">",
"      Vellozzi C, Burwen DR, Dobardzic A, et al. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine 2009; 27:2114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/5\">",
"      Waibel KH, Gomez R. Ovalbumin content in 2009 to 2010 seasonal and H1N1 monovalent influenza vaccines. J Allergy Clin Immunol 2010; 125:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/6\">",
"      Li JT, Rank MA, Squillace DL, Kita H. Ovalbumin content of influenza vaccines. J Allergy Clin Immunol 2010; 125:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/7\">",
"      McKinney KK, Webb L, Petersen M, et al. Ovalbumin content of 2010-2011 influenza vaccines. J Allergy Clin Immunol 2011; 127:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/8\">",
"      James JM, Zeiger RS, Lester MR, et al. Safe administration of influenza vaccine to patients with egg allergy. J Pediatr 1998; 133:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/9\">",
"      Chung EY, Huang L, Schneider L. Safety of influenza vaccine administration in egg-allergic patients. Pediatrics 2010; 125:e1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/10\">",
"      Gagnon R, Primeau MN, Des Roches A, et al. Safe vaccination of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine. J Allergy Clin Immunol 2010; 126:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/11\">",
"      Greenhawt MJ, Chernin AS, Howe L, et al. The safety of the H1N1 influenza A vaccine in egg allergic individuals. Ann Allergy Asthma Immunol 2010; 105:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/12\">",
"      Owens G, MacGinnitie A. Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy. J Allergy Clin Immunol 2011; 127:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/13\">",
"      Howe LE, Conlon AS, Greenhawt MJ, Sanders GM. Safe administration of seasonal influenza vaccine to children with egg allergy of all severities. Ann Allergy Asthma Immunol 2011; 106:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/14\">",
"      Webb L, Petersen M, Boden S, et al. Single-dose influenza vaccination of patients with egg allergy in a multicenter study. J Allergy Clin Immunol 2011; 128:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/15\">",
"      Fung I, Spergel JM. Administration of influenza vaccine to pediatric patients with egg-induced anaphylaxis. J Allergy Clin Immunol 2012; 129:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/16\">",
"      Des Roches A, Paradis L, Gagnon R, et al. Egg-allergic patients can be safely vaccinated against influenza. J Allergy Clin Immunol 2012; 130:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/17\">",
"      Greenhawt MJ, Spergel JM, Rank MA, et al. Safe administration of the seasonal trivalent influenza vaccine to children with severe egg allergy. Ann Allergy Asthma Immunol 2012; 109:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/18\">",
"      Reisinger KS, Block SL, Izu A, et al. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J Infect Dis 2009; 200:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/19\">",
"      Szymczakiewicz-Multanowska A, Groth N, Bugarini R, et al. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis 2009; 200:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/20\">",
"      Cox MM, Patriarca PA, Treanor J. FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respi Viruses 2008; 2:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/21\">",
"      Chichester JA, Haaheim LR, Yusibov V. Using plant cells as influenza vaccine substrates. Expert Rev Vaccines 2009; 8:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/22\">",
"      Allgaier S, Taylor RD, Brudnaya Y, et al. Vaccine production in Neurospora crassa. Biologicals 2009; 37:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/23\">",
"      Kang SM, Song JM, Quan FS, Compans RW. Influenza vaccines based on virus-like particles. Virus Res 2009; 143:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/24\">",
"      Frey S, Vesikari T, Szymczakiewicz-Multanowska A, et al. Clinical efficacy of cell culture&ndash;derived and eggderived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010; 51:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/25\">",
"      Barrett PN, Berezuk G, Fritsch S, et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011; 377:751.",
"     </a>",
"    </li>",
"    <li>",
"     FDA news release. FDA approves first seasonal influenza vaccine manufactured using cell culture technology. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm328982.htm (Accessed on November 26, 2012).",
"    </li>",
"    <li>",
"     Flucelvax prescribing information. file://www.novartisvaccinesdirect.com/pdf/Flucelvax_PI.pdf (Accessed on November 28, 2012).",
"    </li>",
"    <li>",
"     FDA news release. FDA approves new seasonal influenza vaccine made using novel technology file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm335891.htm (Accessed on January 17, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/29\">",
"      Treanor JJ, El Sahly H, King J, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok&reg;) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011; 29:7733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/30\">",
"      Treanor JJ, Schiff GM, Hayden FG, et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 2007; 297:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/31\">",
"      King JC Jr, Cox MM, Reisinger K, et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine 2009; 27:6589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/32\">",
"      Kelso JM. Raw egg allergy-a potential issue in vaccine allergy. J Allergy Clin Immunol 2000; 106:990.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute of Allergy and Infectious Diseases: Updated recommendations on influenza vaccine and people with egg allergy. file://www.niaid.nih.gov/topics/vaccines/research/Pages/eggAllergy.aspx (Accessed on September 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/34\">",
"      Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 2012; 61:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/35\">",
"      Committee on Infectious Diseases, American Academy of Pediatrics. Recommendations for prevention and control of influenza in children, 2012-2013. Pediatrics 2012; 130:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/36\">",
"      Kelso JM, Greenhawt MJ, Li JT, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol 2012; 130:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20967/abstract/37\">",
"      Erlewyn-Lajeunesse M, Lucas JS, Warner JO. Influenza immunization in egg allergy: an update for the 2011-2012 season. Clin Exp Allergy 2011; 41:1367.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2389 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-118.195.65.248-57510F31CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_30_20967=[""].join("\n");
var outline_f20_30_20967=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28638413\">",
"      RISKS ASSOCIATED WITH INFLUENZA INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK OF ANAPHYLAXIS TO VACCINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fatal anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      VACCINE EGG PROTEIN CONTENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SAFETY OF VACCINES IN PATIENTS WITH EGG ALLERGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ALTERNATIVE TO VACCINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ALTERNATIVE METHODS OF VACCINE PRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OPTIONS FOR TESTING AND ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Skin testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Administration protocols",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2389\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2389|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/31/42494\" title=\"table 1\">",
"      Influenza vaccines summary",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=related_link\">",
"      Allergic reactions to vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=related_link\">",
"      Antiviral drugs for the prevention and treatment of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=related_link\">",
"      Clinical features and diagnosis of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=related_link\">",
"      Clinical manifestations of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33944?source=related_link\">",
"      Egg allergy: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13223?source=related_link\">",
"      Egg allergy: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35224?source=related_link\">",
"      Influenza and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=related_link\">",
"      Influenza virus vaccine (inactivated): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/21/20824?source=related_link\">",
"      Influenza virus vaccine (inactivated): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=related_link\">",
"      Prevention of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_30_20968="Post-cardiac injury syndromes";
var content_f20_30_20968=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Post-cardiac injury syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/30/20968/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/30/20968/contributors\">",
"     Brian D Hoit, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/30/20968/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/30/20968/contributors\">",
"     Martin M LeWinter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/30/20968/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/30/20968/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/30/20968/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pericardium is a fibroelastic sac made up of visceral and parietal layers separated by a (potential) space, the pericardial cavity. In healthy individuals, the pericardial cavity contains 15 to 50 mL of an ultrafiltrate of plasma.",
"   </p>",
"   <p>",
"    Diseases of the pericardium present clinically in one of four ways:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute and recurrent pericarditis",
"     </li>",
"     <li>",
"      Pericardial effusion without major hemodynamic compromise",
"     </li>",
"     <li>",
"      Cardiac tamponade",
"     </li>",
"     <li>",
"      Constrictive pericarditis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acute pericarditis refers to inflammation of the pericardial sac. The term myopericarditis, or perimyocarditis, is used for cases of acute pericarditis that also demonstrate myocardial inflammation.",
"   </p>",
"   <p>",
"    Pericarditis with or without a pericardial effusion resulting from injury of the pericardium constitutes the post-cardiac injury syndrome. The principal conditions considered under this rubric are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Postmyocardial infarction syndrome",
"     </li>",
"     <li>",
"      Postpericardiotomy syndrome",
"     </li>",
"     <li>",
"      Posttraumatic pericarditis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The term postpericardiotomy syndrome was substituted for the previous postcardiotomy syndrome after it was discovered that the syndrome can occur after the pericardium is opened even if the heart is not invaded (eg, after surgery for bronchogenic lung carcinoma). Furthermore, the provoking cardiac injury may be surprisingly minor (eg, percutaneous coronary intervention, insertion of a pacing lead, radiofrequency ablation) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation, diagnostic evaluation, and treatment of post-cardiac injury syndromes will be reviewed here. The clinical presentation, evaluation, and treatment of acute pericarditis, pericardial effusion, cardiac tamponade, and constrictive pericarditis are discussed separately.(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=see_link\">",
"     \"Etiology of pericardial disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=see_link\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/44/713?source=see_link\">",
"     \"Treatment of acute pericarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link\">",
"     \"Diagnosis and treatment of pericardial effusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25607534\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The post-cardiac injury syndrome, including posttraumatic pericarditis, appears to be initiated by the combination of damage to mesothelial pericardial cells and blood in the pericardial space [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/2\">",
"     2",
"    </a>",
"    ]. The initial injury is thought to release cardiac antigens and stimulate an immune response. The immune complexes that are generated are then deposited in the pericardium, pleura, and lungs, eliciting an inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/2\">",
"     2",
"    </a>",
"    ]. The following observations are compatible with this hypothesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prolonged latent period from cardiac injury to the clinical onset of post-cardiac injury syndrome.",
"     </li>",
"     <li>",
"      Pleural effusion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pulmonary infiltrates in some cases.",
"     </li>",
"     <li>",
"      Studies in patients undergoing cardiac surgery have found a statistically significant correlation between the postoperative to preoperative ratios of antiactin and antimyosin antibodies and the clinical occurrence of post-cardiac injury syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The excellent response to steroid therapy, and the occasional relapses after steroid withdrawal [",
"      <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial prospective study that identified immune complexes in the post-cardiac injury syndrome compared children who did and did not develop a postpericardiotomy syndrome after cardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/5\">",
"     5",
"    </a>",
"    ]. Those in whom postpericardiotomy syndrome developed had increased antimyocardial antibodies resulting from myocardial injury. Several subsequent studies have demonstrated the presence of antimyocardial antibodies in patients who develop the postpericardiotomy syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/3,4,6,7\">",
"     3,4,6,7",
"    </a>",
"    ]. Antimyocardial antibodies have also been discovered in the pleural fluid of one such patient [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/8\">",
"     8",
"    </a>",
"    ]. However, the significance of these antibodies and their relation to the severity of myocardial injury is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Support for antiheart antibodies being an epiphenomenon comes from a prospective study of 20 surgical patients in whom serum was sampled for antiheart antibodies before and periodically after elective coronary artery bypass surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/7\">",
"     7",
"    </a>",
"    ]. Antiheart antibodies were absent in all patients on the day before surgery. Three patients developed postpericardiotomy syndrome. All were seronegative at the time of diagnosis, but became seropositive within the ensuing 14 days.",
"   </p>",
"   <p>",
"    The post-cardiac injury syndrome has also been described in children following orthotopic cardiac transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/9\">",
"     9",
"    </a>",
"    ]. Because these children are immunosuppressed, it has been suggested this syndrome is not always an autoimmune process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25607602\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop post-cardiac injury syndrome present with signs and symptoms similar to those seen in patients with acute pericarditis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pericardial effusion in other clinical settings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=see_link\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link\">",
"     \"Diagnosis and treatment of pericardial effusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In brief, the distinctive features of the post-cardiac injury syndrome include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prior injury of the pericardium, myocardium, or both",
"     </li>",
"     <li>",
"      Latent period, typically weeks to months, between the injury and the development of pericarditis or pericardial effusion",
"     </li>",
"     <li>",
"      Tendency for recurrence",
"     </li>",
"     <li>",
"      Responsiveness to nonsteroidal antiinflammatory drugs,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      , and glucocorticoids",
"     </li>",
"     <li>",
"      Fever, leukocytosis, and markers of inflammation (eg, elevated erythrocyte sedimentation rate, elevated C-reactive protein)",
"     </li>",
"     <li>",
"      Pericardial and sometimes pleural effusion, with or without a pulmonary infiltrate",
"     </li>",
"     <li>",
"      Alteration in the populations of lymphocytes in peripheral blood",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the post-cardiac injury syndrome occurs after an acute myocardial infarction, it is also known as Dressler's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/10\">",
"     10",
"    </a>",
"    ]. This disorder must be distinguished from the pericarditis which may occur immediately after a transmural myocardial infarction (MI) as a direct complication of the MI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24055?source=see_link&amp;anchor=H2#H2\">",
"     \"Pericardial complications of myocardial infarction\", section on 'Peri-infarction pericarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presentation and clinical course of the postpericardiotomy syndrome is comparable to that of the postmyocardial infarction syndrome. In a cohort of 360 consecutive patients undergoing cardiac surgery, 54 patients (15 percent) developed post-cardiac injury syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/12\">",
"     12",
"    </a>",
"    ]. The most frequent signs and symptoms in patients who developed post-cardiac injury syndrome in this cohort were pleuritic chest pain (56 percent) and fever (54 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/12\">",
"     12",
"    </a>",
"    ]. Common findings on physical examination and diagnostic testing included [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pericardial effusion (89 percent), although cardiac tamponade was rare (2 percent)",
"     </li>",
"     <li>",
"      Elevated C-reactive protein or erythrocyte sedimentation rate (74 percent)",
"     </li>",
"     <li>",
"      Pericardial rub (32 percent)",
"     </li>",
"     <li>",
"      Electrocardiographic changes (24 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chylopericardium is a rare manifestation of post-cardiac injury syndrome, especially in children who have had extensive surgical treatment for complex congenital malformation. However, any operation involving dissection of the ascending aorta and the main pulmonary artery risks injury to the right efferent lymphatic trunk and subsequent chylopericardium [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5126?source=see_link\">",
"     \"Chylopericardium and cholesterol pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical examination may sometimes disclose a pericardial friction rub (",
"    <a class=\"graphic graphic_movie graphicRef56608 \" href=\"UTD.htm?0/18/291\">",
"     movie 1",
"    </a>",
"    ). A pericardial or mediastinal friction rub or \"crunch\" is frequently appreciated in the first few days after cardiac operation and is caused by surgical emphysema; it should be distinguished from a true pericardial friction rub. As with postmyocardial infarction pericarditis, delayed pericarditis after cardiac surgery is more common in patients who had active pericarditis early after the cardiac operation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of post-cardiac injury syndrome depends upon the characteristic clinical picture: pericardial effusion, which usually appears about one to several weeks after operation or myocardial infarction (MI); chest pain, usually pleuritic in nature but which may simulate the pain of MI; fever; and leukocytosis with an elevated erythrocyte sedimentation rate. In addition, the diagnostic evaluation typically includes electrocardiogram (ECG), chest x-ray, and an echocardiogram.",
"   </p>",
"   <p>",
"    The baseline ECG is seldom normal after cardiac surgery. As a result, it is difficult to make the diagnosis of pericarditis by electrocardiographic signs. However, when present, diffuse ST-segment elevation in association with PR depression is highly suggestive of pericarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23669?source=see_link\">",
"     \"Electrocardiogram in pericarditis and pericardial effusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The chest x-ray in a patient who has developed a postoperative pericardial effusion often reveals an increase in heart size; when this is seen, the presence of an effusion should be rapidly confirmed or excluded by echocardiography. In a significant minority of patients, the chest radiograph also reveals a pleural effusion, usually unilateral, although this may become apparent only on a subsequent film. Pulmonary infiltrates are occasionally seen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16728?source=see_link\">",
"     \"Pleural effusions following cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When typical symptoms and chest x-ray findings are present, an echocardiogram should be ordered promptly to confirm the presence of effusion, document the size of the effusion, and provide echocardiographic evidence for or against cardiac tamponade. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serial echocardiographic studies have shown that postoperative pericardial effusion following cardiac surgery is considerably more common than is clinically obvious, occurring in as many as 85 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/15\">",
"     15",
"    </a>",
"    ]. The effusion is usually present by the second postoperative day but may not occur until day 10. In most cases, the effusion reaches its maximal size by the tenth postoperative day followed by gradual resolution.",
"   </p>",
"   <p>",
"    The risk factors may be different for early and late effusions. This was illustrated in a registry of patients with significant pericardial effusions after cardiothoracic surgery who underwent pericardiocentesis guided by echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/16\">",
"     16",
"    </a>",
"    ]. Anticoagulant therapy was a contributing factor in the majority of early effusions (&lt;7 days), while postpericardiotomy syndrome was an important contributing factor in approximately one-third of effusions occurring after seven days.",
"   </p>",
"   <p>",
"    It is important to consider infection, especially with cytomegalovirus (CMV), in the differential diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/17\">",
"     17",
"    </a>",
"    ]. With CMV infection, the patient complains of sore throat and has an atypical lymphocytosis. However, in contrast to the post-cardiac injury syndrome, chest pain and pleural involvement are absent with CMV infection. Tuberculous pericarditis and pericardial candidiasis can mimic post-cardiac injury syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. If infection is being considered, appropriate serologic testing should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREVENTION AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    has been demonstrated to significantly reduce the incidence of post-cardiac injury syndrome following cardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. As discussed below, we suggest the administration of colchicine prophylactically following cardiac surgery in an effort to prevent the development of postpericardiotomy syndrome. For patients who develop postpericardiotomy syndrome following surgery, or for those who develop post-cardiac injury syndrome following a myocardial infarction or trauma, antiinflammatory agents are the treatment of choice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/44/713?source=see_link\">",
"     \"Treatment of acute pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5921218\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;When administered prophylactically following cardiac surgery,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    appears to prevent postpericardiotomy syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. In the largest multicenter trial, the Colchicine for the Prevention of Post-pericardiotomy Syndrome (COPPS) study, 360 cardiac surgery patients were randomly assigned on postoperative day three to colchicine (1 mg twice daily on day 1, then 0.5 mg twice daily) or placebo administered for 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/20\">",
"     20",
"    </a>",
"    ]. Colchicine significantly reduced the occurrence of the primary endpoint-postpericardiotomy syndrome at 12 months (9 versus 21 percent with placebo, relative risk 0.42, 95% CI 0.24-0.73). The rate of side effects, primarily related to gastrointestinal intolerance, was similar in the colchicine and placebo groups.",
"   </p>",
"   <p>",
"    Given the clinically significant reduction in post-cardiac injury syndrome seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    , we suggest that colchicine (1 mg twice daily on day 1, then 0.5 mg twice daily) be administered prophylactically for 30 days following cardiac surgery to reduce the risk of developing post-cardiac injury syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5921225\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who develop post-cardiac injury syndrome, first-line treatment consists of nonsteroidal antiinflammatory drugs (NSAIDs), though there are no randomized controlled trials of different dosing regimens.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    may be tried first and, if that fails, a nonsteroidal antiinflammatory drug (NSAID) such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    may be considered if there are no contraindications (as discussed below). The 2004 European Society of Cardiology guidelines suggested ibuprofen as the preferred nonaspirin NSAID for treatment of pericarditis because of its rare side effects, favorable impact on coronary artery blood flow, and large dose range [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two commonly used regimens are [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      &mdash; The dose of aspirin should be 650 to 800 mg every six to eight hours, with gradual tapering of the total daily dose by 650 to 800 mg every week for a treatment period of three to four weeks.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       Ibuprofen",
"      </a>",
"      &mdash; The dose of ibuprofen should be 400 to 800 mg every six to eight hours, with gradual tapering of the total daily dose by 400 to 800 mg every week for a treatment period of three to four weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In pericarditis associated with an acute myocardial infarction (MI),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is preferred, and the use of an NSAID other than aspirin should probably be AVOIDED, since antiinflammatory therapy may impair scar formation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/6\">",
"     6",
"    </a>",
"    ]. Aspirin may also be the first choice in patients who require concomitant antiplatelet therapy for any reason. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24055?source=see_link\">",
"     \"Pericardial complications of myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With any",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or NSAID regimen, gastrointestinal protection should be provided. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anecdotal reports have suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    may be beneficial in treating patients with post-cardiac injury syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/25\">",
"     25",
"    </a>",
"    ]. This is consistent with the apparent benefit from colchicine in patients with recurrent acute pericarditis, which also appears to be mediated by immune mechanisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11177?source=see_link&amp;anchor=H9#H9\">",
"     \"Recurrent pericarditis\", section on 'Colchicine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the patient does not respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , NSAIDs, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    , a short course of steroids is generally effective.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    is typically begun at a dose of 60 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/2\">",
"     2",
"    </a>",
"    ]. Once the patient is asymptomatic and objective findings are beginning to improve, the dose is tapered, at first rapidly (eg, 5 mg every three days until a dose of 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    is achieved) and then more slowly. If pericarditis recurs, the dose is raised to the lowest that suppressed the syndrome, maintained there for several weeks, and then is tapered again.",
"   </p>",
"   <p>",
"    Among patients with recurrent or persistent autoreactive pericarditis with effusion (not limited to post-cardiac injury syndrome), pericardiocentesis with intrapericardial instillation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    (300",
"    <span class=\"nowrap\">",
"     mg/m2)",
"    </span>",
"    has been proposed as an alternative to systemic therapy to avoid systemic side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/26\">",
"     26",
"    </a>",
"    ]. As these data are limited, this approach requires further investigation prior to widespread use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11177?source=see_link&amp;anchor=H11#H11\">",
"     \"Recurrent pericarditis\", section on 'Intrapericardial steroids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PERICARDIAL TRAUMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the pericardial syndrome that can arise following a myocardial infarction or invasion of the pericardium during surgery, the pericardium is vulnerable to traumatic injury. Pericardial injury may result from blunt trauma, as with steering wheel contact in an automobile accident, or sharp trauma, such as that inflicted by a knife or bullet, and can result in one of the following complications:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute tamponade beginning very soon after the trauma (pericardial injury syndrome) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"       \"Cardiac tamponade\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Delayed tamponade which may develop either slowly or rapidly after the passage of considerable time (post-cardiac injury syndrome)",
"     </li>",
"     <li>",
"      Constrictive pericarditis months or years later (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link\">",
"       \"Constrictive pericarditis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with acute injury may present either with shock due to acute blood loss or due to cardiac tamponade [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/27\">",
"     27",
"    </a>",
"    ]. The volume of blood responsible for tamponade in this setting is much smaller than that of most pericardial effusions that develop more gradually, thereby allowing the pericardium to stretch and more easily accommodate to the increased volume (",
"    <a class=\"graphic graphic_figure graphicRef75068 \" href=\"UTD.htm?3/55/3966\">",
"     figure 1",
"    </a>",
"    ). Blood in the pericardial cavity may be defibrinated by the lytic activity normally present in the pericardium, form a hematoma that may create local cardiac compression, simulate a tumor, or cause the late development of constrictive pericarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=see_link\">",
"     \"Initial evaluation and management of penetrating thoracic trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with penetrating chest wounds may also develop delayed pericardial effusions and tamponade. In a review of 24 such patients, postpericardiotomy syndrome and sepsis were the major causes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68322924\">",
"    <span class=\"h2\">",
"     Blunt trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt chest trauma, often the result of an automobile accident, is a frequent cause of death and an important component of the work of trauma centers. Blunt chest trauma may also result from falls, explosions, and crush injuries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study of 59 patients with blunt chest trauma requiring emergency surgical treatment, the cause was an automobile or motorcycle accident in 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/29\">",
"     29",
"    </a>",
"    ]. An isolated pericardial rupture was present in 29 percent while 63 percent had rupture of one or more cardiac chambers. The diagnosis was made by thoracotomy in all of the patients who arrived in cardiac arrest while, in those with vital signs upon admission, the diagnosis was made by urgent thoracotomy, pericardial window, or during laparotomy. The mortality rate was 76 percent overall and 52 percent in the group who arrived at the trauma center with vital signs present.",
"   </p>",
"   <p>",
"    Other lesions can mimic these findings. These include myocardial contusion of the right ventricle, which results in hemodynamic abnormalities that develop over a few days, injury to a coronary vessel, ventricular septal defect, pseudoaneurysm, and mitral valve injury [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Traumatic valve injury associated with pericardial effusion after blunt injury in less critically ill patients can be identified by careful hemodynamic evaluation at the time of pericardiocentesis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20022?source=see_link\">",
"     \"Acute aortic regurgitation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28376?source=see_link\">",
"     \"Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Severe blunt trauma, as with a fall from a considerable height, can rupture the pericardium, resulting in the potentially fatal complication of herniation of the heart. This event should be suspected if the chest radiograph shows pneumothorax or air in the mediastinum distributed between the heart and diaphragm [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Iatrogenic trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;All invasive cardiac procedures and therapies have the potential to cause trauma to the pericardium, although some, such as transseptal catheterization of the left heart, pose a higher risk. Even Swan-Ganz catheterization of the right atrium or pulmonary artery may tear the pericardium. Similar accidents can occur after placing a parenteral feeding tube via the jugular or subclavian vein, with penetration of the heart, a great vein, or the coronary sinus by pacemaker electrode leads, or during electrophysiology studies, endomyocardial biopsy, or valvuloplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition, guidewires placed in a coronary artery during angioplasty or stent placement may perforate the vessel, creating tamponade (",
"    <a class=\"graphic graphic_waveform graphicRef55709 \" href=\"UTD.htm?7/35/7734\">",
"     waveform 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/34\">",
"     34",
"    </a>",
"    ]. Recurrent post-cardiac injury syndrome following pacemaker lead insertion that mimicked cardiac perforation (the latter excluded by surgical exploration) has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link\">",
"     \"Pulmonary artery catheterization: Indications and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac tamponade must be considered when, in one of the above settings, a patient develops hypotension, particularly when associated with tachycardia, or in extreme cases with profound bradycardia. If the patient is still in the invasive cardiac laboratory, pulsus paradoxus and disappearance of cardiac pulsations by fluoroscopy can help to establish or exclude tamponade. When doubt remains, echocardiography should be performed, a procedure that is also helpful in monitoring the results of pericardiocentesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11158?source=see_link\">",
"     \"Pulsus paradoxus in pericardial disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25159?source=see_link\">",
"     \"Technique of pericardiocentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Echocardiographically-guided rescue pericardiocentesis may be the procedure of choice in patients with acute tamponade resulting from a diagnostic or interventional catheter-based procedure. In a report of 88 such patients, this approach was the definitive therapy in 82 percent and was successful in 99 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/34\">",
"     34",
"    </a>",
"    ]. There was a low rate of major complications (3 percent) or minor complications (2 percent), and no deaths. Continued bleeding into the pericardial space requires blood transfusion and prompt surgical closure of the bleeding site.",
"   </p>",
"   <p>",
"    When shock occurs after an interventional procedure involving the coronary arteries, the problem is more difficult and the operator must establish the cause quickly, eg, acute vessel closure or acute stent thrombosis versus perforation of a coronary artery. The coronary angiograms obtained during the therapeutic procedure should be reviewed since they may reveal contrast flowing from a coronary artery into the pericardial cavity. This abnormality may not have been initially recognized when the operator's attention was focused on the lesion being treated rather than distally where the wire can perforate a vessel. Suspicion of perforation of a coronary artery calls for reinjection of the coronary artery if review of the original arteriogram fails to show contrast medium outside the artery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16329?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link\">",
"     \"Periprocedural complications of percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Constrictive pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both blunt and sharp trauma can lead to the late occurrence of constrictive pericarditis due to scarring of the injured pericardium [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/36\">",
"     36",
"    </a>",
"    ]. Other rare mechanisms by which constrictive pericarditis can occur include post-cardiac injury syndrome and an intrapericardial hematoma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20968/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/14/38113?source=see_link\">",
"       \"Patient information: Pericarditis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/53/12115?source=see_link\">",
"       \"Patient information: Pericarditis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4430971\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pericarditis with or without a pericardial effusion resulting from injury to the pericardium constitutes the post-cardiac injury syndrome. The clinical conditions considered under these terms include postmyocardial infarction syndrome, postpericardiotomy syndrome, and posttraumatic pericarditis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The post-cardiac injury syndrome appears to be initiated by the combination of damage to mesothelial pericardial cells and blood in the pericardial space. The initial injury is thought to release cardiac antigens and stimulate an immune response. The immune complexes that are generated then deposit onto the pericardium, pleura, and lungs, eliciting an inflammatory response. (See",
"      <a class=\"local\" href=\"#H25607534\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who develop post-cardiac injury syndrome present with signs and symptoms similar to those seen in patients with acute pericarditis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pericardial effusion in other clinical settings, such as pleuritic chest pain, pericardial friction rub, fever, and leukocytosis. In addition, widespread ST-segment elevation and PR depression on electrocardiography, cardiomegaly on chest radiography, and pericardial effusion on echocardiography are commonly noted. (See",
"      <a class=\"local\" href=\"#H25607602\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       Colchicine",
"      </a>",
"      is the only therapy that has been demonstrated to significantly reduce the incidence of post-cardiac injury syndrome following cardiac surgery. As such, for the prevention of post-cardiac injury syndrome in patients following cardiac surgery, we suggest the administration of colchicine (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). If prescribed, colchicine (1 mg twice daily on day 1, then 0.5 mg twice daily) should be administered for 30 days, beginning on postoperative day three. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Prevention and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of the post-cardiac injury syndrome is similar to other types of acute pericarditis, and includes the initial use of nonsteroidal antiinflammatory drugs (NSAIDs) with steroids reserved for refractory or relapsing cases. However, following a myocardial infarction,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      is preferred and other NSAIDs are usually avoided. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Prevention and treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/44/713?source=see_link\">",
"       \"Treatment of acute pericarditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pericardial trauma can result in acute cardiac tamponade, post-cardiac injury syndrome,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      constrictive pericarditis. Common causes of pericardial trauma include blunt trauma (eg, automobile accidents), penetrating trauma (eg, stabbing or bullet wound), and iatrogenic trauma. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pericardial trauma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/1\">",
"      Wessman DE, Stafford CM. The postcardiac injury syndrome: case report and review of the literature. South Med J 2006; 99:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/2\">",
"      Khan AH. The postcardiac injury syndromes. Clin Cardiol 1992; 15:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/3\">",
"      De Scheerder I, De Buyzere M, Robbrecht J, et al. Postoperative immunological response against contractile proteins after coronary bypass surgery. Br Heart J 1986; 56:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/4\">",
"      Nomura Y, Yoshinaga M, Haraguchi T, et al. Relationship between the degree of injury at operation and the change in antimyosin antibody titer in the postpericardiotomy syndrome. Pediatr Cardiol 1994; 15:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/5\">",
"      Engle MA, Zabriskie JB, Senterfit LB, et al. Viral illness and the postpericardiotomy syndrome. A prospective study in children. Circulation 1980; 62:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/6\">",
"      Bartels C, H&ouml;nig R, Burger G, et al. The significance of anticardiolipin antibodies and anti-heart muscle antibodies for the diagnosis of postpericardiotomy syndrome. Eur Heart J 1994; 15:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/7\">",
"      Hoffman M, Fried M, Jabareen F, et al. Anti-heart antibodies in postpericardiotomy syndrome: cause or epiphenomenon? A prospective, longitudinal pilot study. Autoimmunity 2002; 35:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/8\">",
"      Kim S, Sahn SA. Postcardiac injury syndrome. An immunologic pleural fluid analysis. Chest 1996; 109:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/9\">",
"      Cabalka AK, Rosenblatt HM, Towbin JA, et al. Postpericardiotomy syndrome in pediatric heart transplant recipients. Immunologic characteristics. Tex Heart Inst J 1995; 22:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/10\">",
"      DRESSLER W. The post-myocardial-infarction syndrome: a report on forty-four cases. AMA Arch Intern Med 1959; 103:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/11\">",
"      Khan AH. Pericarditis of myocardial infarction: review of the literature with case presentation. Am Heart J 1975; 90:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/12\">",
"      Imazio M, Brucato A, Rovere ME, et al. Contemporary features, risk factors, and prognosis of the post-pericardiotomy syndrome. Am J Cardiol 2011; 108:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/13\">",
"      Kan CD, Wang JN, Wu JM, Yang YJ. Isolated chylopericardium after intrapericardial procedures: possible role of inadvertent right efferent lymphatic trunk injury. Tex Heart Inst J 2007; 34:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/14\">",
"      Clapp SK, Garson A Jr, Gutgesell HP, et al. Postoperative pericardial effusion and its relation to postpericardiotomy syndrome. Pediatrics 1980; 66:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/15\">",
"      Weitzman LB, Tinker WP, Kronzon I, et al. The incidence and natural history of pericardial effusion after cardiac surgery--an echocardiographic study. Circulation 1984; 69:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/16\">",
"      Tsang TS, Barnes ME, Hayes SN, et al. Clinical and echocardiographic characteristics of significant pericardial effusions following cardiothoracic surgery and outcomes of echo-guided pericardiocentesis for management: Mayo Clinic experience, 1979-1998. Chest 1999; 116:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/17\">",
"      Prince SE, Cunha BA. Postpericardiotomy syndrome. Heart Lung 1997; 26:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/18\">",
"      Meysman M, Schoors DF, Noppen M, et al. Tuberculous pleural effusion following coronary artery bypass graft. Acta Clin Belg 1995; 50:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/19\">",
"      Rabinovici R, Szewczyk D, Ovadia P, et al. Candida pericarditis: clinical profile and treatment. Ann Thorac Surg 1997; 63:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/20\">",
"      Imazio M, Trinchero R, Brucato A, et al. COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J 2010; 31:2749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/21\">",
"      Imazio M, Brucato A, Markel G, et al. Meta-analysis of randomized trials focusing on prevention of the postpericardiotomy syndrome. Am J Cardiol 2011; 108:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/22\">",
"      Finkelstein Y, Shemesh J, Mahlab K, et al. Colchicine for the prevention of postpericardiotomy syndrome. Herz 2002; 27:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/23\">",
"      Maisch B, Seferovi PM, Risti AD, et al. Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J 2004; 25:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/24\">",
"      Imazio M, Spodick DH, Brucato A, et al. Controversial issues in the management of pericardial diseases. Circulation 2010; 121:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/25\">",
"      Madsen SM, Jakobsen TJ. [Colchicine treatment of recurrent steroid-dependent pericarditis in a patient with post-myocardial-infarction syndrome (Dressler's syndrome)]. Ugeskr Laeger 1992; 154:3427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/26\">",
"      Maisch B, Risti AD, Pankuweit S. Intrapericardial treatment of autoreactive pericardial effusion with triamcinolone; the way to avoid side effects of systemic corticosteroid therapy. Eur Heart J 2002; 23:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/27\">",
"      Trinkle JK, Toon RS, Franz JL, et al. Affairs of the wounded heart: penetrating cardiac wounds. J Trauma 1979; 19:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/28\">",
"      Harris DG, Janson JT, Van Wyk J, et al. Delayed pericardial effusion following stab wounds to the chest. Eur J Cardiothorac Surg 2003; 23:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/29\">",
"      Fulda G, Brathwaite CE, Rodriguez A, et al. Blunt traumatic rupture of the heart and pericardium: a ten-year experience (1979-1989). J Trauma 1991; 31:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/30\">",
"      Ruder MA, Flaker GC, Alpert MA, Selmon MR. Right ventricular myocardial contusion simulating constrictive pericardial disease. Am Heart J 1984; 108:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/31\">",
"      Fallahnejad M, Kutty AC, Wallace HW. Secondary lesions of penetrating cardiac injuries: a frequent complication. Ann Surg 1980; 191:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/32\">",
"      Shabetai R, Aravindakshan V, Danielson G, Bryant L. Traumatic hemopericardium with tricuspid incompetence. J Thorac Cardiovasc Surg 1969; 57:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/33\">",
"      Roebuck EJ, Minford J. Traumatic rupture of the pericardium with herniation of the heart. Br J Radiol 1983; 56:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/34\">",
"      Tsang TS, Freeman WK, Barnes ME, et al. Rescue echocardiographically guided pericardiocentesis for cardiac perforation complicating catheter-based procedures. The Mayo Clinic experience. J Am Coll Cardiol 1998; 32:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/35\">",
"      Krishnan MN, Luqman N, Nair R, et al. Recurrent postcardiac injury syndrome mimicking cardiac perforation following transvenous pacing: An unusual presentation. Pacing Clin Electrophysiol 2006; 29:1312.",
"     </a>",
"    </li>",
"    <li>",
"     Shabetai R. The Pericardium, Grune &amp; Stratton, New York 1987. p.155.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20968/abstract/37\">",
"      Meleca MJ, Hoit BD. Previously unrecognized intrapericardial hematoma leading to refractory abdominal ascites. Chest 1995; 108:1747.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4915 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-AFC96612BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_30_20968=[""].join("\n");
var outline_f20_30_20968=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4430971\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25607534\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25607602\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREVENTION AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5921218\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5921225\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PERICARDIAL TRAUMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68322924\">",
"      Blunt trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Iatrogenic trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4430971\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4915\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4915|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/55/3966\" title=\"figure 1\">",
"      Chronic versus acute tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4915|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?0/18/291\" title=\"movie 1\">",
"      Pericardial friction rub",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4915|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?7/35/7734\" title=\"waveform 1\">",
"      Hemodynamic tracing acute cardiac tamponade",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20022?source=related_link\">",
"      Acute aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5126?source=related_link\">",
"      Chylopericardium and cholesterol pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16329?source=related_link\">",
"      Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=related_link\">",
"      Clinical presentation and diagnostic evaluation of acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=related_link\">",
"      Diagnosis and treatment of pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23669?source=related_link\">",
"      Electrocardiogram in pericarditis and pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=related_link\">",
"      Etiology of pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=related_link\">",
"      Initial evaluation and management of blunt thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=related_link\">",
"      Initial evaluation and management of penetrating thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28376?source=related_link\">",
"      Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/53/12115?source=related_link\">",
"      Patient information: Pericarditis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/14/38113?source=related_link\">",
"      Patient information: Pericarditis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24055?source=related_link\">",
"      Pericardial complications of myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16728?source=related_link\">",
"      Pleural effusions following cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11158?source=related_link\">",
"      Pulsus paradoxus in pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11177?source=related_link\">",
"      Recurrent pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25159?source=related_link\">",
"      Technique of pericardiocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/44/713?source=related_link\">",
"      Treatment of acute pericarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_30_20969="Nephrology pattern 3";
var content_f20_30_20969=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F52798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F52798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nephrology pattern 3",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADzAXoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDrfBfjjwx8WNLn0XXrJbHUpV2v5YwHPHzKezcd66b4feCIfDGsrbrOLi2hUmA9G57n8DXk2leDotDuJX08PHdL+8Rwck45x7dK9h8BaudZgE9yxTWILfaImcrvTs2Oh+orrrQcIvkej6Hv1MPOjScoy0ejPPvjk2oa5czQQRySGFwBCgJJRev1PfFVvgdpFyLi/nn86KJgHVCcHPTPtn+lcb4/8T+IdR+ITxWkctvAJQqLCGwx4ySe9e7eCozY6XGzn99K2+VAMduvtW1VunRUEErRpaKzWhuWZvbGwkRQrK7b/LfnqfUfyqjeBLLVLG6SaWIPIEZYpeHPUKR6ZyP0qzqYuREHVSo4X5ZMEg8cfSs/XopZdQtLQRtPHHNHJ5nmDJHcEdscVyR1+ZzQSvd9Tc0a8e58SX87I8LTQIqK64zs3H+tZZ1E3l6sepxiMW75V1P3h2Oe3U8UlxrAj8QyJI+N+3yYTjfwMnHrW/qVhZavpb3UaqshGdy8MCOCP5/Wp+BpyW9ifdg05Le3yOR8WaXdXizzW6iQ2koZPJJIZe5weFPHNc38RdYitfF+i3sEMcsUECmVGfbgHjnHUV6LplxB/YxSR3QxAby2eTjg479K8Av/AApqN1rF1d3MwnXcxRQcM6ew9OtdWHXM/e6afedNC8nZ7L9T1/XfHHg8WcV1q2pB2uY8CCJxIyHuPbkVVuX0vUdP+0aVaTlFKqD90sDx+PX9a8rt/g+2q3STJdvbgfOVnjIXt0b0r1DULebQ/DS28xEfzgs6EdB6fkPahwhBpQeo6dPklyp9drmHrF/NdMLYyIkMRKqhHH4+9V9PURK8/wAoEabi5GAOucD8RWHHqCxXsjSxNJuYqiM2Rn1Jq20/nsEv5Qlokqo+wfKCTwOPrXTy2VketKMacbPRDbfU2S83WyB5M43Hp17e5rYjtobZWP2cfaJmLzTNgk7hyP51reIItDs5wNKgbyIv3eVXO+TGOKxUGpNGg8tlZjvO4YB9/pUKXMr7GfPGolJK3qcvq+uBr8wwwk2+7YpAwu7AP8jW1ZwyagwjghdpAmcZ649BWza+Fz9nkvJ4GZNwlxglQQMZHrxU2veE9R0nxHpWsaPqyR2ksWHiI6Hucdwc03Vh8KOd4m3u31Ma9SCGKO21CZf9KXay4C4Pv6dSPwqDXNFvJ7GOxu9Uiuog4mPlLjcyqQuW9lCiul13QbHVNQju79sCMYRYxl2b/wCv/jWRrrSadYW+IASpZIgCNxA7f59aIyva25MOWo05dDzrwva6hcXZkSLfbljGileADx17cbua7/TrLTdFTWk05pLh7mYRefIoB8rILbQP93GeKybDVng3iKBoUlwHRgSjDrg+nfn3q80gkm+4yIMEYcNx3HQfh7VrO7epvGjGUrt3J7jUL3UVMNzdTTJHwiyMX6j3+lbuh3E9r8PfEZjL7SQg3L8rA4DYPrg1zYWFrkHz9kbH77L2+gzWvq99BcaPpWk2bSNbWkrSvK42iRjzjbn3PWspxvaKRriIqUVTgtLp/dqVINOu4PElpqV3C0WmIA0cuQwmIfPHOegXHFcjoum3V5e6ydZt1aKa4crG3IXk/dJ/D8q7d7uLyLZJXKLv43ElYuew/E1bsZNLa5AgtLq9fHMhAjRmJ4AA5xT52lqjnhFUnzvVmZpWmW1mkFrptrEjuCu1QAG6ipdW8Em6vLBdZuZJIxGJY4S+5IucdPoK7e38ITwCO91S/trTYCFV+AnoN2feq8mn6FHI7vrxu7oHnyXBAxwBkHpWHtk37r/AwlioSlaP5XOY1jwYF0OWHTbjT512eYIdu0qvTnj14xXnlx4Kkllto3j8lh8sgTOD9c8g17IItI2NFIlzDuU+XcnJXcOeWzVVrK41CO7ujF5nlAO0oPLDpj37VcK0o7lxq9JnGaLDFpljJayrHHdkBgi84QkdPevoTw+gj0WzVTkeWD+fNfPkFqn9uo4bMrAK3UnGcgc17NpLXK20ICycD7mSR71jjI8yWpz5jTvBK5nXlzeWw1+bT7X7TdMu6FGwMFs/lxXjngf4XauNam17Wo4YogzSJEyglnY9/wATXvmvwQJFE7O1vPIPnKvtLcdzXJ6/Jcz3ItbdzKrqqKAfu9/x+tRRqO3u6XM6DU9Y6f8AAMG607yNSjnMiku20eWAVHOMDHpxUOo7LBpXmyXjOFeXkAn09KyfjDrE/hXS9N0/RXb7RMWe5mXkhugAP51yfhLxPJq8E+ma3G8srDdHMxAJI7e9dlODnHm6HXCreSH3i6hqOuvK7ymJyroM/Koz19Ogx+NRa54a1vXvEsUs8/maJGQwQHCKAMlcevvXXWGkyhIo7eF5IcfdweR3J/Wt+XUJtH0C4urO2BZWA2nDKDznI96uVS3wl1lG2hu3niDQdK0Dw7pt1JFbkqpEKNuK7QDgfU1d16C8vNHSa1aP7FOTcF0JBOeR+H1/+tXjXhPwFq/jLxul/qzS29hGDPLJt2gHJwqjoM/4167qHiOytdPutK0iCSWKEmMFuFQjsCeCPpXHUpqEkoavdnnqLjNRjq7/AJnG2yu9ykbMiqzEbyflxjsPxNY3i83keiX91FcpGIXCoY2wxxnn6cVT8c63Joi6d9kbbIrhnUjKsPQ1JqEA8T6DusZVyw3IAfzU+9daTVpdD1L3dih8J9c1DU9VvdMvfNmt1gebDN82QOmT65rE+K+n3Wm6hZX1srRw52tg/dfg/wCNUrm1m0WaGKOV47lz+8AyGwD0/SvUdVgbWfDtp/aMayi5zOdwIJAOMetVO8ZKS6mXK7uN9zNsr5n060nV2G4Iz5b72ef0rY8N6fPB4t1rxNrhZ9Ns4fOhBOQxC9cfSubvLi30spAsMhKr8qJggAcA81saT4jhurOe02zI6IYZopWwQD2K+lRUi2ny9R1oOWiOp8N6tqHihbLxFo0UsOwgSWxcoJU3c/XIr0lvEGnIxV7qFWBwVZ8EH0Ncz4ft0fwa0Glf6NcTIwJGcIcYB/CvJbr4S67PczTPNEzSOXLef1JOc9a4JRp1JNSdktjzJUo1XaTtbQ6v4nSf8IzCdQfa1hJJtJxubIH8qxfDOu2mqpFfaXIPtKK0UbqQHU4HB/Lv617RrWgafrOjS6VqMXn2kwIZTwRznIPY18yeL/gt4is/EkVt4YhLWR+ZZRIF288EnPXpWlCtCcOWWjRtRxV48r/4c9Xl0qGHTJdZkS6+0O+PLCc5z374JrV0zUIbawhhuZ0gzCrhmwqfN/Dk1LqKT6Z4W07TUk36j8vnybtxGOTnPXJryrxxY6xrt3oulxokNhLKTKI/9aCpBxn6dDRTSqq8thuTqq776HscrC5uo4Ji0kUu1YDjgkjkn275Fc94+vo/CtxG9wSY5l2rNjlD0wfb6V09paS6lLA5UxLGNuA5DAjgENjrXKeJLbVtRFzp/ibSRPbq26G5B3EL0xuGBn2NZ0WudX26oyg3zJJkzCHWLC11y38m4cyxxxzBDhWbA4zwRz1Fb17ImkzW9vHcKGmYRTQsRyw580Y6cnBHpXKeDrH+wNH1LQ5rhZoGVp4RIchc9MZ6cgfnVF7WeXUNS1vVZ98LQEW8K/xvjA3cY55rTk5na+nT9DX2bbtLZf0jtNenitoLlUxI5jWIgc4UZJx+dc1pUFzeaur2sMFoT8kQYb8AY68day7kXNnpVpfJNhrmMx7Cc4yMYJ/GtaFJbq6FhbzCykWNJY52yCSOw9qpQUI6Gqh7OLs7m74R1Q3fjPX/AA1qttva1RLm3lcfeRhhuOg59Kk8beF2utNhhtZWeNcjBPI9BmsnwE2o3Hi2a78RFYrgQGOB4wBvAK7txHB6DH4113iu0ZLKSWzmdA5A2ofU81hJuFVWfb0OO8qVZK/+R4Xb6bex32LOIsFJ+eQdMZ659ajnniDWWnXLxrMQpdlX70mCMgDpnPevQJNKvYImnkBELAk7hgZ461zWh6XYS+JDdXkD3LLlj5Z4zj5RmvQjVTTZ6kn7X397HU+A1ttM1Z7jV5VLCFfs8RBJXOeQD3wK07O7ttV1q6vbtFFrGwdYyM4GeCR6cGuX1hTbM87go8ybVHOcc+vb3rAtDczu0SXG0S48wse39axdJTvO+4vqntr1L6s9F1/xJ9v1P7Fo8yC3ibdLckAKQONo9eprE1Kea9vBLcO07OApO0nHsqip/DmkQPNJHuTzDhd56L9B3P8AjTNSv4fBHiKVrlZpLBzlZwORkcqcnHcYP1qYqMXyQWpjalRfLDdIyr+3u1u5Ylt7tGTuUZcD1qlqWj3ot4JrmKVHf50KPk59sGu70zW7q+1OK4trgS21zbh4hJ8rMpIyQO5GcVreK9Ug0Q2UmrNbxCeXCnHfHP8A+uj204yUbah9cnC0WkcJ4Z8BX+oORdzT2lsw3bmIJz7CursfhxbQ3bIdQuXhGG4AXJxx0o1fVbu6tVttAnMt7MAyCMggA+tWr/UtS8N+GTqWv3FpHLGmWji3ZdscLnP5kVlOpVk97X6HJUr1ZO8Xa/Q5LxJ4Uis9QcWbzzWsS7pJZAMI3oTxmsfxHqnhfwzbQyXl59rJj3RJByGc4yD64H86xtEj134t+L2kM8tnoNqVMhXKq2Oyr7+9eya74d0HRrOPWJNIgvLnT4fLjeUA7VznOOmc+1azqezcYSd3/XU1lipw5abd2YHhxLvxzbWjXegzaPosCh4DIVDzZ746gYx2roNX1jw74IjCLGDduvyxRcu3bk9q5zUvH8+p6TjSozGhby2dH2uMDkDsO3Nc3bra6xpV491bj7UpDRTZJZj33HPP/wBeo9jKT/eaLsgp4WpUjzVNIdkXta1yTxTqdvcSoYLVF2rCzZwT1NV7bwjImrNpFgD9skbz57mXq2QCD6bQOgHrTPCOlpLNA2oBpbXOODjc39388VLqeqzu/wBjt7i6gjBaOQC4Z1ZeCACeRjkHnvW1uV8kOh2W9nLkorb8P8y9r2vaB4V0uPSr7xDHc3aSgFIgXEYzkhsZx9KwtU8VQ+HdFhc3JSNg0bsDkSqTlcD3BHSsxfBGj6yyiW7WCe5BBUDAXBz19TW5YfDW08TPY6le6i0FhYXBjjjUAiTYAAefpim/Z017zuc8n7JNzd/l1Ot8D+FrebSbbWr58faEEoQqQUU9M5712Oo6vY6NaoSyhmHyg/xY461Nf3cNnYrCGVjsxt6YUDrjtXHajplpcaHbX9zM+1HIij4AYk8k+1cF/bS5p7XOKLeIkpVm7XOd8a6nfaj5gjkEYYbi6jO3HGAfTit221Kws/D1pLZo00xwrTniTd0YkkfWqOp6TDLaK9vIjkt97oMYJP8A+qqMk1uLYW0TbbSLJbJ4znH8667KUUl0PQdOnKKUeg+00KPxFqBjnuIVic/IJ2UyMMdQv+etc1408Bajol4knhHRbe/uUTfI0s/zKefupuHpx161Y0vQdT1rxGLiK+trXT4IWkkQqWk+UZDZ7c4/Kn6J4pS7hUzzi4idiCucS5H+0eRV++pe49uhE+eUmovboL8M73xX4h1SWy8XaXPaWltExErxGIAZxtyeveu4037I2ip9hhXaJ2815F3AjkZ9uucVHp9paXWlTT2V5d3FsuQyTSHMRPPK8ZH51RWYpaNbRp5bPhlYDqB1rJvnfYyUXPZ7G1LeTabfRaPpCJ5HkkksMAyNngnHIxzXFmxudB02ZJ445zc7XWVZc45+YAfp0rq/DjR3NpPHdGTz4z8kyuTx0wf04rn9eVU1oRKdsUKbtyvnJHQ//W7UU9JOP3+ZpQSU3D7/ADOP8R6J/bdkhhCG6b5UV1PDH37UeEtCuvDsclnqTxlnJbZGCdh6dSPaulW2MkgkS5eCR8gjB7+oqnP5qykiXGSFf5QST/8ArFdKk2rdDse4r2UTW9xK0e6WL+Ix5Lc9z1xWT4h8Rpo97p1lqEUkYkUqQMHAzk9Ox4NdFbQu8bfPsK8MM5BGcZrI8T+GLXUhavcwo7oxMcjEgnPbIOKSavqTq3uLf6THre2S1wbiDDoc4LgjGAAOf/rVQ0jRhDcXdzPK015ctulYnC59hjFammTz6Vc27PENijCjO3I6YyKuS2sojluJYmW3ZchicjNO7jp0Hs9TS8E389hfmKXJhJ2MM5FeimJGJb5Bnnp/9avKtLMbRLdW8qSFJMK5PVsDPHf616Qki7F3yQlscnHU1x4iPvXPPxcPf5kYVt49j1HSVm0iDzHQ7XJcHae2O5q5FLc6vps7y3k8Sq3lvGnb6cV4to15NoOvXuh+F2a/to2bzoZIG2wTegkXJIGTya9P8K6ddTQ3U+u3CwzRgnyIjgQgjsfU+tOpShT2/wCCQ4wUbxVi9oCW1gr3U0axxAbUadiXb3APWsvUtTtxqxvolKyNwARx7nH0FSvp9pbaaJQ8txO67VeaUuEBJ4Gen1rPs7ZJbvypkTDMeScZApxUW3JnVShB3nI9F8LxNLaefKDuc7gQMc1uMiSqVf542GCCODmorJRHZwRxjhVA5+lQarqcOl2wlmVnPIVUHLEen5V5zvOWh40rznoeTePLSS2lvmgcG4tlKqrHqr8Dj25rlPh1HrGg6d4ivfFJlSK8t1a2jJDq4J+9jkggVZ+LWsXN14J1TV4I3gmluRCD2CDoB75zk1B8A5k1bwRrDamr314G8pDMhdY4yAevoT/KvXu1S97uj1XKyjGfTc3Bq1rqukw7rRYEhmVfvYB4AB+oxzXQa5qGmvqVqiTxjyoPLADYLOccZ7jI+vNebfFLxHH4etYrWytUWZh+6CjEceOrY79cYrhvBc9/4u8XWsbElrbDkenOatUk1zPQ3qckp+7ofSdldWn2xQ3nGJolKlT8sZ4BBA61JrOqmygVGiSOfhhkFlkAPH48D0rM029VNY+yNHGp4V1b6D9a1b+2a3jkaSJWcOWDkZwP/rVyNJSVzmcUprmEt4dR8S26vqkscNltBMMQxgZ6mudvFstH1CRrR18uH5FLfxHvS/28dAiupZvspikbmeTPy5PA961tK0eC8iW41B2ubh1LrhxggnsBxjHtVK8NXsbJ+xb5vh7I5XUVudSljS1jeSSUE5Bxgn1zXW+HPCljaSE3LpPOqBs9QW6fzq8I2USRxsd0YAQBduOwz+VVDqrQ31l5MaJ5DeW8YPDEtnkYyccnNKU5TXLHQVSvUqR5YaI0tZW38N2z6rK3l2gdTKko6EnAwT9RXP6neaf4q8Pa3JBAt0DGrKemw88+1R/FLw/q3jDRJWj1FYLa2Uym0xjc6gnn1OM4+tch8P8AS28L2Sz3ciyQvCS5WTjzARjdzgjrTpQThzX94woxco8zeq/qxe8HeGdQ0CbStRe7a8tdheGF3IMCFgXABqT4l2dr438R2UsX2pra2iKMkfRyTnr2rQ0GSXxlfymM/wCjR4GYhuQ88jNepWVnZaLp7OUhgiiXcz7ANoA7mirWdOfM9ZDrVI0ZJyV5dvU818H28vhSCQWOmu0j5G6UljgHgZ7VvXOgt4nmS88VyCGwGTFab9qn6k+1Qa149muUaLw/bB33HbcS42BfUZ6nPavK/GVrrmvrc/b7s3syJhYQ+BGc5LAcD2NVGnOpLml7r/EtUalVe0sov8T3KXVvDnhPR0SzktIoF+7DAwZn+gGSTXkXjf4ypb+MYrGTTJJdFhbbdJMpV2UgchfUZzz1rgNK8I3dncxTSssDRMrAo+SCOe3+RXoF4dO1y6a68QaTbauFUKXVjHKAP9scnHoc1ccNCm+b4hQwTj7z1ZI7aRAPtHhq6gvNI1ACTyWJ/dkcYboQf/r1n+ML2fQ7rRke2ZdKvycuM43ZI49MH1q6E0FYtOt9E01tPZbgrtZt+Yz0+b1z/Ouz+JV9aaXNo+jz2qXNnJ88odA21c4yPQ55qudxlFWve+50KVRclNLV3/Awby4jt/DmnLZT7dl2Q+BhvZh7Vr6xaQ2V/ounQWcctldqHnu26gHqQR0x1rmtQ05bfV7zTmlBiTa8L47Mu4ADNdhpWj6VdWC/ZL3VUkjADqqg4JP93H6iom0knf8ApjquMEpX01/Hb7jzRDPb31wMsQshRCB74H0r1X4X38S6fc6XeMokWUyJuPDA4yB9CP1rj9W08Qa1dQRStMCyqrAffGAfmFa+m6eYxbyDDlZVeUqDkAc4/maqtapCwYhRrUrM6X4p+LdJ8L+FLi61AmYOwiWKEje5PYHtx3rzKHxOfFWlw3NihtrGOMrBa7v9XgAHJxyxP8qh+Lnhm61bRtVW2O+S3kjMcXoWzgAe+CPqaj+FWgto1hZWFzIRPcSbpEIAMe7Hy89KmjThTp33Zz4al7J3WqWo3WNZurLw1dKkhS4WIjL9BxxVj4HeCrm68NXWqeI7qWGxmbeqluSB1OTnArY1XSQbHVfNRnnhkbKFQVVAwH4cmu18U2/2X4dWlhCwh8yOKM9hjALfmadSraKjDqzSvNSlGNN2bdhmjXSW7s3h3UotVtkGZrZ0AmZf9lsDOK5bxn4W04+HNR8Q+G+Xf5hGflELZw2R/So/BOl3Daxbagjm3sbRx5szEKrY6j8elbnhmeLUvEniqKCESaTKwmMZX5WOMMR7tismnTk5Re39WZnWp+wqN05Xta/+T8zz34feJpL2Ga2E4S6VfLmQ8B/fFegQTvdiOzvojE0SnDgYz05/IV41qN7o9l8QY4/C1perAXIm3klV9MdwK9s0e/W70qG8c75IX2up67e2P8K3rraSW5U9uaxl6DpTaZYak0srrZz3OVbcTsyOjcev9Kbf20tpqcTO25X27ZXO4N3GTWzDdZ1CWwkjMUd6CvlsCFfv26HHFQ+LL5n0lYUtoo/JkBZCTuAA/hI7etYqUnL1FCUlO1tzl/BGoHVRcNu23yXHleUCDhST/F36fqKj1SSOS9lSCPKb2xsXqCc81NafZdMsN1jDsmmbc0ij7vc/piufvJrhormODesjJhGB4Jx65+ldCjeTaOunFttm7Zz4bLKAWyMfpipZZidoO5njPzLydo5rA8PLdxhWuJnZ1IKeZ17enbmtXUL19Ou45mt1kimjDlW/j52so9+aJR10KW5NqEUtxDC8CxPLk57EHPSsNNcvJbCXT0tSqSnjzcnYehx2yQK1NYc2MUMTli8oVliAJKgjozdP89qo3E7TTW0/HmI4LnPzFen6Z7U4q61GtV5EzK2m3WkWEixm6uCCkTY3MoIGT+teof2hoy8PFMGHBAdgAfpXl3jlbK18Uw6/dSBl06xTYO2Rk/j1xUFn46intIJmYgyIrkY9Rn0rN0nWSaOCsuezmbPg7XE1Lw5cDTpIrW+usTG6bksRgY4HXtzXb2NtJaRSQXjI7NGvmEDhjt/+tXnvw90dNIt1McUnlruiKdyDnn/69egXUz7GRgzZAGG5/Udelc9VJSaQ8RFKfLHqZWoSG5eKGPnozbR+n+fWrlho8FkjzRRqk0SEjjaDxkA/570umQ7S9w8ZxHgDnqan1W6RNLmUOrSuOin8Klu/uompJ6QidJp91cS2ysgjIOMkd+mD6f1rI8UQ3l1c6e25YLeHJlYch8jAHtXHS/2/aQRtpkty1sQDGI2LLjHQ+hBrr5r67TwpDLeRkzrgylBnkn278jNZ+z5JJprUwlR9m1KLTucd438Lz6p4ZktTHvtT+8jRD83H9fSuJ+Fwbwx4hudHskma0udglWQFmVh34HPWvX7C7e5nEUtx8pQGJQMFSBwK8Y+ME9/4d16HUtMdo5mYsxA6Hjt2zg12UG5p05HTTkmnGaO8+Jei22u2Vrpmm2oupSfNjKL8ylep56e9J4K8N6Rp8LTaZZxW97cIGlfO5sZ+bjqoyMVw/hn4lXEmlXtz9ikutTMJiVYOCC7fe79Kg+DNvqFnf6rfam8sL3aiNWfJO7dkn1qpUpRg4t7fiHLLl5Vt3PWdb09Llhd267LiMEkMPvD61UfxHJAUi1aGQRxopEkLfe4zn/GtNXdoHidwZVTa5IyGB5BH4VNCltbwxyQkx3W3eueQ3qCD61zqStZq5N0laSv2PO9c8R22saXqugf8IperLeoVhdvmG4/dcEds4PFdH8PNK1bwtoaabrV0l/GkgFu8eS0S45jJ9jWpc61oUNlIEFuLgvl0i4Jb046VGNbSxCRJIpD4dlYZ8vj1rRtyjyqNhezc9l95qhhGRGLVWtg4ZXdsMnJzznp1FStBaxajHqmlxCZwdzxq2RuxggHnkdaof2grTRyKAYpWxkA9T2A79Kj1y8eyWBpZFWNPnCR8cH1x1PIFYqLbsTySvbuP8T64bVJRM6GR49shC9OeR+VeM65H4g8T6xDpuiwyNbMQjogwFGeSfSvVfA2ht4juzqOpD/QIzmOPn943qfavR7ew0zRxPdRQwWqkZkfhQAKv6xHD+7FXYTr08OvZpXkQeEtDtvDugWun20aRiJBvK/xN3JrhtX1h/Efic2bOW0e2l8p7dHw0pA5Zhnlc8AVs+LPF8Z8MPdeH7iOcSt5K3SYKKec498V4R4L12SPXrpZ52liZztYv0fPUH0ow1CUuapLczwtCUm6s92er6lLoseqKwnCRbQotgcbSOnPauY1BZnvHubeNjbO2C5BAYj0NV9ehjW4E6crIwfHQbgKsW17FLYyi5kAYyIQrNx0PTNdUIcqTR6kIygr3MfUIpWKYACRHnb/GOD+lWtOt4pY7gpDIoXnKjP1Ht9frW/ollFq14Aw3QvGS7iTHlsM4Xb1OTj6100cmn6Po/kxBZHmcs+056DAB/OlOty+6lqRUq2dlucPBYyDSJtS8qS3hFwqws7AkKOvI6nkc1qardxeI9St7mQh3jCozKMsUGT09T/WuV1vxat3rVnosZnuriSbYsEQ+SNmPT3wK9A8OXNpYeJbbRPs8blhslmGdxfGcewH9KVS8VzNa/oPmteS1kr/JGLeGS+ury9lRUaaQeWpI3KoAAH4AfrVi01aS3v4pbfLSwbdxP3WwCKj8Tyiw1vUIYyjTh9yjGRx6/hXJGPU9SvxbWkrAzjJCHHOOpPoBTjFSjd7Fpc1PbQ6M6jJPrT3MpUXEoJYFcDJIwK25bh5o1uvPVXMYLAHbnJ2gVz66ZHa2KTQT+dGodDgfxKASD9c9afolzLdTw2o2IjHczsPlRVBJJ+gzxRKKauugSgrc0ehp6jMYL2ISxPHbTNEJsHhShGWP61PrWg3LfEVbrTYlNjJLBIzqwOAcZPXpwak1aCG88Jf2rZu89vE4SdXGG29CR+deA6dYalfeLDHa3c6MZMjDHdjJ4z9KKcPaXadraGEZyg24b6pn0q6x6hJfxB1WC/uXkklXtBEw5+rMMCrXipmu9JkulCSWEeFAIyuO3696ydbiex8B6fNZ8u8ieZKvJCbTwf0rU8d3kOnfDj9yFSCZYkVieFDEEn+dcf2o272ORLlcZLq7Hkni7xzPZQRfaY0NurER2tuvlqOgz7/Wu80dzpGnaVqVlcxw3eoRCb7DL92YY+7v7H0968f1q00zxQ0NtbXgkmtGWR0GcGPPI/z6171q3h+38S6Lp9zpk0VtZ2UJSAMuBgADn0A29/0rrr8sFGL0T3OitKKkot2g/wCvzOL+HHxD0nW/FWp+H9Y8Lx6Xdzytuc/PvbOCHJAwfSt3xDYp4Z1iOC3Ja0uBuRTzt56VxutiVNRl1ewtWkdpw8bBfvMu3Le+SCa9L8QKvinwlZavAuJEXcUzkqe/5EfrWUkqcoyWz0fqZ+zdGcW37svzJtXkttQs0hWEi9KKYvKB4Y8K2e2PWqXiq3l1KUW2n2ryNjynkQfeYdSfQZBqpoqfaNOVpJJImClkcEjO37w/Sug02O/sdJjvrMmeKQF3RuXC5PI5545xWL/dvToZv907p6ruefSQNBp9yJgUmhZExjocnOfwFUXtoF1FpLQhrXcMM3y57Gr+pTS6rqcggIkWeQytIRww45wAcUM4nY+RCsM8XYHK5A6Y/rXYm+p6MW7FSK2EshROSxA+uKZ4k1KS3u4Y7IkLBCIpJUXOGJJI57jA/OtC38u4jaYhgygsQD97Pp9KqyCMx+TEhUjcWRhn5un48CnfXUaXNLXoZLtO584zvI64Iab5ye3P86841q11zTPH9ks81wyXEim3ZTuRo2IyFwSP/wBVemanDNHGgEf7skJujGMD1NX9AjXYbu4j8+KyQtEG4GSeOfqelVz8vvIVaN46GJ8QZorjwbrTzfLKVWGKE4LHDAZP6kVwVhoV09jbMIhgxqensK3NH0rUfE/xUlWe3kOmRECQsp2AAdux5Ne0f2fbQ/uktkCp8oGB0HFCrKh8zmlJOViTQAGtbhUwhdQdp+8cjqP1pYoiy5MhLKe/5Zq7aT2bSfa0kjjDrj72AelVJ7J7dJJ0kVoGkaRSG+7k5wfbmvPvqYqXvO+hoOq2+mY34JOQe5J/lXEeHor6XWryAhhYoSweZhhT/dNbM6XWyKWRisMmSjl88DvirWkbDp813PFlpf4QPmfHfB79Kte7F+Y7KCb3bOTutSvLOGeC31Jra1RsEKdi56kcDrVrxd8Y9J8Jtp+jW9u1+diidicAKV68dTXIfGG3+z+HGRQ6TEK0gAzz2+n+FZOmeAYvFH2fVL24kty0UaOCucttGMH1rp9nTklKZvVpxqxTtsexaPNb6rZ2V7alVWYLtGTxzn61R8eeEJdespGDgFFOzqxJycYH+f0rS0DTrayWG1iUpHbAAsOmQByQfbtWvZXk08EzXlnLZzKzICRneF/iU+hrl53CXNE5ZTcZe6eBeBdCu7DXi5hkRrY4cFCo56fWvYdJ0yySOB7iEeYAcyH16g8fWr2nTR38cwleOdwWIYJtc4ODuA7c04NGlo5jYgqQv0HStatZ1HroaSqO3KM1cBrlRFzIsecDhie1QaJP5+iu86lyzMPLQ4IXHP49au25gUXOpykiGGMhstgEL1bP5VS8NtpDaOLuxuo5ba4LSDLBiAeMcdCKyv7tieZcvL1VjK1DRLMactzbQnerCd2YFuAOn8s1SiilNwsAjBupT5fJI64Pfnb2/Cuxt8CzNqBuifIGT90D+lYV5q2lWetxWllKr3q5GB93GOe/OOa0hOTujanWlqi/a6WY5I4ldDPDG0vJwgJGD0/GvOvixrbzNb2UEgjmunEQxxtTgfh1/Wu/urtYHR1kecyIybI+DIxOOfb2rxfV7efxV8RbPTBHMH8zaNoPTqT7Aeta0I+9zy6CSfxyPqXwzp0OkaBYafbABLeJU49cZJ/XNeQftUXutJ4Z0+z0cSfZJ5iLtouvAyFPt3xXttrGYLSGN33FEClj3wOteAfE74ota+N5/D+lWlncQrKomeeLzAZAoHAzxjpmuHCRlOrzLWx5eHh7WqZnhPxNonhnwPpmieP5LgNet9pgjhQhoYiAAzY5GecD0qpZeGPBOtzS3fgvxY0bxLua0vE+Y884OAcdPXrXa+KfBVl8RfDdtrkFqkOqwYSQKMLIBjgf56V5N4N8I6lp3xNhg0+xl/cEyMucDaQcgnsOa9CDTvJOzW56MYyu5KVrPVdv67noE9vLb3Kwak6lY8IACSp+h/EVytxI1zFcRxui3zSBVaSPctugYgnaeCTgetdP4g04XVibK31S2e7jGSqs2zhiSA/c1zEF/wD2W91DqsUpntmZZ5VYFUIOcH1xx0/Wt6equtzsnJ2Slsdz4K05o1jllljhhyymWY7RI55woH547U5BI2rT2+87IptrgLngZ5pIXSXw/pjMwHmEzWjkgcbvmDA+p5B/CtC4sbjSIZr66urCG2uSJHeWdTu6nr9SelYOWrbIckupw2o3lj4G1aWfTbA3Op3UZlW/uH3GJWJ/1agDHQjNdh4c123hsLfWBpzf23IhVA33FLZwxH97GPzrO1Wz0mXS1vb1Yry7ChYmEm5QgyTwOozmuY0vxDL9sigC4lWQTQtjqR2x36VpyKpHYmMFdrv+JY8C6teeKb7WzqziGSKVkSRx8zSHd8vP0/Wn+KtK1NdKu7jSQ5nspY9+0/MAemPXpXoGnaXZ65q8OsrPM0ESl5bdlBAIyTjgcfgTXB6X4rvdO+KWq2V8ImsrnMbRSIQGjYjaw9RznNRGbbfLuuhUqnLHkvd9fLyOk8KC+X4dXWo63BtvbqQ29vGVKEKQMtj1IzWFqfii28NXbrJA81usSQ3EsZGY1fhiPU12fjD7Ra39zbAsLS2tt1pHnghgCTnvyMfQV5paaXpupXMdxf3zLZSyKtxCDk4U5Occ06VpXlLZkwjKcHJPfU9M1iWKLwwLLR5PtFvcW6yFl4UggfP/ACrH8Jabbz3dm0ny3c8jLDIF4DRgHn9OKuatdWVtYXk6bLeyMW2NC3SJMHj9K5/wv4jXV0nXSJvkUHcCozkjG5c8j04xURi+R2KjdQavqzU+Gs+ow6re2GpLNcWN2zIUIymwg5YfkPzrufiJp1vc/D640wERCKIFF6lVHA/Hmob/AFmLw7DobW0cfkzWpG7347/jXPXHjbTo79bjW53jhmIjbOAq7uCcdxxWElKrNVEv6RyKhOb9ql7q1PJ9Pit9Jgm1i/kjWPaLUCNCvPBJx3wK7fS7lLvR3mguZWtWbGFc7MerDoaj8cfDaPU7qxtNOmD2F8++zuIn+T5jk54weDn6Ua3Lofw1ks9CvLt7u+nBdoo1G1ExjLZ6ZwMDrXY6salrbs6FWgkkrWZvXSxaj4egjdxa3MSukMr/AOrmXIyp9GHBq38K/EunT65ceFra6jvCLYySyRjKbwQCAe/B5+lclpnjTTrwy+G2jlCXIElsJ1Aw3+ywPGRnr/8AWrO8OeFLPw1rJ1fT9TvGvkDNbwhAmMjo/PP0HWspUrxlCXyIq81SDpra5293Hf6VdXGm6gULICytH91lPcfn+FetWCCDSbeMJuVYVAVe/FeffEOKX7fp91NGAJoOR/dYYyP1r0awYNY2zDoY1I/KuDES5oRkcWLlzUoS7nh9zqj+BviPe6ZM6lJ7d7iyO7C7WB+VvcMPyryPwdrfiDVPFLi9uZ2Bd5JYmH7tepPHavffjloDXttp2qwqBPbXCAvwNsWG3c++a5K2aKG0CwRxB2bcXA5YdufT1/Cu7DzUoKfXb7jtwz9pFVL6mtYq1vuRlVVaMBsdQeSB+dMe1kkjM8KgwpxJ0yufb9Kltbq2lntZHcqFGJVA28gcEepPeuY8R+IZhfR6dpZVGGW3uPfgZH1qlFydkdSk73OnEcchiRfMYOm2Td0Gc4xjn/8AVVeCTyodRt0VPs7jhduCpyO34ZrN8K+JptT1SG11Nbf7RkBJlGFbrgt7ZB/Ouv0mxVvE10syo4gYq3GBwOP51E/cupEyqKKd/U09A0v+xPD9xcMEF7IpdgxwDxkL/n1pILaW7gjuZNRiV5lEjL5fQkZxVjxqjxaLDKrL5TOqlfXPHWs9tJgkYuJEXcc7d5GPbrXFKba5+77HFB8y55PVkMUSTMq2scSDbhI1UNsXpz6VaFjMVlniLkxA5xjBHriuv0uxtrG0UQqvzDJJA61nalqltZX0VvM64mcqwVhuH+97UlVcnaKMlWcnaKOUnlCwtNcndGOI1Gev09+K1YWe20+3aNMB48kuOQTjFZdwjajqocqpt4nIQKvy+3vwK1kDySCLI8iJNvyg5z06EVtLoaz1SucvqMNxql6FhtWuFRjuYNy2OMH86taW0VrMglMypbsW2QQZC++7nJ60mi3Z0zVZ0YStHJuO9FPDcf0FbzSveXkSowMXU4PQf5NXKTXuvY1nKSXL0OdTxLJFrcrSWrLBLjccHJHryPaujm8R6fbqk5kWW2J+b1A9MGkvLVBbObxlKHgKV7euR0NcN8SY57nwkZNJglYxHO1Od/bpRGMKrStYz5adS2h0+n6tp8dxKbe4CLO7AQ/dJXHHPfnFYmrWFwge48yUvnDqFyMHkdK84+G/iHWrm7ktbrT4zFHkNK8OGjPuSOK9bvbm4Gms0FxEjFcFo0Gc/Q5H5itZRdKWhtH3XePXuec/FQ+IrrwnZ2WkGQWolaK5iQ4DA8qT/wCPVp/Dnwyuh+HIX1STdcKCyxoeBnpn157U3xfqWoWulJNaosxDBWK5BUn2/rWhDeyS6dBNcKYmSMLtPAVvc/jmtWnypI2VNXbW5v6dqzJNMt1DviZhjDYwpGKj8aeDfsTR6noiIWjxOVzzjP8ACT+HGawrS5a4sXeNopYRHvEiSBieecjqD17V1Wj621pbx206CV48FN5JHXjr+ArCSlCXND7iK1JxanT+aC8tbqS3W+ktfIujtlVHGFGRz/OqXwvsY5PGcl0EBMMDAZ52FiD+fJFdBqmrPe27Gezb7UgyU3ZQAAnOfw/Ss34KA3v9p3+DHtm8o46OR7+3Ss5SkqMmznnNqhPm0PUXjWQDcASpyDjoa+YPEfhEQ/EXWr64lCubtzGCueGG7dj6V9RD9K8J8fXIXxPqTbSuJtvmFsDoBj2rPASak0jDK9ajXkM8J6zqei6vZyLMZdMeM+ZEgyBzyxArsdZu7PTPEMesKwm0+/gNrcugyY/9rjocdRXjmi+IWubtla08hBIyLMHO9T9B+ANeiaXrlkulXFrq1tO3mAZKEMDg9V9DyK7K1L3uax2VKanL2iW+jPMv7K8Tw+PZrSJIX0FCQly5VY5I+oYN3PTgVveKtJgvdYvbu3myZkVHXHEjBQC3IzgnNdZcajplppg+xaRdJKTiOeUggjnqM/Ln8adpOrXNxq1lbztaMkrKxWJAW6jqemelUpy+K2xrzTacpXe+4tp4GK6PZvd36W7ohSOGVgvAAxjnPNeYar4R1K/8X/YNStpYbaMgb9m75OuUHcnn9M1L8VNM1LxL4wv5I7p0XzmULITtWMHAxjtxXqnhOyl8PfC5pbm4kudUePyIJZCSwXPCqT0HJpc86UU27t/qZOVVJc3W34nJ65op02xexhtGs7ZojHGCxZlyDncf72Dkj6VnW+i3s8dreSW+yOyQrG+7duJ6nP0rqmnvZtDNlfIgSSUyRF+ZGYgjP096zfiLqw0PwCyW8vlzxMm1B1K5wW/MD9KqM5aRNptU7c3Qv+EtSaI3thLDN9lnUtKYHw0eOMj1HtUPiDRrLXtfsVaAS3NhEFF5CSpdckgHHXr0rj/A2tXosVu5UzLcQPFvBILZOM49MDNeoaHYOZNPtkTyRdAvvP8AdHGfepqL2cnIJqKvNrR/5EvxGOn6d4Wg1zUJXh8xRbyMnzfKQcAA9+K8u+Fei+GrzVJLk6691LHlxCImj2p3Lnkdx+temfHnQLvWfA9vpWkRF7kTAqmQFCj+I88D61z/AIZ8P2Xgnw4LGMWst5HEn2lyA/m3UgOAfVVHQdM81lQn+6snqzhozlKKS/rUPEFpp99ZPGLsTI5kWdIwcRowAG3PXp+grk/hlYJ4d1O7milaWQZI/djG0ZHI+probK0vFt7641ORY5JPlA3Alv8AgI6AevGKTT4YonlFvBL9plXYwTk59cd+a6Iu0XE9KdNJWvex2vjXw/e3Oh6JNaxnZa2+2VOrDgHOOh6etcDqvhyHVNEaC4uYxdSw7xHtxgE8DPZsAH0ra0Xx74t0e8TTNSsbe/tUO1Zpg0chXtk9z06j/Gp9VtLgyzXs6JH5snMI+9GMZGQPu4rGmpw92W3Qww1SrGHsp7fmP8NMdK8M+F9Jtg97cwTys6s3Rxnv2AzXNar4LsdW1mfxBdwvetHuafZMWxn7rY4O0HHStTwpcxWV2Z7gExpJLG2PvbXQjI/E10Gm6DqOl6dbarNLZWpKbJY5H2q6Hgg9RyDnHb1pyfs5N9X+pPJCCd9O33s84g8K2X9oxXeoXKhYAJE8sYfPYZz2611Wqz3R8p8kW0xZooIk4XHUlv7xPOK5rWZoNTEkekzGW3jn2sFG4lAfu9f8iq+jtcW2o+XFaz6faKhaWKVg0bufulRyAc+ldDi5as091SWl0etX91JrXgK3urpWNzaTGFmYctxjP6jNdh4MvBeeHLNt4Z408p/Yjj+WK4QsbPwFHK0/nJe3COHA+6ccr+la8q3Pha6jv7BfN065RTLDnvgcg+teZUgpJxXd2PPq01OHs493b/I67xFpy6to11ZuP9ahXpXmHhnRBHp72N3CSIZMqxY7wecj6Hg16zYXcN/Zw3Vs++GVdymuV1yMW+pXMltb5YJ5hdDg59P0rKhUcbwMcJUlG9M5jV9IxBANLgM0rpvPOc+3PTBFcfq3hi4W5c6nGUnJBG09Ow5Br1TSr22s4LUXqSK8QZmY8gZOc++SRUup+eb+K4tl3lY8spbgZxz+vT2rpjXlB2O2GJlB8rWh45pOgQwTbrYsZMj52YnHp9Dk17D4e0sR2TooLSv80zynJc4HT2+tV30ixthFdXEAGGaczBgoB68ippdTlGj25tpP9dIEDk4YAgmprVXVSsRXrOskoLQg8bzQyabDGjH7PCyuxH6D681wzatqMTGOK+j8tDtXJGcDp2re+IE8FvpC7mPzEyHn+FR1xXjT+NLfe2LVyM8YYVvhaV4bXOjCwiqfvH0LqPiC3t/3dlMJAF56t+VcS8k0F9LdXsDTITgy5B2k9Pl9OenvWJr1l4g1FrTfqNra27zpkQRsv8WOo7f4Vq+JtYt9J8TjS7YJLKyrt2uGIJAzkVMKSj7sdWzOlBR91LVm7cahiEIirHFu3F8bQP8AaOOe9WHmkmvXlFwTFs2Ocbd3oR7VxkOqXGreI4rCK2jjtrPM02BhTjjJPfk9a355ppkm06JM3E7JtZTlV/H3/rSdPl0Dks7F12WDUNPaDakhnywCg5HJP8qsaVdRF4toLGRyJBjPcgj17V5FL4ovZ/iFZ6dYmQxW0zRsM53BQQ2T9BmvVdACQW5mLSFowXIHbk5+nenVpci1FOK5bnGeIPFraL4s1OyubeeRbny5YueM4wRn07VpeGdW1C7guZL7T0tLMHEcTsWLZ7njitCPzNW1F7nUtMjKwylkO35liByPx/xp99fqHEEKKI+V54z3zmrbTXKlqXCL0jYkSdUt5SscCiT5WcD5iPf+VYGvTvZxiZnBypLKCccZ4/Sm3N0GKxD5U2ZBI+8fY/Wia4jlsxY3e0YOVCgbkx1J/OrjGzudUKfI7s4fQ/Fmra9r8dqlrGlryNsaY2+5Pfmus8R2sd1aS6eshBmgZdw4IY9P1wPwqOz0/wCzSFrKOOFc8bAQWJ79OTj+VdhLp+mzeHnmu7t3vFBEe0jG7HH4Yx6VU5qLTRbtTS5tbnzr4Nt9SsvE9vCRIH3+W8fPI6H6ivdHuBBK3mKpJCgnGSpyCcfrXMza7pVpqVpYLKX1eST5lCBfL74JPUn/AArp3XzNZt/NjMQCLMygg8EcHFOo77kpKK5U9DpHeGe4uTuUQiPCuq4B3Dn/ABH41N8DpCmg6lZMu1ra+fnH3g3IP+fSqxEAlhTzMW00RLhl+ZWUcfhnpV/4OOHsNV+QowucsPfk5riq/wAKXyPOxCXsJP0PQnYIjMxwoGSfSvItYg0vxrNJEJPsOpuCYJ2+VZx2D++OnevTPEkUk2gajHCpaRrdwoHU/KeP6V4xJPtuf7QgWCW2kkQJA67sbF24YenOKywkLpyW5ll0G+acXaS2Ofu/B8+jaiZL60ktZS2BISTExI6hvu/1qV4xauGuSc9dqkNn8K7mXX7ua4stMBgtra9QOsboXB3dA2Twp6e1R6tf6YNDRU0mxh1ESfZ0hjiDuz4wzYHIA/nXeqs9FJHqLEVYq0o79vzOQ0Q3uqxvsAiIBC+aQuW7dfb+lb9rYR6ZYSXN3PF5vOUiZWJbsM4x+RrOS0Om281zrCv5sUbTTQCRFKj3HYZI7VwEniWbVZpLWyjliaTPk7WxuGP4R2/h/AmtFH2j02FKd1a506X9nNqP2aORZbpydyrxg9x7mu11LVZo9Ghs2+bLKq7h93A6/wAq8+8FaBdy6zDfzQtEFH7qEELlwMFjz16//Xr0G88rTNa02HU1YIE82QggKN3p7AHrU1eXmSWonJO3N01M7xJu0uyQXVxbW9xNEH3FC0jjPc4JH6Cue8Q6I3iXTba3e4QOiksSvQdT25Pt61P8ZNX0+3+IUOmlr26vpUVjtKrFEGxsHTJ/OugW0gs/C0WpPNIJ7lmBHYDtj6c5qYS5YRl1Y41Kc6UUt3v/AJF74deG7HTNEiurhPOz8ltEx/hHGT+IP61talLJeXlwU/4+I4xtbJAAPYDtVvQVVdI0aOVdsIhBDg53BmyT061Bd2dvpeuz2wv2lu5oTIsDR4AXJ53Z9RXK58023ucanzTbe/QZZ+IZLPSbW1s4U1C+nT948kgRM45XJ5YjPQV5H8QtH1DxXdPcefHbOXKSwIhIUgdce2MfnXS6ZZS3mvWFndjbDbyeSW4wqKxc5zx3Ncn4sW61SZ7uzmKB53BRRgEEk9v89K6qNNQnpudMcPCn5trU0fD2jtoGgW9is8c6oxeQqOckDOTjp6fjVDW9YvbHVp7eziCPCgkDyHa/PIK89Rx/9ar3w3DJFcy3vzQ2hefygeMqBtU/UkVtWPzodR1CKK6sDIYjDJGsgdyM45Hy/UVq3yyd9S0m4e7pb+rFT4f+N9a11L7SfGIM+UW50+98sBWZDuC5H94f4d67/wAMX+n6de6vFqj757qUzwPs3B4yCcr79fyrlvsNmbtf7R8yGI5JitEA2DsB6dhV68s9K0a1tX0+XUZXlYMss+0qgPUZA/pXNOMZaJWv2Ob2MUuTW0g8YQWQQ3kLrDbSkOdoGSP8c+ted6/Pd64I4ItVkWAD/UsGAUjjqDg/lXSeLWurrQmjklRbpmbiXjOCAB+lc/YaZPujadPkhPyOxBZiw5zjjHeuijHljds6YwatB6l7wz4fh0qw8pmMizn94zt8xODyB254rRuLHzoYV8p5J45BsjwcsexxVmzmufstwLa2VpI42SNhHvCvz17cGsPRrvXZtRkhvVnkO3J/dgbTjHBFPVtu49na2h20MrSeDH0m9XbPaSfaYiP+Wi7vmHswyfwNeiBY9R8IWzphl8hGH1Awf61xPgnw5M8v2y+ha1sYjuInQ7pTgr0PQfMaZ4U8V2tpJNoNxdQvbs7pDJG4Ypzjaw6j8a8+rHnvybp3OCvBTl+6d+V3+/c6X4cSNEmoWTsdqSeZGpPQHrj2zj866bVYPtFu0cYHmnkHjtXBWsDQXPnRym3ZH27lzlSOOfX+VdjoN81zNdQ3GftcRGSRjevY/wD6qwrR97nRzYqm1N1YmC6FR5c4IxkB1XrzTbW7/sxri4ucyGMfu4wOXHQda6q802GdH38KQSR2rghfWtpFM+xmtmJCMOTkEjoOoyKqDVRMulJVU0a6adNqllbyatdbIwzSRwKeEyeM4HOB61S02JrzxK1lgJb6egJIGc5HH4/4Vq+H7t55IYJ49pbLqd3J/wA4rIl32mv6nPGNqy7It+Tkkrkfyppu7j5FQ5ryj9xy3xAWPVb2+tFmVSITCuWwC3Of514w3hHxEjFRYuQpwCJlwf1r0X4m62YbtLjTY0gwvlsCM5wSMj35rjh411AAArKSO+etelQhNQVj0YxcYpHoGk+MNN13S/scKq/kHBxwAfXpmopvDtlL4w02+ub5l1GW2kuWiOSNv3VIP4etcf8ADnRj4XN9bahNCNRu1Bit2b5ig53Yxxn3rvpbyCazSSaAf2mhEfnHr5Q5AHtnn8Kza5XaOxPI5Jcqt3NiDyrWxmmSOBLhmHmTRgh5FHZ+cZzj2qjp4MWp+dI4ZpFLkgjYOeo+lFuWuPNgikMJcBp8kfvBwB+NV9akGnWsF5ekFHl8lUUDPPHTnofX0qEunchLlbT6lLQPDCaVqGp6tc+TJNcS+ZEMfdTB7+p6GupsLw3Burg2jROV2FYzkHjA+nWufbWg8QiijLMDh2k6H0/Suks3KxLcNIwcjbhOR37dqJ3est2KUOWOqLMl1MscUMrRRhUC7MZbj1rlY4t97kodpYhjuPArUaVri7kRYxtz8jZAJHqawtQ1ywhuUs0uoo3LZJZ/mceg9v8ACiEWtEaUo8ux518XNT1LQPF0FtZXMkSJAHQgD5iSTn0NdxpwafS7F7ot9saMNKSOVJXow/z3rZ17RNO8XX2m3+rWw8+1AUyqTggZK5H4dKfDCf3gChnQ7wBksMEknnrmtPaXik90VScldyZsQtaaHb2up3yi6uZUH2e2jyq7lBUuTjpj+dZN94nn1JZItQt4FI+aEQryh9R68Vf8fxCDw/Y6vCGnKLtj8tsAnHAx6fSvEvB/izUdU1v7FqSxlZVYgqgVo9ozjjtx3qaNNTXO9wpOnK0pat/gex694F0XxLaL4r09pTqVpAC44BmZV53DswGa5awv7l/F0NzMS1tcwICytnG3t7Hj9a3fhve3WleIZbVJBJp96mG83KqX7Y9znFTeIbU6Vqg017cLk+ZH5YBO3k5yOT3FEG4ydN69vQIx9lOVJu/Veg/xPiLW9LEb/K1qZVyAucMw5H61vfB+6jS91eyJPmMyyjI69Qf51ma/a/aJ9Iu9i4FpLEu7HB4I/DJp3wugl/4TG5kTcIBbncD0PI6fjWdRKVF/11MaqUsNJP8AqzPXmPbaWB69K8O1Xw+9hrNztZVgMjbdzEEjJI/n+le515F4p/0vxlPHPNIEgwERVzkden9a5cG2pNHDl03GUkuxy93qM9msMcqIJrclYZHQ7og2SMHuOcjIOO2K0tNFrp2mreiVmvZASZMZYhs/dJ6d+awdUWOa6KTZkidlJycEYHX8qbAsD+WbqSWOzgy7nPIVR91c9WPSvTcU0e06d15GmttBe2txZ2UEjrNERcyzPnK5yenQcDnvXjWn2WpDWbebRC8dw8myPb82wZ57dBxXpVx4802C2/suTTLKLT3cM0ilvOX0O7qze2MV0Pgi40P7JdaysRnmtQP3O376txkDvhsZ+vSnGbpxbaIxNNw/ibk2uoumaZcXF2q/bpoENras/wC9JAA8xgPu5wT+NbOmLc+KPhul/qEOzU7DzAJGTiSMAhh75U/niuSudWvftJk8xZG+YBXCuh5+6FI4Arunu5P+FO6h9jDQ3FnC6OiDJLA5PHoQTXPVTio97o5q8JQjCT3ujzTUtF067nttckuJ47m2ijjaNiWV3TOwhjyOCOK66a6UfDC4cZybtY1Tsuea8q8Nanda9FDCqSLHbA7zngt616AfMeKGyJMMDThlTbvUHAAOe5repDZN7HTGnF2tte52Pha7SUjRr8vBmNHgYDJUsoyv05B/E07XtAvTPDfGWR5LchYp0O4ccBSp5xXC+IftEWoLc/aJfNkJ3HPcfy4xXrHgPVzqugCe4d/MgXyZAFzyP4vc1yVU6S9pE5K8ZUEq0dnuchq9zFa72vIAGP70oyn94c9Pp0H41xUVxBbRrD5kRuHOVTdggdzt647V2vxDeJ7i1ng3y+XJ80cpz07HP06VwGvaI+sNZXVnm312xnCBgp/fREg7CB3U5IPofpXRRs4pvqdFNtU1USOrsLPyJZbmGNTbSIQQR9/PBx7g4qY2jTQR2jHyrbz/ADyirhi20gdOgxmutfTQ2hxQNbj7Vp6xxH5sZyAxOOnfvWRej7EwMgIBXgAg/QfnWSqcxlGt7TYzZ7SR4EMVzukLsGVyDu6Vl6x4t0i0gh0a+eF7iQkBkVsoenJ/D0qYFxdkOVtlwXy3XoTxiuC1DwZc6r4pbVri6WOz3DdgZclQMj/6/vW8IRb940kmddqVubuKF22shQKDnqOxI+lOsh9pkS1UESyYUbcYH+elbVhbQL4mtdKu4dsMwEO1SSUyvHPcjjms+OM6Zr8UgyxguVVgV6gMAcCkp30NefS3W10O1q6nttRhtdMubi1tLeEKqwzFckjJYgd8k1q+Blvde8U21zLOxeyQ+bcKFzIvG0N68+tYnju0itPF2orAR5XyuFx0LAEge2c13Xwht1s/D97dyBt80oY4HO0DjA+uaxqyUaPMt3+pni3GGEU4rVpfidh4i1ez0XS5bvUZfLiA2jAyzE9gO5r4+8X+ENQ0aZ9f8O6jJeWM0xZnX5ZY2JJw69vrXsfxTttW8V+JrU6e0h0TTzh3jIwX4LHBIyRwKteAbLzPDmu6bdoPPnxJCcg7tvGPUHOOD61GHj7Cnz31e68jz6FFUqfNLfQo/CHWptd0WZNRMjywD5mxkH68da7I3txpd7BdWWZg2FlDDgx9semDXM/C7UIbbxfq3h6SMR4G2Rcfx45/XIrq0gLXV5aXMbBYSdkqnqpNFa3tHppuaTcedxeqE8VeJ/tlneWWmNGJEQvId3IQcnj6V434V8dQ6l4ki0v7O6RPmFLh3zhudvy4457Zrr/EENp4ZabVNUmR5r2YIqxthWUg5H5Y6VEnhzTp5o9WjtLPT7txvhKkh5T2bGcAe5rSlGFOOmz/ADLpwUIcsdjs/D9y7XaR3MRNwkWJAhAG7OcjPb6VtW+l2s+mvJcMzSzMXGWznsPyFeM3l74s8MeJLC5lxc2lyMkNICQucZ3e3XvXX+PtW1a20e3bR5LZLxAXj6O7AjjJPTg1jUottcr3Mp0pOaUHuYniTQ5jfvJfQS26s7MhPGfUfj71if8ACNt/Bb5XsfMTkV2ng7/hI9b0ISeKnL3Lq5Cp5eDx8uQO9ZDC3ViPlGDjBU8fpXTTm17l9V2O2jVclZrVHmk+kX998T3vHhujaq5dLkAlHVVAUBhwecDFepaRbPNdJ5sWRCpeVJBjt+lcN4V0HVdDt73/AImaTiYbUjUkhfm5ZS3Q8dvWvRfC0k8cF7PqUxDXEZViRuGPXPY060tNBK8KbK5v18+RNPWEb0K446+uf6VXfQ5o0D6hdxSQb/NEvmb8E8H+v51zfi618STkN4ctG8mJg29Gwxwe4OM1xOq694tR5ItQeRFb5WRYwNo9MVcKTfwshtJ6HrGs+FYdRnsp7e52WkTBti85z7547VqT3qERoh/c252hScZwP1rkNG8YxiXw1pMcJBuObkyA59ice/Ndd4vtpNPvzbjZInl+YjopA5zxWTvdRkOKvPlZPHYjVrW9OmyxNNFHzCflYjOeAfpXgGraJqF347ubaOOQszKQSOADj/8AVXd+K9Vu7HTvPsyRPj5G/u8c/wD1vrW78LNSt/FF1aXepEvPbZ8yU/xbTkZ7mtFelFy3RrKPJdN6LU9I1bSodD+H8YedYPsqrPPLJ7D5s/hkV4d4U8eXGsa/qc9tBtsomIgdmYsV5xnnuO2K93+Llj/bHw61a1imERlh+8c+3+ArwLwVoS6DZLbIfNa4YtJI3C5XAwPzNYYP3oNy7nJguepq9rs7LS9dur6xgtL+CRBG25ECgr7evasnV9B0bRLm71vS3M1ysbSyxshGSQeB1xngGtO78PTa7qFjHBNPa6hOjXEEindFtUcAr+GO9c1pN5qj3kkV/FH9otyUGCFWYemOvT8K6YpXvF/I7Y8rdluZ3gPxrcajqEVpPBCl00q+VIhIA69R/WvSvjf4ig0G90qSYl5fKCyFB6nJ6+2T171x8vgaKC8tPFen20tvYI6u6ZHDc5AHHAIxXT/tQaS2r+DdJ1S227onDbNuCysuefyrKbi6sWvP7zlqVZKcXu9TZ0GZdXsUnWRZLUKrRDfwY2xnr/nitz4bL5Wv6nGyjeq7d30auC+EEhtPh3BcSFQ0ZG0yDODk/wCNdr8NnMuvzyqcqIyGPuT1/M1lWj7s0TWu6U30PUK8O8QzTaZ4q1h9NiDToSY8EYB/r34r3CvnfV9VGreLJ9WWUJDbzn5U67gHXafTrXPgVdy7HJlqblJeRzdr4h1e68SRwaraRqLl/JXEIAXjgjHGM459K6C8gjeA221ZdmSzLx0GOPas6x8bWGo7bJopWhimKwzKqKiyMD1zyR15roXW2m+xWZRbdQ+Lm7U7gQx/oK9OWnSx69GfK9DyvxhZ2seooHleJzFny0jDYUk9TkV2Pgu0th4dgktd6zAFvmPJIPPT2wa3dY8PaXfXaW9ift8uSofy9oUDjknpx36Ul3ax2QayspIpXihbDxHKl8dFIHP/ANeq9opRUUS3epz33OR1W2+1anMlwzLbwsskZPIKkgnj869D8JXJ074W3hmVna/nmigGc7UOQBk9TisPT9IiXTIFu4ka4wXyfmKg4O3+uPeum8W3CaZa+H9OjeNTZRs84AyFY4yD79azrS5+WHn+RzyhzSiu/wChymk6L9lnk+zBUFsvnNhsDnghscHqK0Lu8uZGL2xhNxH+8ARcL6H5elavhOSzv4L10ljmJjPlqOzE/dP+fSsPSUE2pXH27EbJ0Yrt+XjI/wA+lK9279DshKLk+YtajDLJo9tdXCt55bd05OeOK1fAOo3Gn6jIULJbMw3JnII7mon1CHUrKWG4hkeOVttqwXBVVIG4fh1x61X0XJ1uOGNjHu+VSCPX19xUP3otNES9+nKMloenah4dstW1RZriNwmBIVK4DnPOfWqmrat4f8MzRWtvFbi/ABROgQdMs3O0dff2rrZmMVu7qCdik4HU4HSvA/E9pK5XWZ8u12zNJJ2VyfuexAwMe1cOHj7Z2k9EeXgqbxU1CctEdN4hvtXW9a7u0eO0mYcwkPBjGFO4dePXFY3i7xbDYWdxPHGZPIiEcTY+WV89fwBP5VX8N3jJKtiZZDZXwMUkJ+YbyCAw9CDg1TvrZr60Sz3+WJCpDsu5UZWGGP5YNd8IJNJ9D0Z4d0vd7bGT4e1pb+3nupkTzNqSLIGLY3E9fToa63RYYZ47mWfd5McbujYIAfA49+lcl4d8LTeHFntrpleaVlb5VbadhOO3IOTzXpl7DFF4Wt7i1hSOe7Jhxt5LMMdPp3qq0op+71JnOXKubdl3w1pbT+InuZ3Zo0AlEhIGDgEAH2rF+In2Ea/Z6jYXME0MxHneU4cblI5479K3dXtpNd8Ea7p+jzvFqUcXlI0PDOUUfKB6HGPxr53+GWl6nDq00d5FPDbqrCWKQFMOPY+4rChHnk5t2t0OenKU63M+mlj1vWYTc+JJ7y5jWe3ZDKgVjlm28DA/ziunudUj0H4W28u4x+YNrNnB+ZiTj86868VSarpPhwanZLuZmEfEm9gO52jnGK53UPGes6v4YtrW+sVY22EC8JlWOAcdSOPTitPYuolbZP8AI3rLncU9o/odvrcttdeCormLIEDMCGHGCc5x2+venfDzUIl1PRBCY5ZkkMLAL1DgcZ7leT+NcX4X8Rf2pFLp11CYbiHKOgY4YCul0bT5tI1eyuNKyf3m8bz3wRirnC0XFmjfPScOmpt/E20k8OfEXR/EWmDBu2EFzHjO7GDvH6V1WsXi2OhXtyUcCSFpEcjOVI5z7jJNcFrmtX1/4va21nzfs1usZtT5fyklfnJbHXcpOCemMV6JqEcep6WbGUxy/a4vKwo6hlxkH1xXFLSEb9DhceSMeb+rHgV9FdeMfDFhqNjcTTxwagZJfN+XyR3XHQ9R09a9FutDvPEfii3t4cQxwWMSbs8EDJz+RqC/jt/ClpZ+FILIQQyYlDjli+cc+vIH51seHtS/s7U1vPstzcTrF5OE/hHU5Hr0rplN8vNFd7G8OZL2kfiRzX7SKyaf4e0HTraVVMa7XccHYAOo/CotJkd/hBBq8aj7ZLF9nEhbPKuQD9dox+Fcv8ULq78V6m9st1aJdsQGt2k+dQOdvtjrXovhHSrC48C6PoUM+7aC7sISAzAnJJPelZ06MVLvd/mZuLhy3e2/5j/gm+oLoN6t/KZAXAjLc445Arrm0aNmJYR5JyeR/wDE0yxktLJI7OGDy443MYCr/EPr9aeDKw3Lc3IB5A2muWo3Um5LS5jK6k2tD5r8c+INWk1kW+myPb2ikBSq4LFif88V7D4egS70YRs5dQec8598dK5LSriDWdCtYLy2iinhYuv7sFiwzgZPPeu38Im5ntZle38uygym7jrjnjv3z6V213pppY7arcFuSXNl9gFu9q8scXnEsWclSvc4zx+FRvqmnzX8VpdRF3nYiNzDwxAyQDWdN4s06/146BbTo9xHbsYWkxsaQA4BH1xxXP8Ah238YS+PLO48QaellYQ5PmxRARk47Fs/U4rNR0fNo0jJvT3ty4/hqG48SXWqCdbZmwkMaqcoOmRzx0xmuh1eYNi5vfMZ2jO1uudoxgdvrUzWNvLPdPFL96QHcrbsgnqD35zWV8VIp7XQ4RapIzGI7Np5Jyfz6dKalzzSZrBpzRmahbQ6lZxq9orLxwfm6+3QV0/wl0uy03Vo4be3WJpEkZkA5HQA9frXC+ALm/bQZE1fD3MjHCuoBVeRz6GvQvBuyx8ZQxuv2ctG0YRmBL98/jTr35JRNcQ+alJeXzLvxvuJrPwLfW+no3nzhWj2nleecD2x+teN/A3Tr7Vre4OqyTmPeWVpG5AHUjPvxXtfxwtwPB/9p7Wb7C4lYIDkqeDj05xXkXgjxNHJd2tvIzxyzwnaBjoTwB6mpw13Q905MGv3fNGVnqdwbu88O6klxDBKYLVlSBZNp3wsW3gHv0B9sV4r8QopbD4gy3KtLDtkWRMcBQDz/Kvf7/W7ey8PiTVBaiOLB8yU85z2H4GuV8TaPYeIfCUE5lMk99GXSZBkDDHP1zwce1aUZqMrtb6Gl3L4tyK68Spq/gvTLbTkxbGJnORzu3EEHt6n8a2Nc1Iap4H0S1EjSvAm643rkhs4Uc/X6V5TpPiKaDxXZaLCEi0lZRaRRhRuI6bieuSea3o9dik8QT6ZLOv2oPsK5wGwf6Y6VbopNeWpvCEZJd02/mz0DUYxZ+BLUuVNxqF1GuxF2gKo5wOw4FdD8KYj5+oSbfk+7kfUf4VQ1+K1uItOmd1M9ugRIVJGc98dj/jS/C7xBaweIdR8P3H7q7kAnhLH/WAdR9R6VyVLyoyscVZv2EvM9Tr5We0lj+KnjDSoId0a3El2sQOMjG44/A5/CvqW5EhhYQuqSEcFuleM2Emlal8UW161cpdurQOpU7XKoVBB75/DtWOCk48z8jlwPNFuceiOG0bwVYyapbyaWbqZCzTLCXAXfjg9M8eldPosNwJrmaSJ5oIJN1xtxuVcehPPFXp00+DwhYizuvK1ZSwniDYdWz8wZT0A/wAKg0W6ltZ5r21kW3BAhTc4w7HqDnrwK9Bzckz14u8HKBzXi+TWJdHun0a0nuZCdz/Zoy2yPsSFHNO8HeFPFlrodte3VlM63J/cRbcyAEZyw7Z9zXoPw01a9vPEtxaiKOG3K+bII1wCRwOO1dl4y8WWnhyKNGPm3suNkI64z1PtWNTEVIy9lGNzjrVqsKypwWpzng7wDcW94mo+I5YpZF+dLaPlVb1Y98VyvxCeO98TXyW4QxCMRkpjhj3z361sX2t6lrsZvNRnGlaGAWSMPia5xxhQOefyri2mSUXKv5VtuYGFFUsGwQCCeucZ5PrRSjNz55vX8jowlCpKbqTd3t5Il8KW0Gl3SRea0lxPwV27QoPNaXiaOS51aytrOOQySZDqOCRkd/THOazdMiSTxJDLFgW8W5jg5AyOBnvyRV0Tv9ouJpHdbjZtYj7x/vA/XFbS+LmOqpDkno+hX1nUzHHNscuLeIKzKMKFH8KDnAzyT1PWrPwhtdY1rXxeySqLK2Cvl0yuSc4XpnvWp4W8GSa8ReXStBpYOQuSTNgnPA5+leniXRvDNmsTS29pEBwpI3N+A5P4Vz1sRGMXTgryZ52MxMY/uqWrL2pXUVpaSPM6KCpxubA6f5/OvNLWeS0EgAimjm4mgmXdFIMYBx2YeveuqvfEml6vpV1FbNJKxAXaYyDycZAPpVXw3qWiT3DaVLZSW14QPlvUCtN9P8K5aSdOLvE5KCdKm3KLPOtYvv7NeJo9OtbQzyMgeBGGwjHTJxjBHNVtOtZpFWSK0NxGSQjMSAcde/NdZ4z0GL+07e282T7GHjSRy3+rVmJP+GfpXP8AjtgmuTWsaFY7YLFAgONiYGOnUHg1305qSSXU9fDy9s1GL3RFJ9tiFvb+a26QbcLngYycjtgfyrovFOsbZIoIFjFvbJsiA4UNjG4+/Oa5zSbqE+H9Ra6lC3Nuo+xvjLEsCGT3Uj16VPpWmyanplpPew+XmUJGxk5dR147gDvRJJu8ugThGNT950NDwxfy2Je6jlkDJ0Vs7XJ6sQOT1z2/pVKG1utS1Ka6juYJLiSUSBGQr5vcgcDnjoTk1g+LPHkdv4pHh2wiDW0iIjTJx87dPqOla9k1vZaJKsdyZNSknThAcQ7TwS3T/wDXRyte/bVk6T5qi0b0NP7PHbRXF0l3FLaTuA8KxOG3A8L8w4PXjJrL1zTLdTA+o6WIiQCFcbC6n26jpXS3HiAW8wmkto31DgBkOYw+Mb8Duc8VxviDUSNVmk1Ry9woXMRbLN0wOOgx1/KlT5rhRjOrKzX9f11OS8VSWXhnULfWorFYN/yBI12hwOp44/Guw+H+oXHifUluJrdrfTYRvAxgk9qrWVreeMbpNPkX7XCW3rE0eUhA6EZ4WvVND8Iw6DpqfbbxYbSFdzRooAPrub/CitVjCNpbk4iSwzcG1fsjk/EyCW88xYyzlgB23HFdxoulSxadZi5DFrcB98ZO4N6D2wf0rD07b4m8USTqgis4IysII5HTDY/xrcv9Ugj1J7K1mH2mKLzHOSCB0AH+e9clSTaUFucdacpJU1ugv9Dsda1O1uplbzbYliAvP689xx7Vy/xSvZkkh0LRGazuLiMs1zCmZBjhQPr61twava2CCfd/pBO5lzlmB7nPf2rKu9duLi5MkRRJjwrhQcUqcZXV9UiaVKSne10jkPAnw08P+GJU1DxfeC61Vm3LCzfc9yASc/XivU4LizvbHy7SNYLFchFXCj8B0FeXvZlNWLmUu8ijJY9W9zXY6M0d9EVuJFDxEZjQ4zgYwPyrWvFy96Tv/XY1q4dRXNczvGVje28trPpWoTi4zlkkfIK9hg9DTE1G+CKJoiZQPnOF5PetnW2EFqYkVfOkX5txzjHpWOsFiVBeRy56kORzRB3ik0VTtyq55x4EXX4fD2mXVvaRXU9uzbBOSp8n3+nJFdbf+O9Gs9KWyFz5d00eXhjB3AsOh6evWtDxLcQWNvb2duzGGYsMrngZAAwO5Oa5OP4fzN8Sb7V9QRG0h9kseDncu0DbgdwRjmt04S96aCbTSbR5hH4W16axa/sIp/tTSmVZNuMx+oOeue3ft3r2D4caN42vWGo+KdTd4tgCQvgkemQMAVtS606NJEdLa1SABYd4wJSRyFIz061p2+oJfWDwkpBdyxhFkY4VVPUmirUlJbfqTyu3NFE0xuRbWMJht44Y5NiyoTubqRkY+tRfE2CP+ybFiz7lbHK/Jn1z+dW3jWa2F1cBZCQoTavp3xXP/EsTanottDBIfswjKZBPDepH4n86xpq84lUVerFrocULvyIHa3UXd3kFoww+ck9OD0rsPC1vca54nhZ1UfZ8zzsvPQ4Ax615bouit4UuZdWuLppYYVLOFG0MM5xn1r0T4MeM4NV8SXwtbWZY2Qs5OM9Qcg+ldVdNQbiddecowbtaVj1L4g6nZ2mgS2t1HHO18DAIW43g9c+gxXlHiDwl4f8ADGr6db2l35N4ISyRMSwVjztB/PrXWeM8a8DqVtM6rbt5CW8ifMeeXHPuBXh91Nr+o+MLea8tZDbwzFC5B+7nG4n1xWOEpNR0du5xYak6cYtfM9M1ez0XxZay+G9dum0+TUEjlsZgflWZQRg+pOeh9fWofBxuPB+jr4W1aeG8uUkMdrJACVZGPAOe4IPQcVt6Hptiz6VNqlqtxG8mVZgCYmDLgkenFa89jo41t2msI7xiiSxzW4CtCwbJ4JHtRKUU+Xp+oVIpTbRw8WhafDrP2iWK3FyZMtMVyd3A615Z490+4s/iqr2EbOJGikXC8Z4BFfQl3pmmQwXO+Vg8n72OORCGHtWTqmiW0WoG6tLdkcQF1VyeG29vYHA+tawqpvU3541Lbox/DeqHU/E9xbyuXWGABck8nOM8fUVSeyEXxw0LZIyXCsnzDgNkc898jNXfhzos1hfm+1QJbST71jBOQwGc5xwAc8fStW50yN/ihoV+JWEcM6xhFHcjA59M0TklKSW1iJu6a8j1vxNeQafoF9d3WfKiiYkgcjjHHvzXingiY64l+yR2lpDZK01nMgCzvInIypPzA45r27xBpcWtaNd6dOSqToV3AZ2nsfzrxDW/DV/4RsbrUdT06K4lVWjhu7WYhFJBClkxnPJ5rhwjjyuN9TLLJUnTlTk7SdrGRbeJovEd3LfIEFxF/o8rFCu5h3x6+/tU01wEv47aRSV3YAI+YFjg4HqcVX0bWI5P3t1BEwSHYJYkCMz44ZsDk+/etrwdoV34l1WM+bNDHGS0tyi4IOMYB6Z5r0ZNRTb0SPVnD6tBup0O5+ENnts7/UHUgSyiJGPcL1/DJ/MGuU8fvFqPje4vJQzWlnGLZASQJZB82Mg5xzzj0r2PTdNt9N0uGwtFxbxLtAbkn6++a8b1nS7hb64inDbknLxtj5W4wc4+lcOHqKdWUzycHONbESqSZzV/dTsYpkEauylRkfKFHGFXsB/Wla3NxHDFGjtuGzah3Nk9QMVVNrra63bu1sIdIiDF7iZvlcEfwj610Gn30IurfTtMa3lupT+8KvsYg9gf4Rjjjnmu96LQ9uWJhBe4tg8E+G9O0O0uV1O4JtbeUAWytuaRz82C3oCe3cGtm61W1uwLOwIge4YK9w4AYLnoDxxxWHfvJFDcy8eRFP5RCcIjKPmA+metZ32+4iSMwvtV1wMdMZ/Ks+TmfMzCnhnVXtL/AOR634W8RWdhbvYXVxEY43byZI2D5BY4U4/izXnviKe61DVNRlkLNI8rZQgDaAcKPb5eabZ+Kb1rqK11Bku7YEYR1GfwYV3/AIX0O21EXbX1mJIWwY3c8hueB9PWsOWNBubRySgsDN1prVnnWqXsuj6bZm2la8u0TKpAd20sQApI6+vtmsubWHm1C3S7gMEoVVkVSSS45PP9a7bWLG2tLTXNNnmjj1ESrLFJMNokiA4UEcA/lzXIwaI94Q8ktvCkAEhbzBkgEZx6nnpXRCUWrnXhpU53nM9S8P6nC00VrdrC73Er28clw2TMg6r7kHj3xTPFHgi0nvop7WdLWJvlkjcbwMdCueg9uleVeMNPu7+fRLqO5jSytTNJbxI5L539T7ivWo9VsdU0OwjvpJGvEiTzHWNmJbbz7nsa5Z05U2pwe+55c4TpTVSDsnfYypPDOn6azS6xdfbEhUtFa2sOzPfBA/U/nWTrmreXGlmYBbuf9WgILxqexx04r0Xw5JpVzp4tLW8hu5TERLhhvweCCByPSuC8beCpdFtLzWrBxexwKZTbSKd2BzjIPPpU0qqc+Wo9SsPiIOras3focR/Z1oL1Lx7SNrlflM+OQvT+ZxUH9uWUerQab5c09zLJsk2jADfXqTXLeDfE93r32xLpQ08Y8xdq4XBPTA7ZrptB0KJLyPU5mY3kT/IMjCnsfcivSaUfiO5y9pFTh1Ojhmh0/XAZHIigbLiXjaeQMnPbj8q5SO3m8T+JZbLw3ENTnB/eTKcQxdfmZ+n4DrXS+IvBM3jfSRa6fqMMGuQTPLcxXC8zgnhg307V614C8MWXgfwnbafEYw0a7ricLgyOepP8hXHUxEaSutZdjjq4+dBtU/i2LfhfQrbw7pcVvGE8wIDPNjHmN659K4H4oeM7WOJ0EhGmW7DzpAuRK+eFHrWH8S/iR9k1dIZIbkaS5MbTQnIx/U57V3Fz4b0fxT8MFsrS5jktbqJZ4rtR/H1Df0xXNGHs2qtXqciXsZKpV1k/wK3hNGGmtcRQsUurdLmNthGQexP8J/CuZubGRdSvtYtpZle8PlIWfoFHIx2B65NdhdywaJ4Qhs7eTYRCsKhD97sT6n/69eVat4oilvJ4baNpfs6gFA3+rXPU981vRi5ybR00G5NzkaFvJM08zFHmKcseTtwc5J7DirFprMN5vitl3SAclSPl45PPXpXKahr9/Db3+n2c/lwahb+aFYKGkYfw7j27475rH8FLcJOl0ZP3SsVwOMEjGPpzXX7K6bZ2OXM9jtxI898okOXbAwx459fSum8O7ZNZs4V+6u9RMM4PHGc+uKxdKFvE8klxLBGYlKjepIZjxnjnjPatjwtGI55bpo5JFhX5G29WI9M/Suepswrv3GdE9ob/AMQQW26TylRjM/cLkfzPFdolnboiqvlAAYHyisnw3aJLaz3UsmZbpjyp+6oyAPbufxrQ2OvyqMgcAmQ5P6V5tSV3bseLVm5PlvseS2819cW1t5sUcU0QaMJJg7S2GJB9e1dEthcxW9vMkpW2kDGVVGCDj7uT7iqtjb3AmjhWFEEjNN5jjkKe+B+HFdLMqw2hiefJ24JUDH1rqqTs0kdlSdrJHD3ZuGiW3RnwGO3ODgE+4HauafxLY2/xE07RdRgkjhkVVRiQFZ+cAj0rpNQuUuUmRJFkvLZm84hhkY6Hn2rjPHXhEeJZ7TUElNtqVmoIG3maMHKnA6EV0wSas9Dd83J7p6xqmrLHcT2wSGWWMfKCQQB61yEOpv8AaIo5WLwjcypxgMc4OMfzrrtOuVeCOS5gTynRFEoGBnHIGOcVzGpWUdprwkbIt5WZVZVzwenXvnisaXLrFomioxbjY5bxdoX9qWNp9rnl8lmLMinuP4Saj0e5sfCOnTXFq4gURMHJQOZM8bT0681uT+WbY2m50iyNhPzMGAIyce/XjvXP+M/BWv61pcY02SzFlGR5hEvLdx0/GutSTXLJ6HZJx5fe3Oy+G17pfig3Qsb2a2YKrtghg5HZgRxzg4zVe7E0OsXIuIIRJHne6pgyZ7kD2rQ+Heg6L4M8DMsd3BLq0zb3dmGRJjACjrgD+tZuo6kyajJNJGbkMzMQ42luAF564zk1hBuU5W2OelJynJ2Nu0hVNAEgjdZoW/fKzDIBPpVDwzFjU9ZutcuFjQqZkBj3AAE846GqljrNtHrL6Vr8n2dry0aSBm+UF1OQPx5/KttNW0IaWlvfXC3hYeQAmJDyASQByOtJ3V1bciUmrruTQajaaxNbRLfLfQ7N6logjhz2wMcVYvF3pdSFuN4UgsflA64z057VTvfC8Hh+PTNR0ZyACGKz8nae/wBADW9dPaXEMLRRxxlmLyA4BY+p7Ed81m3HRw2MuZaOOxw3iK/m03QHuSm53xFEoX5WJbqfYAHpWddXUz+G7PU1d0uITudtvO5Gz8v5Vta9ANaikhs2hWOOUtHtI27gfmHvyP1q1aaHJF4Xa0ndX3KdwxwuSTwfTmuhSioq+9zdSs9ep33gTxNa+K/DdrqVpIpdlCzJnmOQdQRW3dW8N3A8F1Ek0LjDI65BHuK+U/D1/rfhDxo8mllhDI2JoT9wgdSfb/Ir6e8O6qdY0mK+aAwBwflLBunBxjtXBisM6L5o7M8rEYZ0nzLYwrz4eaFM5eGKa2z/AAQylU+mO34V02m2UGm2MNpaRrHFGuAqjiq9hrum3yqbe8iJL7AjHa27OMYPPWud1zx7YWmrf2ZpbxX98ELSIkg2xAHncfXn3rK1ar7juybV6zVOV36nZTP5cTvjO0E4Fc1bWtr4k065d2lSViYzIjbWX2yK4zXta1/VrqGK2uEtkRy5WHK4Uf3ieT34rqtG12OzQQSojySTnBiXaCuBhjz69TWvsJU43W5t9WnShdfEcf8AE34Tr4he0kstburW4VRGkTkujMBwc549+tct4G+B+raHqjatreoxSy23zxRWzsS7erEjgfnXv8d7ayxNJ58WI/vksBs+vpXO6v4he8Ig0OKW5QnDzRJlfoD0/Gqp4is1yomnUrSaj27nE3Wk3VnYahpktm9zFLMzRSKjMd/5fhWJB4T1WQENp92E6K3lNx+Ar2Kxu5bG3ze286KV3dNxHqDgn2/Wp77xDpdgqG8u0iLgEIwO7n1A5H41SxM1pGNzsjmFamnGEb3OC8HfDyWK7ivNYO1YyGSLPzMexPp/npXd6tqthodn5t1+6SJSEQDG7joPWoLrxRpUUEssdwk3lZBC54YDp0478151q2o2/jTV418zyrdchDJIFVCBk4PvjrUKM68uapokZJVcZU58RdRRSPiK71C8SBjbSNJHjayDcOOAGJBOB1ri7+O7k1S3gtISIVY71YnqDyOOvSob7S4pPGdtqGsXq2Gk2rn94gJ8wL0CAcmu8tLDTNSgub/QdeZ4lbzWiltyuCTng9uc16fu0rW/I9BVIQfKlZGRbx297ciCPzmeNHaMyHAIA3FVxyOM4rIu/HF3b2E406zlg0uP91PdbsyhS2Mj09+9dLLBJa3kV4YZzEpyJFB8s5H978etcfc+HLPU45olt5SkjeZLslKKhz1xnDflRHlfxGk4KavA6vUJ5NFvLLUNOaSGNQrQzAja6bQTg9MdiPrmvYhqVtqHhdL2THk3VtuwASOV5H868eljGl6dbW0RdImQ7dzZDdgcHj/9deo/DsCfwVZRSqPkDxEH/eP+NcOLS5VLszhzCK5IVGtVoeFeCvC2k6Vql/KLia4acOzEAIkUYyxX69vxr0LwppX/AAkdlPBamOKC3kG6VgSxOfuj04FWrfwA8es3MU08sGlk+a2xgd4zwCSMj6e2au+LNWm0TTrCx8M2ZgWUtHHMAODyMY6nJ7/StKlb2jSpvX8iqlaLXJQ3f3IuXer6P4W1F4hFI9yQd0hiy3A4UHrz+VYOoa3qfiVWDR/YbBTtZmJwT6/Xn8Ktw6dJp9qs+sr9q1N0wM8hT6AdO5q34pt/J8K2em2sbPPKwZghwy8ZJ9+e1ZR5E0933MoKClFrVvr+pk6VpOn33krdRo9tGSXiYFlkxnDdOp/wrrJrbTtEsY9P02KOLzWDBIcIg554HArG0DcujyRBHciIhS68EH09xzWjLMLVY0ZvMyAsYzjdjt/OlUu5WuKteU9Xscp4punju2QqVkI8uJXIIjHB6/jmvOvDfgW9l1DUksxFuaVpZJN/JjHUYPTk+vet3xvPdSQXEzK5kkcSA46KchmHp2H41D4BjvLWK+utVa6lRIv3MV0XVpGPGckZKjuPpXdTThTujqcUkorc1fE3hOxlksYNTvhiODzH8lRuiQKAAPr/AErn9I0+xto7fSYbqKEyS7YYpcAtzySexNeo6foFrrOm23k6fEqqFd5Txu55Vcf19K8L8eaFqUfi+7C2h2KwitzbnI3A4z7cn8KmjPnbg3qgpVE7q+qO9udLvLPV2t54cRoDGgQ7l5zjp1/+tXoOm6ZbQ6FLAsgklEJxtGCGI7g1y/w8tL2bSorO7eSV4pld7hmJLMF4HPod1ejahDHawxpbqouCu0E4BOB7VyYio78hjiq8pSUXuM8HTQSaNHDbyBnhysi9SpyeoreD4ABVsjjgVheG7UW007ruaSVVaZtvyl8nIH51v/N6D864qtud2PLrW53Y8rtri7uIhD5qefDAu94s8D0/D+lc9c6ndWoMjyiG3B2rK5A25bAz9Sa6BNS0rRNMFvbZu76fbJLIycA++OnsBXnvxssr/wAySO3gd1kjRrdFTAyO6juQO9enRXNLlaPYorV6el/I2jJHEJ9cudPS/kaJgksSr+9boACOp4/StHQ9WvbkTOdDksAyDY80wDe+9QCfzPavOvhYNX02BI9SEhtd2FtJFzx9PevUbm7/ALOjhNt5u51BiQvyAf4SMc+lXNa2sXUg7LTc1dOKz2jtdDdhAqEf6teccA5755qrrMd7faTvkREt4m8uSRWyFx3Hr161p6ZCbqANcpgyP80e3GcVRjaW3u2igLGGUbGXqrkk849a509bo54r3nbocVfPI2IcYCH70a4yPr9M1qW5vbfSmZphb2Up2lF+9JgHnnOK63WNIjs5rG2CKkl35iB04wAuSD+FXri20qCHzbqaIpaQlZYm6jjrg9T9K0ddNKyNXik0tDxbwldT3N/qAm/eW0Lbw7dMk44Nd94UsLd5WvtRieWGNwqhRnJ5yT+nFQ6KtrqMkk+m2bfZmLMqM3YYGfzJro2sLqxsYEPlYJGYCBtDEev4VVapzaLQqrV05drnN+N/DCeIvE9tqMcyW0VjAyxkJuMsmCQCe3pipZfs+jeGdIgs4401Ey/aJ5SozkHPJ9M9vQV1XiOH7J4dt4bFgblsH26c15t4vvYNMsmkuJdrKgIjHLHcOACfrSpN1El0Rnh0qiV3ojXOs3F/Lc3d5NJJcyx7AgyFjGc8DsK7OzstN1bQZ49NQw6h5BTJ5ZSR/ia8n8I6/ba5FOvlPDPbghlBBwCOCG/DH412dheTefbTM3lyPlVOABkHrkdB74oq07aLSxtWpJxXs9LCeGdFk0q2uLWZCPIzITg4Zj97n15yfrW887QGK2jjLxNxkc9un5YqFtZjN2Y9V8zLttXDDAwehxWgkHnkLChZR8yqGJIHespybd5HNNu95r/I43X7CFLqNmw8WxRICRkOe2fwro4tUv8Aw5p9vdzsH0nakbFQCsPOAT3+pqC5tLa4tp5JY3kYTAMo4Zj04H0/Wm6lf28Xg3XdJ1yQxQLZyNFLIMFxgjA981cnzJJq5VWXNBRtcp+I73UNF19rfw/iX7aqs8+3ed2chsDAB5rktN+HbaJqUutJcTAsHbyzhmZTwT6g5qX4F+IDrPg6OG+8y8u47sxLJuw0cYGck9+K9Z0y4W5ivZ/tImRh+6QqFMYK5I460SqSo+6l6+Yva8iUkv8AgnE6DDdC1voxvlRFzCcBTv6dep4NWtGjM10IzgsUAAznPBOf5Zq19qtYJHt4zBa3MsxDzuw4T6dvStHwZZRy6HLdwMokjnm8llJIPQD6jjpSnOycma1qloym1a5aks9F0TThd67LHuKk7HP3wewXq30rkrjxtf6jFBDp8cenwSS+SioNrEYzkenH4cjr28f8X3mr+JvjPcLLFcTx2lx5KxIpIVU9uevX8a6q61OSXWdPsdKsIZdWvrryIRNuUW6qACWHtjtzxW0MNZc09X+CMqUI2c6rv+hc+GvjPVfEHijULB5Zr1Ioy9tvlZRng4b1xzWz4i0i9b7VfXMiziSUrNMu7ETj+EgD7vTBxU0eiweCNe1Ce5SBpr+NJTNGu3a2759vPGah1PxMk17NawtFbacp2JPs2qxODgDoc++afxT5qa0NKUpKSnAqWA32nkatHA1njJk4D59FI6/Q1JBZEWszxQSR6asmVlk+Ukf7vU1l6/PJbxW76b5N/ahVB5I2gjuP6irMWu6Zps9vbXt0sSzxhzFLIASew/kMmrs2ro6JTbd0jC1bQNY13WYDb2E9zGybYiM7UGeeeld1pOnXGjeHLrTJrOa0l81C8kqfII+B94cYB/nWBbrqus+IpbOC4mitW2rb28UpAiOB6ew611lt4mk0u/8A7A16ePU9NkXymlf/AFig/wB498fnU1ZSaUV62MKiqX0V+tupyFpHqaa5EIllNzvHBOVZe+c8FcZrI8Sa6mjamYra3Msckknlln2KFHcEj/OKp/ETWtX8Ga7qel29nbPak7oJpo8nYw4IbIBxn8xTvBupWviLQYpNdFrczxkxqhiwBjpux1+taxX2nsdEq7rNcq6HT6NNF4jj0yIuILSVQYmYF2ySMqB+Jr3TTLG30nTYrW3G2GFfqT3JPvXkPgzTP7U8Z2r2sKRWFigeTy12rkLgAY9TzXrmtahHpunz3DkZRSQvcmvOxsuaShH7jysc5SnGl+HmeY+INdm1W9uLmJ3hsojhP4SwB7/jWzp9wYLldZ1ZM3jxeXaw4ICLnrk9zXNI1rK7S6jLHFp0bF2XH+sJOdv5nFbtxI13JbPC0cdpjfGOpHJJPP1rWUUkopaHXUhFJQS0/rQdbagZr2W4un5ifakRXADE9T+prBi8RzeKPGq6Vo6NNHbHMs/O1R0JGKy7q11HxX4jOk2G+2s4Y/390uT1J5+v+NeneC/Bdh4Ts1srF3YufMkkbhpG75I6jpxSqOFJXe9tEYV6kaT03OksbOC1tVihTapXn1P41weun7Lq8lr5aSBIPlRsgAHgkEemCa9DlkSKNpJGCIoyzMcACvIfF2uLKl/fRYzcnyI3K/chXgn2yc81y4ZOU2YYJSnNspzhbzR7i+8xUSNxCsa/eIPOT7dKs6atzbeFZ9aljW4a2JVN4yCDwSOMnHFc8tu9w63NpayxxyxAHLZVwoIJA9O2a3NDsdUvNEbTbG8byY13NExxucc7ATxyfXFd81ZbnrVoqME0+v4Hb3i39v8AD1V0mZxerATG4h2E+5U9K8r05bjUNZtYZ1C7wTJFITwT1Jz+demyePrOzv30/UIZTJEoDToNyFsZIIHQ9PzrI8NWUeu+ILnUp0KwF28tH49ev4Vz0pSpqUpLfW5yYapKhGcpxtfr6mz4f0iLT7J4I7oTI7lgY+oIJAPv24rK8S6u1rqSIgSW5JVFOCdvY8f/AF66XVLaw052nFx9nY4RY1x8xPbH19KyfDFvPceI5Zri1jTytxMgIy+T8vH4dayhJNub1Mac1rVlqdToBuBp6i7O+YsSx24x7d+nSr5hUknJ5rzPxp8TodA1s2OyAyxDJWZiC4Pp0/rU8PxRikiR/wCzHG5Qf9aP8Kj6vVn76W5hLCVpe/FbnPT2dkk+qvPuIbEcTpnBwPbgcg1S1jW4dUMUd2m5YU2o552DA/Ns55qaRSJgiwlWDK7oc8MeM/ofzrQ8K+El1G/E1yy+Ur7jGwIz/XB/Cu+8YLml0PWUqdNc83sSeFtFgsNNuPEU5Zo0Q+QrdORgMc/WmeHimqWEu5o5ZJWIhDk7lPXjt6nmrfjDXk1G8k0ewTNlakCZl4DsONo44Az/AJxV/QNM/sOwhGlzxXKKvzseSWPUCsnJ8vNLd7HPKcpLmnu9vQg3SaZYBbknfHyBu53dv5iobZ3CTebCXHlEOwPO7GeKi1G5M+qW88zKltbhpZN56nBwPzq9aq2p2JkgjPlYId8YBJ5IA+gxRsrsb91e91L89ykmjWUrSStLandEzHLOMYJyevFeCeLNd1jxd4xii095LS2LbZEUZ2hOrN6gCvbdQ0wahavYwXZjfH7kBsbeD/XFY3w70S2Gq3bSQeVqvlASkjoCOcr756+lXRlCnGUnuZxtCLkh/wANPFmh65eyaJ4duWMlrH8zyxbTs4BxnvnvW14oF6Nat9Lt23iG3a5y3WXLbSSfUV5L8NZtEtvi1eahpyvaG3ElveRMvyZLYyD25WvcdZWJvG+hyJJtWKCYNgZ3DAIH6VnVXs6unYzblCpzb6Mh0eaGeB57ohpYFMYjByeRjj/Gvlb4w69fP4vkgYMiDHXk+nH06V9a3UdvFdIZDE0j8qwPzIoOT9RXh/ivTNE17xLeTXNmJUWbzY2BK4+bof8AZPPFaYSS5mzbDxlPm9mHh+1tdI8OJZQW5W8mPmyT7su4OPlYDp0GBXaeH7R7+8stNtp5HtmxLIp4COBzz3wOPxrGisxeyCG1ixE53Ki5G3HTk8Y616P4J0trWG+uA8R1A4hUkYUHaCf58/Srr1FGLfU68TVjRpu25xXxB0640vXBIwV4Jh8hyQoPT8+K6LwZq8V7DbS297DLJBiOR4mBAzwVP0/wqv8AHt2t9BsJo9uTc7Tk852tjH6188fBufXtJ8YFLa0nuLKWRhcqGwABklvriphH21FN7nOpOth4Nruj6J8bO+nanZ3kC7rYzpvdM5R1ORn2I4rQ+Ix0278No0Ri84sJFTAOQ3BBHpzT5XhvNEeCMi4imG5AfvE5x+YqLXoxfSWqi3WFYDuuVKjd04x+Bz+dYx3jfoYr4oX+yZ/wf0uztI5xYQxW0QyZI1HDbuvH4Vp32qaZY332KOCe6N3LuXygNqKwxj9OK5rw+txpPjW5EEo+zm3cEHuOoYY64rsYo4fD/hE3kyrNdyRhlZuWycbeeo7GnVVp8z1vYdVJVL73tZLT+rFO1vdMmeUJY2ULI3KuoL4G7gg+/wDI1r6Fr0Vy0lva2qRyceVEPlXHAPIHTvXgPjHxveaZrYsYFjcqgeRpMsee3613nwt8Rxag8WpSqbdQXjdQuRwBV1cNaHMaVsPFxkt2VPENuui6tq8uXW/ursmXy22714Ktx7H9KxLnXNN0jX4rnVrxlukUSxuTmaNtpH59vpmvW/iLoI1HTDqWnr/p1uPMDJ1de/4gV43q3hbSvE2ppJDqN1HqhhGUIG2XIySpPfrwSM1rh6kakbv5mlCrGrR91arcyJvGN1rd5e297m7kuoWW1ugcmJ8ZH4cYqx8L9MuLnxpp41xZhpdkjXEiTtuDzhSflGeRkA49qzPBWjX2j+JJS9jutVjz5p5wy8bl7jJ6jtXqCWkttZx2yyW0d4p88IM5dduSCSMZxzjPtXRVaiuWOlxOPNGz0KvibU4dZ1i4uLeGNbVYvKAA27PfiuW8U+GNL8RT216LV4dsaKZLWUDzAFAIYEH5uDyMUtx8TNa8Ja0kdroenGydijKFO+Qem7ORjOcdOa9sv/Cmk6sbfVoy9lE8QeVIQqiRSM88cHHcVzyqewtdWXQmpXp05KE4+70OX+HNpa2HiJI1ZkRbYKu9+dw+Tk8Z4H61Ru/A093NqOrJeK1jKXmiO8EgDJ5NXvEQgttc87SSCkSqoCJxwMY9/WkgsNe1/S30u1uRb2LAgt5e3YDyfrWbk7+0Tte241OdP97GVrpXv2OzsNJ0fxJ4XsP7RtYNQheJWDTDec47E81Rb4d6IJovsUSWtgMl7WGJQrn13Y3A/j2rS8B+FofB2gJpdvdTXKCRpN8vGCx5AHYe1c1rfj210jxHLawzeYhU742ydrZwGB6joeK5IupKbjReh5dP2k5P2TO0tLTTvDumlLdFt7deSepY46k9zXmnifVbnX75ERDHAuVKD+IZ6+3+NWdU1WbWBHcTsWhKKyImQu5hgfpz+dXtN037OqzyBXcEfIRjJPT6VtTh7P356yO6jS9h+8nrJmJc6HHfNp2myQqdj73AY49c9egrF8S+JLxPGFl4O8P2sMhmX9/JjLIrdvbgV6BBBi7NzKo2IShTBGS3UZ9MfyqPwlpFpaXOo688MT3bsyxEDlUGcZPp/hV+1S1lrb8xzqNLm/q5oW1s2jtbadoq7nXDSnszc8t7dPwrrY1IRTLt3gckdK4XwV4r0nWNYuY7eVvPxnLjAPJz345BqH4g+LJo4vsOiMrO5IllHOwZxgf41yzpTnNQa1OSVGdaoqaXqyl8RfFUdy40TSnDO/zSOp4ODyuf51zjaReapo6QPG6AmOEBl3LIS3QH8c/nUUWkMtmlxIqmZ2+Uj7xzjI/+sa9D8Hf6dNH5ivHFYIqqrjaXfncxHseK621Qh7vQ9KfJhaS9n03OM1/QH0EWcclxBHMmXSSeQ+UEA5ToAOnT3FVba/S7Gq30cjQ2u9JYzBlU2gBcjnj0p/x507Wr7ykiVZLVjmJk4CjHIYn/ABrlLKxuLTwidJjuQguYwJH27t53ZIUdh2rSnedNSb1LpudSEZPVv/MtW99HqBlkhnEshJZn56k+vfp2rsLpm8O6FHcy3LCNog7KHxtIXOT+nSsDw94WSxsYxcIVQAPnpnHIroPGvhiTXfAs9nAxiuWCv8/3n9Ix07frSrSjdRT0FVqrRPYqeCpbfxbINZhf7ajPszLIcxMvIOOPyr1XQ7eW3sR9oLee7lm5zn0B/CuA+D3g658MaBFFPgyM5ldGHO48cYPYAD869P4yuQqscnA7/wCc1xYqa5uWOx5WJquWhwXi74baJ4j1tdR1BnDrwVUjnHIOeo6Yrbi8OaFDEkYtsBFCgZ6YrQ1C6FvHNKY2kMa48tVySfSq6T6wUUnTLcEjkGY5/lWaqVHFK+i8wUqjiry/Gxxfh/T3m1+C9ihIjiXdMzN8rHGAB75yfwo1C7bSPH899NdgoYdht1BxjGQOOnOPzrM+LdxZeE/Cgupp5RdRqFjhRiA8pPU/TBNeV/DnxHf6yL/UtYllnt4myRwW9/au6FP2i5+j0PQhy1Hdvoz3nwpBG0t/qVykT3FzNulRwDs54x+dM8T6hp8hgstOcC/NyiNHDwf89K4weJbjX9H8rQLaW2iilG+aTG4kk5II9Bj863PDOiW8GswShHFxBiR5HbJZu44qHT5W5yevYz9mk3Uk/kcn4yvpP+E/XQrZZJDEqNJs5JZuf5Gu98NXC+c4uSYrdd3yBhhj06Vi6TDCLnxB4iumR5rm4Kws2c7RwoB/p7U2znW2gEkxZsbRtAwAehJrWa5o8vb8+prrOHK+h1KRpeWwQIIJVl3s64yBnnH4dq8q+E3iDVLb4x+IIdbvHmikt3dWZeCqsNpHoMV6vfIktnA8u4ZxuI7A9zXMah4c03T/ABB/alq5a8fCFxhlWPjj/PpWdNxcZRfUwilNcvc5X4WeHL618d+KH17S5Le11Bzc2rt8pb5zwD9GGRXoNj5sOus8+5obQm3UnnAYZX+gq1qYuiouTOZIsLJaq2NwOMsWqvptzHeTa9ZLu3vCsyM4+8cYb64z+VEpud5MUU1Ft7B4x1qPTdOzGu6e7PkqynGcnGCfqcV5h4aupL6O/N2qmGykAukiAYOTyMP7ZAOK2PirZSyeFLHT7EzSzlnmDklVDZBA+vFU/hVodzomlXV5cXcLSMsjvDI2Ebj06sOB2rekowpX6ndh4+zhdbGl4blAne4txGbWHBe2aTLAZwWGevHJr1DwVc/aUuo4ZBJDDIHVyDzvGcZ/E14xZ6hcW1+j3scSlY2RgqbA2cncPevYfhYB/wAIvv53yTMzAnJHAA/QCscYrQuyc1hy0+fuch+0jdKPDNjagHzXuQVPpwa8t+G1rfaZrlrfzQOLTlZTn76kYI/WvWPirpr+J/EemWChltrZXdmBxubOMc+mKxb/AEiTRrNIC5e1ZxkHrjPHNXQsqSi92dGAqRp4VUnvL9Tf8PXEFinmx8RxQyXJj+8NwJIAPUjH64qfQJZfMa4mQ4YGSVTyQvv6HmsvRJJbqeD5WU26mMRoMlufbqTXT7oIjBbW/lxi5hcSO2d5bjAHPHfg1E9G13OKraLa3bOY8U6/p/hS+tdauyWtnZoMqCzZ6ZAzjv8Aoa9E0+S28Q+GElEaz2txHuhLoBkY+U47V5P8RtAj8S+D7fTY5lSdZQySMM7W5yeOxr0X4bmPS/DGl6K04uJ7WAqWQcAKcc+564rOvFezUlujlxKlyqS6f8E8r8SeA9M1O5gnvZhFeKAvlCXbKeTgMpHPT9a0LaGPTbGLTLC3fYkblQgOR6kk9zjv6VxPxZa61H4q3DW1y4WORIxg9B0yPoQa7S8Eos7abD7pVI3D7pIPOT+INdvvcseZ7nqUVzJSluz1zwg6yeHbNeSY12HPbHH/ANauF1LwNcafrhvNMs/tSGTfBtmCeUck4YHqAT2PtU3gnXHtdRg0yBt9s5UYYbSuRnIGfY/l716LcX9rbzxwzzLHJJ9xW43fSvOk50Kjt1PKqOrha0uT7X5Hzj4vi1/S71YmtZYgVPzRpvy3se2TzW/a29/dWFlJfxul0YPKllK4THTIPfC56V7kv2e7TcPKmTOM8NWcfDek/aRP9jQOOmCcfl0rb68mkpRsyo5hZ+8tTzzwv4Aj1jV4tc16JWt4ZDJa27Dqexb24Fegarpn9p30cMkhW0jUF4x3PbHp/wDXrTvLq3sYPMnkSNBwMnH5VkNq7JatNar9qCt+8KEYUnsTXNKrUqy5vuOd1ataftF6I0bbSbC2x5NrECBjJXJ/WriqqLhQFHtxXB33jG7VSkMIMhAPA6E9uvNZGs3/AIheBXuJzCr8bYzjb/jTWHnL4mUsHUm/flY7fxFr9vpsRijkVrth8qg5I9zXksvh/TLvVTdmCWS+mJBIbrkHOfxNNS3ma9O53d2OOCSxzW/azQaRq8dkU8tktzcSzNkkdguO3Jrsp0/YL3XqzuhRhQjyx1bNGbS0sIEur24j8hGAijwAu70960klM8RULhuWAYjkeuKyL4y+KBo6ac8i6VZSCSXYgYyyAYABPbrmr11JJGVtYkXLlmJkGduMEg8/Wsnd77mer0luSXs0l5pj+XEYv3e0c8lxjp+VNltS/hi7tDcGJZFB3Mu7J67eoxzipwotLDZcNiNXyvy4Ayf/AK9TxyRy7FgcuoPHcAg1DemhD0Vltc8btdEPgu1uGnu3aaVN8pUbRyc49+feui+G88XjO+uIJE8iKxiDEg5Mm4859eRWp8S4B4i1G10q1McMsYVZZzwqncDg/r+ddD4G8OR+HI5bHTUVlnyZrtj8zEdQB2HJxXTUr3pc0viZrOq40lbRmZbaHDF4zS5guZDY2aGVol5UsM5H8v1pCbHxPr95d2NxcWrWluXkeB9ocn3H616PBZQ29l9niX5NuMseT9T3rg4fDdtpmv3NjZHbHeguyl8YGOVPfBrlhWU73eqWn6mNOuqrbvql+HU5rx/djSNL0+0W/kaC7j8xkllzgjuB128j61k6EyXl5aLIMDap46j2rQ+JGg6bfeJLCR40ilRfLOJNy7R0JB6D2pPBtoW1W5EjhFjBCkYwMZ5rrg0qXN1PQpO1JyZ3CQNqkwtXZhDgM4PTA5H48VZMEl3eSbZAWts4H99u2PT0qhDfNBpmIdryT7dgU8k85z+HFZekJct4rj0i8GQU85nQEBWBDdR97niuTlbv5f0zj5G03e1v6Z3ujWbwQiW4JNzIoLjfkKfQVS8Y6wulaHcTM4gkYbI9zclz0x/P8K3SAoKSM20d68i+IcDeKfFFhpFrM5gsZRPc7FysY2kjJHfPb8axpR9pU97br6HHRXtJ80tkaugG715IlmubmJEKsxBJjfGMc+uccV1zSa7uOwWAXtln6V55p3ie/toHttDRXtLbPzuuWcZ5P5+lRH4h3QJDSoD3HpXROjOT91aHfUoVJy0SsR/tARRvplsjorK8mGDDPGP0rx6eCOw+Gc/2NfJ3XS52k89aKK7sL/DgbUkvq6fkz6Q8HWFrb+DLNYYI0WRAzgDqdo5qp4MiQX1+2MlmdTk54ABH86KK4E24zucib5JnN31xKWht92IYlZkQAAA+vv1qzexIulwkDlmIJ9RiiiuzZxO56ctjYFxLL4fj8x92QFOQOgIxWpbRp/Zun/IvzoN3HXrRRXLLTbuziqaLTuR6qobTYGOctPtPPUfMP5Csuwdo/HFhAh2xfvPlHT7h/wAB+VFFOPwS9GOPwv0ZX8dQRf2ZKNg5cN+O4D8OK4C4RVuLyNRhIsKgHGBmiiurD/AepgH+7/ryGXn724kkkJZ8pyT/ALIr2r4ZMf7GaPPyKEYD3I5oorPG/wAIyzf+Av67FDxAzDxTDg98fzFReKjtsJCMZVsDI7D/APUKKKxh9k5KX/Lv0OIS8uLbwL4lu7eZ4rlIHZJUOGU7ux7da5H4KajeX1jrS3l1NOIYiY/MctsO1+maKK7bLlk/66Dn/FZ6lYMZ9LheXDMbOIkkDrha8m+Ems6j/wALmSA3cphnnlWRCchgAfyooqIpezmKr8D/AK6HYePbeGPxlrMyRqJfNHzAc/dX/E1thQ/w50iRxud533E854/+sKKKH8EPl+R1L4aPy/Jmj4Ct4h4itJQg3+W3P/Aa0PihK8d9ZFGKlYZGGOx9aKK5nriF6f5nPPXGxv2/zPLvhrr+qweKZIIr+48iSQbo2bcpyfQ19KOcKSOuKKKWYpKasceYpc0WfIvxf8S6y+v3IbUZ9scpiQA4AU44xXrvgW8uJvB1uJZWYNbBz7kjkn1NFFdU0vYo7qiVrdrFbThvu2duWMm3PtVTUNXvovEVrbLPmDzguxkVhjPuKKKm15alS1budLbqq+JCVVQWnIOAB0P6Vf062hbxhrxaMMWiGd3P8J9aKK55uyfp+qOWr+n6nm/x31W/0PT/AA4NGupbAO+WFsfLycjrj6mu+0v/AE/S7We8/ezKAwZuucUUVo0vYxfW7/MNkmi347lf/hGdP+Yje2GxxnAqj4WJOkiZmYyyHLMSSScjmiiso/wfmEP4C9WcBrE0g1CVg7bmmIJz1yDXrnw0uJbnRMzuX2BAuew29qKK2xSXsUdGPS+r39Dpr5isLbSRlT0rzsXEses+ckjeajMisTkgc8c0UVx4dbnFgUnFnnniG8uJ9UaSaVnchss3PRsCug8OsWv/ACyfk8rJHr9aKK9KaSgj2KqtTt5HZ+SkN/uiXa3nZyD711GnIhu7hyi7vMK5x22j/GiivLqPQ8Ou/d+RB4quZrTQr6e3fZLHC7I2AcEZx/KvOfgVEk/gvUdQmBkvb24ka4mYktIR0yfxNFFKn/Dn8iYfw/mS+AQP7B1kADhCR+tdbBp1jJBG8llas7KGYmFckkfSiitMW2pu39aHTiG1N27/AKI//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_30_20969=[""].join("\n");
var outline_f20_30_20969=null;
var title_f20_30_20970="Onchocerciasis";
var content_f20_30_20970=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Onchocerciasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/30/20970/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/30/20970/contributors\">",
"     Michele E Murdoch, BSc, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/30/20970/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/30/20970/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/30/20970/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/30/20970/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/30/20970/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Onchocerciasis is caused by the filarial nematode, Onchocerca volvulus. It is also known as \"river blindness\" because the blackfly vector breeds near fast-flowing streams and rivers. The disease affects rural communities and is a major cause of blindness and skin disease in endemic areas with serious socio-economic consequences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of infected people worldwide was estimated in 2006 to be 37 million [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/1\">",
"     1",
"    </a>",
"    ]. More than 99 percent of cases occur in 27 countries in sub-Saharan Africa (",
"    <a class=\"graphic graphic_figure graphicRef57380 \" href=\"UTD.htm?28/15/28915\">",
"     figure 1",
"    </a>",
"    ). Overall, 120 million people live at risk of infection in endemic countries in Africa. Smaller foci of infection have been found in Yemen and Central and Southern America (Mexico, Guatemala, Ecuador, Colombia, Venezuela, and Brazil). Transmission has now been eliminated or interrupted in nine of the foci in the Americas, is suppressed in one Guatemalan focus, and is ongoing in two foci in Venezuela and one in Brazil (",
"    <a class=\"graphic graphic_figure graphicRef63640 \" href=\"UTD.htm?27/16/27908\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Onchocerciasis is the second-leading infectious cause of blindness worldwide: approximately 500,000 people are blind due to onchocerciasis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/2\">",
"     2",
"    </a>",
"    ]. The epidemiologic patterns of infection differ between savanna and forest regions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In West African savanna areas, ocular onchocerciasis is common; it particularly affects the anterior segment of the eye, though the posterior eye segment can also be affected. The risks of visual impairment increase, in part, as the prevalence and intensity of infection in a community rises [",
"      <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/3\">",
"       3",
"      </a>",
"      ]. The prevalence of infection can vary between villages and was historically as high as 80 to 100 percent by the age of 20 years in some areas, with blindness peaking at 40 to 50 years of age. Prior to control activities, hyperendemic regions were frequently depopulated because of high rates of blindness.",
"     </li>",
"     <li>",
"      In African forest areas with a comparable intensity of onchocerciasis as savanna areas, onchocercal skin disease predominates, with much less blindness. Furthermore, ocular lesions, when present, usually involve the posterior eye segment. A multi-country study in highly endemic forest communities found that itching affected 42 percent of the population aged &ge;20 years, and onchocercal skin lesions affected 28 percent of the population aged &ge;5 years. Strong associations were found between the prevalence of skin lesions and troublesome itching and onchocercal endemicity [",
"      <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/4\">",
"       4",
"      </a>",
"      ]. By extrapolation, it is estimated that 6 million people worldwide suffer from onchocercal skin disease [",
"      <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The different savanna and forest epidemiological patterns are thought to be due to the existence of two strains of O. volvulus. The higher propensity for ocular disease with the savanna strain has been correlated with higher quantities of Wolbachia DNA by PCR; Wolbachia are an endosymbiotic bacteria found in O. volvulus adults and microfilariae that are essential for the filarial worm&rsquo;s fertility and survival [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/6\">",
"     6",
"    </a>",
"    ]. Blindness from onchocerciasis is less common in Latin America; this may be related to transmission intensity, strain differences, genetic factors, or other causes.",
"   </p>",
"   <p>",
"    Black flies are not efficient vectors of disease; a minimum stay of 12 months in endemic areas is generally necessary to acquire infection. Thus, short-term travelers to endemic regions are unlikely to become infected, though medical staff treating returned travelers should be aware of this possibility [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LIFE CYCLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Humans are the only definitive host for O. volvulus, although there are a number of other onchocercal species that infect animals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/8\">",
"     8",
"    </a>",
"    ]. Humans are infected with O. volvulus via the bite of a blackfly of the Simulium genus. The black fly deposits infective third stage larvae into the human skin, which mature into adult parasites (macrofilariae) over the next 6 to 12 months. The adult females measure 20 to 80 cm in length; the adult males measure 3 to 5 cm. The females live in subcutaneous or deeper intramuscular tissues and are surrounded by a fibrous capsule. The males migrate between nodules to fertilize females. The number of female worms can range from 1 to 60 or more (",
"    <a class=\"graphic graphic_figure graphicRef66896 \" href=\"UTD.htm?42/55/43896\">",
"     figure 3",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    Approximately 10 to 12 months after initial infection (the prepatent period), the adult female worms begin to produce microfilariae. Offspring microfilariae, which typically measure 220 to 300 micron in length, migrate through subcutaneous tissues. Adult parasites can survive for up to 15 years, and each female can produce 1000 to 3000 microfilariae per day. The total microfilarial load in highly infected subjects is more than 100 million [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When an infected human is bitten by another blackfly, the vector takes up microfilariae. Over a period of one to three weeks, the filariae undergo maturation within the blackfly and develop into infective third stage larvae, thereby completing the life cycle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adult worms (macrofilariae) become encapsulated by fibrous tissue and form subcutaneous nodules, often overlying bony prominences. The microfilariae move through subcutaneous, dermal and ocular tissues, and the lymph system. They provoke a minimal immune response while alive; when they die, they incite a clinical inflammatory response.",
"   </p>",
"   <p>",
"    O. volvulus adults and microfilariae harbor endosymbiotic Wolbachia bacteria, which are essential for the filarial worm's fertility and survival. Release of Wolbachia-derived antigens from dying parasites can activate innate immune responses and are thought to play an essential role in the development of anterior segment onchocercal eye disease in an experimental murine model [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/10\">",
"     10",
"    </a>",
"    ]. Wolbachia bacteria mediate corneal pathology by activating Toll-like receptors on mammalian cells, which in turn stimulate recruitment and activation of neutrophils and macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/9,11-14\">",
"     9,11-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of posterior segment eye disease is less understood. Chorioretinal disease continues to progress despite elimination of the parasite from the eye, suggesting the involvement of an autoimmune phenomenon. Cross-reactivity has been found between O. volvulus antigen Ov39 and the antigen hr44 found in the retinal pigment epithelium. Hr44, however, is also found in the optic nerve and other ocular tissues. Transfer of Ov39-derived T cell lines, which proliferate in response to stimulation with hr44, have been shown to induce inflammation of the limbus, iris, and choroid in naive rats [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Corneal inflammation appears to occur in response to both Wolbachia and Onchocerca antigens, while dermatologic manifestations appear to occur in response to Onchocerca antigens alone, though the role of Wolbachia antigens has not been definitively excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a spectrum of immune response to infection; some infected individuals have a minimal immune response to parasite antigens, permitting proliferation of microfilariae in the absence of clinical symptoms, while others have a relatively robust and symptomatic immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/9\">",
"     9",
"    </a>",
"    ]. An immunogenetic basis for this clinical spectrum has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/17\">",
"     17",
"    </a>",
"    ], and differing isotypic antibody responses may play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/18\">",
"     18",
"    </a>",
"    ]. A single nucleotide polymorphism in the Fc&gamma;RIIa gene affects the binding to the different IgG subclasses and may influence the clinical outcome of onchocerciasis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/19\">",
"     19",
"    </a>",
"    ]. A genome-wide search for genetic determinants of resistance to O. volvulus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/20\">",
"     20",
"    </a>",
"    ] detected linkage between microfilarial load and chromosome 2p21-p14, though the decisive genetic variants have not been identified.",
"   </p>",
"   <p>",
"    Cellular immune responses are stronger in individuals with severe onchodermatitis than those with milder disease or uninfected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/21\">",
"     21",
"    </a>",
"    ]. T-helper (Th) 2-type responses to O. volvulus antigen, rather than Th1-type responses, were more prominent in a study of Ghanians exposed to O. volvulus transmission and, in skin-snip positive individuals, the levels of IL-5 and IL-13 decreased with increasing microfilarial density [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/22\">",
"     22",
"    </a>",
"    ]. Individuals with skin disease from this same area had more pronounced Th 2-type responses compared with individuals without skin lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/16\">",
"     16",
"    </a>",
"    ]. Subjects with a hyper-reactive form of skin disease (sowda) were significantly associated with a variant of the IL-13 gene which causes a brisk Th2-type immune response with high IgE levels and a resultant low microfilarial burden [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A state of hyporesponsiveness or partial tolerance of cell-mediated responses exists in asymptomatic persons with high microfilarial loads. Defects in T cell responses in human filarial infections have been linked with expression of the T cell-inhibiting receptor, CTLA-4 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/24\">",
"     24",
"    </a>",
"    ]. Furthermore, a subset of CD4+ T cells, T regulatory-1 (Tr1) cells, which are known to suppress immune responses, were demonstrated for the first time in a human infectious disease in onchocerciasis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/25\">",
"     25",
"    </a>",
"    ]. Tr1 cells produce high levels of IL-10 and are thought to counteract Th2-driven effector inflammatory responses in such individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/26\">",
"     26",
"    </a>",
"    ]. Elevated IgG",
"    <sub>",
"     4",
"    </sub>",
"    also acts as blocking antibody to inhibit IgE-mediated degranulation of effector cells and thus downregulates pathogenetic responses, and Tr1 cells have been shown to induce B cells to secrete IgG",
"    <sub>",
"     4",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prostaglandin (PG)E",
"    <sub>",
"     2",
"    </sub>",
"    , which has an important role in innate and adaptive immune responses, has been shown to be generated by O. volvulus parasites themselves [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, PGE",
"    <sub>",
"     2",
"    </sub>",
"    and transforming growth factor (TGF)-beta have been demonstrated histochemically in infiltrating host macrophages and plasma cells around O. volvulus in onchocercomas and TGF-beta was preferentially observed in the skin of infected individuals with &ldquo;generalized&rdquo; or hyporeactive onchocerciasis and to a lesser degree in patients with the hyperreactive form of onchocercal skin disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Downregulation of host immunity may be induced by O. volvulus surface molecules and by excretory-secretory products. The secretory omega-class glutathione transferase 3 from O. volvulus (OvGST3) has a protective role against intracellular and environmental reactive oxygen species. Significant IgG",
"    <sub>",
"     1",
"    </sub>",
"    and IgG",
"    <sub>",
"     4",
"    </sub>",
"    responses to recombinantly expressed",
"    <span class=\"nowrap\">",
"     OvGST3/5",
"    </span>",
"    were detected in sera from onchocerciasis patients, indicating exposure of this secreted protein to the host immune system [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cho-Ngwa and colleagues used molecular techniques to identify and characterize O. volvulus antigens that are possibly associated with the development of concomitant immunity. They studied IgG subclass and IgE specific responses to an O. volvulus cysteine proteinase inhibitor, onchocystatin (Ov-CPI-2), in putatively immune and infected individuals in a hyperendemic region in Cameroon and found that both groups had similar IgG",
"    <sub>",
"     3",
"    </sub>",
"    and IgE responses, but infected persons had higher IgG",
"    <sub>",
"     1",
"    </sub>",
"    and IgG",
"    <sub>",
"     4",
"    </sub>",
"    responses. In the infected group, IgG",
"    <sub>",
"     3",
"    </sub>",
"    levels increased significantly with age, while IgG",
"    <sub>",
"     1",
"    </sub>",
"    levels were high in infected individuals regardless of age. They concluded that anti-Ov-CPI-2 IgG",
"    <sub>",
"     1",
"     <span class=\"nowrap\">",
"     </span>",
"    </sub>",
"    and/or",
"    IgG",
"    <sub>",
"     3",
"    </sub>",
"    may be involved in protective immunity in the putative immune and infected persons and proposed Ov-CPI-2 as a possible target for an anti-L3 vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main clinical manifestations of onchocerciasis are ocular changes, pruritus, subcutaneous nodules, and onchocercal skin disease, in addition to some systemic features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H627283993\">",
"    <span class=\"h2\">",
"     Ocular onchocerciasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first ocular sign of infection is the presence of microfilariae in the eye in the absence of any other pathology detected by slit-lamp examination. Presence of microfilariae in the anterior chamber is associated with the subsequent development of anterior segment lesions and also progression of posterior eye lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/34\">",
"     34",
"    </a>",
"    ]. Additional manifestations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Punctate keratitis &mdash; Punctate keratitis is a relatively common acute, transient finding. White cell infiltrates form around dead microfilariae in the cornea, causing \"snowflake opacities,\" especially at the three and nine o'clock positions (",
"      <a class=\"graphic graphic_picture graphicRef81475 \" href=\"UTD.htm?33/19/34110\">",
"       picture 1",
"      </a>",
"      ). Punctate keratitis is reversible.",
"     </li>",
"     <li>",
"      Sclerosing keratitis &mdash; Sclerosing keratitis is chronic full thickness fibrovascular change of the cornea and occurs in the setting of longstanding infection, particularly in savanna regions. These changes start typically at the three and nine o'clock positions and can extend across the entire cornea (",
"      <a class=\"graphic graphic_picture graphicRef60874 \" href=\"UTD.htm?18/48/19206\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Uveitis &mdash; Uveitis in the setting of onchocerciasis typically presents with flare in the absence of an accompanying cell infiltrate.",
"     </li>",
"     <li>",
"      Optic atrophy &mdash; Optic atrophy is a relatively chronic finding; optic disc pallor can occur following an episode of optic neuritis.",
"     </li>",
"     <li>",
"      Onchochorioretinitis &mdash; Onchochorioretinitis is a common chronic finding. The first layer damaged is the retinal pigment epithelium, and this is most frequently found just temporal to the macula. Subsequently, more extensive loss of the retinal pigment epithelium occurs with retinal death and atrophy and loss of the underlying choroid. The end-stage Hissette-Ridley fundus appearance is named after the authors who made the first descriptions (",
"      <a class=\"graphic graphic_picture graphicRef72413 \" href=\"UTD.htm?20/19/20788\">",
"       picture 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       Fluorescein",
"      </a>",
"      angiography will detail chorioretinal lesions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Subcutaneous nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous nodules (\"onchocercomata\") are typically 0.5 to 3 cm in diameter; they usually contain one or two adult male and two or three adult female worms. The majority of nodules are deep (not palpable), and they do not usually cause significant symptoms. They typically appear over bony prominences and have an apparent predisposition for different anatomic sites depending upon the geographical area, reflecting the different vector biting habits in different regions. Infections acquired in Africa tend to cause nodules over the iliac crests and around the pelvic girdle; infections acquired in Latin America are more commonly associated with nodules on the head, neck, and upper extremities. It is often helpful to ask the patient if they know where any nodules are located, then stand behind the patient to palpate, following a set routine checking all preferred sites (eg, head and shoulder girdle first, then ribs, iliac crests, ischial tuberosities, sacrococcygeal region, trochanters, knees, and ankles).",
"   </p>",
"   <p>",
"    Ultrasonography can be useful for detection of deeper, nonpalpable nodules. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Ultrasonography'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H627284048\">",
"    <span class=\"h2\">",
"     Onchocercal skin disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized itching is often the first manifestation of infection and onchocerciasis should be considered as a possible diagnosis whenever a patient from an endemic area presents with itching, or has an itchy rash. Early dermatological signs due to onchocerciasis include intensely pruritic inflammatory papules, nodules, and plaques. Subsequent lymphadenopathy can develop, most commonly in the inguinal region. After prolonged enlargement and inflammation, the lymph nodes may become fibrotic, resulting in lymphatic obstruction and sometimes genital elephantiasis.",
"   </p>",
"   <p>",
"    Onchocercal skin disease may be classified as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute papular onchodermatitis &mdash; Acute papular onchodermatitis (APOD) manifests as small (1 to 3 mm diameter) scattered pruritic papules, vesicles, or pustules often across the shoulders or buttocks. It is common in children and young adults.",
"     </li>",
"     <li>",
"      Chronic papular onchodermatitis &mdash; Chronic papular onchodermatitis (CPOD) comprises larger (approximately 3 to 9 mm diameter), flat-topped pruritic papules, often symmetrically distributed over buttocks, waist, and shoulders. It is seen in children and adults and post-inflammatory hyperpigmentation is common.",
"     </li>",
"     <li>",
"      Lichenified onchodermatitis (Sowda) &mdash; Lichenified onchodermatitis (LOD) is a regular feature of onchocerciasis in some regions, particularly Yemen and Sudan, although it is seen less commonly elsewhere. Teenagers and young adult males typically manifest with hyperpigmented pruritic papules and plaques limited to one limb with associated edema and soft enlargement of the draining lymph nodes. It is also known as \"sowda\" (Arabic for black or dark).",
"     </li>",
"     <li>",
"      Skin atrophy &mdash; Skin atrophy manifests with loss of skin elasticity and excessive wrinkling of the skin around the buttocks, waist, and upper thighs in adults; the resulting skin has the appearance of tissue paper. In order to avoid confusion with senile atrophy of the skin, the term onchocercal atrophy is reserved for individuals aged less than 50 years old.",
"     </li>",
"     <li>",
"      Hanging groin &mdash; Hanging groin is atrophy affecting the skin of the groin and anterior thigh. Inguinal lymph nodes enlarge in a sling of atrophic skin on the medial thigh, then as the nodes shrink and become fibrotic, they leave redundant folds of loose skin.",
"     </li>",
"     <li>",
"      Depigmentation &mdash; Depigmentation (leopard skin) typically occurs on the anterior shins of elderly people. The inguinal regions and external genitalia may also be affected. Patches of complete pigment loss are seen with peri-follicular \"spots\" or islands of normally pigmented skin giving rise to the so-called \"leopard skin\" appearance. Atrophy and depigmentation are not usually itchy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H627284057\">",
"    <span class=\"h2\">",
"     Systemic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study in Malawi, generalized musculoskeletal complaints, backache, and joint pains were more frequent in infected than uninfected individuals. In addition, infected individuals weighed significantly less than uninfected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/38\">",
"     38",
"    </a>",
"    ]. Inguinal and femoral herniae are common.",
"   </p>",
"   <p>",
"    An association between onchocerciasis and epilepsy has been controversial. A systematic review and meta-analysis of eight studies noted that onchocerciasis is associated with epilepsy, with an average increase in epilepsy prevalence by 0.4 percent for each 10 percent increase in onchocerciasis prevalence [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/39\">",
"     39",
"    </a>",
"    ]. However, subsequent study in an endemic area of Tanzania revealed no difference in microfilarial density between individuals with or without epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from the Onchocerciasis Control Programme in 11 countries in West Africa have shown that mortality was significantly associated with increasing microfilarial load, but not with blindness per se (after controlling for other variables) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Travelers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Onchocerciasis among returned travellers from endemic areas is relatively rare; a minimum stay of 12 months in endemic areas is generally necessary to acquire infection. If infection does occur it tends to manifest with itching",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a subtle itchy papular rash, which is often concentrated on one limb. There may be accompanying limb edema [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/42\">",
"     42",
"    </a>",
"    ] and swelling may also occur without any rash. Other early manifestations include transient urticaria, arthralgia, and fever. The chronic skin changes and eye changes typically seen in long-term residents of endemic areas are generally absent. Symptoms develop in a median period of 18 months from the time of exposure (range: three months to three years) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/43,44\">",
"     43,44",
"    </a>",
"    ], so a detailed travel history is important. Persons who have spent many years in endemic areas (though grew up in a non-endemic area) may present with symptoms within shorter times of leaving endemic areas. Ocular signs are relatively rare in patients with imported onchocerciasis. When long-term residents of endemic areas migrate to non-endemic areas they may manifest more chronic skin and eye pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H627284066\">",
"    <span class=\"h2\">",
"     HIV coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV may affect the clinical presentation of onchocerciasis, as well as the immune response to infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/47,48\">",
"     47,48",
"    </a>",
"    ], although there does not appear to be an effect of HIV on onchocerciasis prevalence or vice versa [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/49\">",
"     49",
"    </a>",
"    ] or on response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/49\">",
"     49",
"    </a>",
"    ]. Consequently, one would not expect HIV-infected individuals to be at greater risk of infection. Among six individuals with HIV in a hyperendemic area of Uganda where onchocercal skin disease is common, the burden of skin disease was higher than among patients with onchocerciasis in the absence of HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/37,50\">",
"     37,50",
"    </a>",
"    ]. Inclusion of HIV-infected patients in mass treatment campaigns for onchocerciasis appears to be safe [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H627284074\">",
"    <span class=\"h1\">",
"     SOCIOECONOMIC AND PSYCHOSOCIAL ASPECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;High levels of blindness in African savanna regions resulted in desertion of affected villages with resettlement to less fertile areas, with serious adverse economic consequences. In a study in highly endemic areas of Guinea, blindness (and, to a lesser extent, visual impairment) were associated with substantial mobility and occupational impairments [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/52\">",
"     52",
"    </a>",
"    ]. Rates of celibacy, widowhood, and divorce were higher among patients with ocular onchocerciasis than uninfected individuals.",
"   </p>",
"   <p>",
"    Onchocercal skin disease is also a significant cause of stigma, disability, and diminished agricultural productivity throughout much of sub-Saharan Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. Even after 10 years of community treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    in southeast Nigeria, the most worrisome consequence of onchocerciasis for those with symptoms and signs was social seclusion or stigmatization (affecting 34 percent of individuals) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/56\">",
"     56",
"    </a>",
"    ]. Severe onchocercal skin disease in heads of households is associated with a higher school dropout rate among children, especially girls [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/57\">",
"     57",
"    </a>",
"    ]. It is estimated that 40 percent of the disability-adjusted life years (DALYS) lost from onchocerciasis occur as a result of blindness; 60 percent of DALYS lost occur as a result of skin disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of onchocerciasis is based on a history of compatible epidemiologic exposure, clinical manifestations as described above, and supportive laboratory evidence of infection. The clinical picture may be difficult to distinguish from loiasis and from infection due to Mansonella species. Non-specific laboratory findings in patients with onchocerciasis may include peripheral eosinophilia and hypergammaglobulinemia. However, eosinophil counts are normal in up to 30 percent of infected individuals from endemic areas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36263?source=see_link\">",
"     \"Loiasis (Loa loa infection)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Skin snips",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin snips are the gold standard for investigation of an individual patient. A skin snip may be performed with a corneoscleral punch or with a small needle and disposable razor blade (",
"    <a class=\"graphic graphic_picture graphicRef51397 \" href=\"UTD.htm?0/49/786\">",
"     picture 4",
"    </a>",
"    ). It should be a bloodless specimen from the level of the dermal papillae. The site of the skin snip is selected on the basis of the site that is likely to give the highest numbers of microfilariae. In Central America, the best site is over the scapula or iliac crest; in Africa, the pelvic girdle, buttocks, and external thigh; in Yemen, the lower calf. In early infections and in localized light infections, the site selected should be that in which the dermatitis is most marked.",
"   </p>",
"   <p>",
"    A minimum of two snips should be taken; the sensitivity of the test increases if more snips are taken. For investigation of a returned traveler, often a set of six snips are taken, one from over each scapula, each iliac crest, and each calf [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/59\">",
"     59",
"    </a>",
"    ]. The biopsy specimen should be incubated in saline for up to 24 hours before evaluating for presence of motile microfilariae. Hematoxylin and eosin staining of the specimen may be required for species identification, particularly in areas where other filarial species are also endemic. O. volvulus microfilariae characteristically have no sheath and no nuclei in their tails (",
"    <a class=\"graphic graphic_picture graphicRef70061 \" href=\"UTD.htm?6/42/6816\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It takes approximately 9 to 15 months for the worm to mature and release enough microfilariae to be detectable by skin snip. Skin snips are inadequate for detecting early or light infection, and they are often negative in expatriates and in patients with sowda. (See",
"    <a class=\"local\" href=\"#H627284048\">",
"     'Onchocercal skin disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Slit-lamp examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slit-lamp examination can be used to look for wriggling microfilariae within the anterior chamber of the eye. Prior to slit-lamp examination, patients should be asked to sit forward (with the head between the knees) for at least two minutes to improve the likelihood of visualization. Transparent live microfilariae may also be seen coiled in the cornea. Punctate keratitis represents dead microfilariae surrounded by an inflammatory infiltrate; it is easier to see than live organisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Mazzotti test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Mazzotti test should not be used as a routine diagnostic test; it may be considered if onchocerciasis is suspected in the absence of findings on skin snip or slit-lamp evaluation. It is contraindicated in heavily infected individuals (who will have positive skin snips) and individuals with optic nerve disease.",
"   </p>",
"   <p>",
"    The Mazzotti test consists of a 50 mg oral dose of diethylcarbamazine (DEC), which leads to microfilarial death and associated symptoms of worsening pruritus about 20 to 90 minutes later; an acute papular rash with edema, fever, cough and musculoskeletal symptoms may also occur. Symptoms generally reach a peak at about 24 hours and then subside over the next 48 to 72 hours. In some cases, severe systemic reactions can develop, including pulmonary edema, visual loss, collapse, and death. In the United States DEC is not available for this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H627284083\">",
"    <span class=\"h3\">",
"     Patch test",
"    </span>",
"    &nbsp;&mdash;&nbsp;DEC can be administered as a topical preparation to a small area of the skin to assess for local skin reaction. In a study of untreated children in Cameroon, Gabon, and Central African Republic, the proportion of children who tested positive with a 10 percent DEC solution ranged from 25 to 77 percent; this finding correlated closely with the prevalence of nodules (a reflection of the level of endemicity) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/60\">",
"     60",
"    </a>",
"    ]. Sensitivity may be greater with a 20 percent DEC solution [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patch testing is a useful alternative to skin snipping in low prevalence areas, since it is non-invasive, inexpensive, and more sensitive than skin snipping. The African Program for Onchocerciasis Control (APOC) has recommended its widespread use as a preferred alternative to skin snip for epidemiological evaluations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/62\">",
"     62",
"    </a>",
"    ]. The test is not available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serology is not uniformly reliable. In addition, the prevalence of positive serology among nonendemic adults returned from endemic areas is extremely high in the absence of active infection, and can remain positive for many years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/44\">",
"     44",
"    </a>",
"    ]. Standard anti-filaria enzyme-linked immunosorbent assays (ELISA) have significant cross-reactivity between filarial parasites. Some recombinant purified antigens, ELISAs, and Western blot techniques with very good sensitivity and specificity for O. volvulus have been developed, but they are not routinely available for clinical use.",
"   </p>",
"   <p>",
"    Detection of antibody subclass IgG",
"    <sub>",
"     4",
"    </sub>",
"    may enhance specificity. An immunochromatographic (ICT) card test detecting IgG",
"    <sub>",
"     4",
"    </sub>",
"    against recombinant Onchocerca antigen Ov-16 (Ov-16 card test) had very good sensitivities in West Africa field trials (81 and 77 percent in two villages). Test specificity was 100 percent (using the skin snip test as the gold standard) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A serologic test using a multi antigen quick luciferase immunoprecipitation system (QLIPS) and four recombinant antigens has been developed for diagnosis of O. volvulus. Sensitivity and specificity for detection of O. volvulus compared with control sera were 100 percent, though it is not widely available [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/64\">",
"     64",
"    </a>",
"    ]. For distinguishing O. volvulus from W. bancrofti, L. loa and Strongyloides stercoralis, specificities of 76, 84, and 93 percent have been reported. The assay could be used for diagnosis of individual infections, for early detection of recrudescent infections in control areas, and for mapping new areas of transmission.",
"   </p>",
"   <p>",
"    In the United States, the National Institutes of Health (NIH) and the Centers for Disease Control (CDC) may be of assistance with diagnostic testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Antigen testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antigen tests may be more useful than antibody detection assays for the diagnosis of individual infections and for monitoring the success of therapy, since they are positive only in individuals with active infection. Further research is required for additional development of antigens tests before they can be available for routine clinical use.",
"   </p>",
"   <p>",
"    A study of an Onchocerca antigen detection dipstick test for urine or tears in Cameroon reported sensitivity of 100 percent and 92 percent in urine and tears, respectively; specificity for urine and tears was 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/65\">",
"     65",
"    </a>",
"    ]. Major sperm protein 2 (MSP2) has also been proposed as a potential diagnostic antigen; preliminary studies appear promising [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mass spectrometry, bioinformatics, and molecular techniques have been used to characterize additional diagnostic antigens detected in the in vivo nodular fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/67\">",
"     67",
"    </a>",
"    ]. Liquid chromatography and mass spectrometry on blood samples from O. volvulus-infected and uninfected individuals revealed a set of 14 biomarkers that showed excellent discrimination between infected and uninfected persons [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Highly sensitive polymerase chain reaction (PCR) tests based upon DNA amplification have also been developed but are not yet available for general use. In a Cameroonian study comparing skin snip PCR and urine PCR with antigen detection, the skin snip PCR had higher sensitivity than the urine PCR (&gt;90 versus 14 percent), and the PCR tests were generally equal to or more sensitive than antigen tests [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/69\">",
"     69",
"    </a>",
"    ]. In a study in Guinea with low prevalence of disease after &gt;10 years of control by the Onchocerciasis Control Program, skin snip PCR and the DEC patch test were more sensitive than skin snip microscopic examination [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography of subcutaneous nodules may be used for identification of adult worms. Deeper, nonpalpable nodules can be also detected. Ultrasound may also be a useful tool for the longitudinal observation to monitor adult worm viability after macrofilaricidal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7538840\">",
"    <span class=\"h2\">",
"     Therapeutic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential therapeutic targets include microfilariae and adult worms (macrofilariae).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7538848\">",
"    <span class=\"h3\">",
"     Microfilaricidal therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7539043\">",
"    <span class=\"h4\">",
"     Ivermectin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     Ivermectin",
"    </a>",
"    is a semisynthetic macrocyclic lactone derivative that appears to impair release of microfilariae from gravid female worms. Within one week following a single dose, ivermectin can reduce skin microfilarial counts by 90 percent, with prolonged suppression for at least a year. Ivermectin also may have some direct effects on adult worms but it does not eradicate infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/72\">",
"     72",
"    </a>",
"    ]. Therefore, in the setting of control programs, ivermectin treatment has to be repeated throughout the 10 to 14 year life span of the adult worms to eradicate infection in the population. However, in general it is not necessary to treat infected individuals for the life span of the worm, especially if they are removed from the endemic setting [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/44\">",
"     44",
"    </a>",
"    ]. Most individuals become asymptomatic after a few years of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7538856\">",
"    <span class=\"h3\">",
"     Macrofilaricidal therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7539050\">",
"    <span class=\"h4\">",
"     Targeting Wolbachia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wolbachia is the endosymbiotic bacteria within O. volvulus required for embryogenesis and survival [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    has activity against Wolbachia and has been shown to induce sustained sterility of female worms with a dose-dependent macrofilaricidal effect. In a study of 93 patients with onchocerciasis, doxycycline (100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    orally for six weeks) followed by a single oral dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    (150",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    resulted in clearance of microfilariae for up to 19 months and complete Wolbachia elimination [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/75\">",
"     75",
"    </a>",
"    ]. The greatest efficacy has been observed with administration of 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    , followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    , can be used for treatment of individuals in areas of relatively low transmission and for treatment of individuals outside of endemic areas. Doxycycline cannot be used for treatment in areas of ongoing transmission because new infections would require repeated courses of doxycycline; in such circumstances, repeat dosing of ivermectin is the preferred approach.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    have in vitro activity against Wolbachia, although five day courses do not appear to be effective for clinical management of onchocerciasis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Rifampicin may prove to be an alternative to children who cannot be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or may be used in the future in combination with other drugs; further study is needed.",
"   </p>",
"   <p>",
"    The heme [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/79\">",
"     79",
"    </a>",
"    ] and lipoprotein [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/80\">",
"     80",
"    </a>",
"    ] biosynthetic pathways of Wolbachia have been proposed as potential candidate drug targets for future research.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7539093\">",
"    <span class=\"h4\">",
"     Other approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moxidectin is a veterinary deworming agent that is a selective inhibitor of neurotransmission in invertebrates. It sterilizes or kills adult O. volvulus worms and also has microfilaricidal activity. Moxidectin may be capable of interrupting the transmission cycle within six annual rounds of treatment; phase 3 trials are underway at sites in Ghana, Liberia, and the Democratic Republic of Congo [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The veterinary anthelminthic drug closantel is a potential new therapy; it is an inhibitor of filarial chitinases and inhibits molting of L3 larvae [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Removal of adult worms via nodulectomy is another therapeutic option, particularly in lightly infected individuals, such as expatriates. However, nodulectomy alone cannot be considered an effective strategy for cure since many worms lie deep and may be undetected.",
"   </p>",
"   <p>",
"    Cardiocladius oliffi, a blackfly predator, has been proposed as potential biological control agent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no vaccine to prevent onchocerciasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7538812\">",
"    <span class=\"h2\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical approach varies for treatment of individuals within endemic areas, individuals outside endemic areas, and mass treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7537956\">",
"    <span class=\"h3\">",
"     Individuals in endemic areas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of individuals within endemic areas with relatively high levels of ongoing transmission consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    (150",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    administered orally as a single dose, on an empty stomach with water. Treatment should be repeated every three to six months until the patient is asymptomatic (",
"    <a class=\"graphic graphic_table graphicRef57427 \" href=\"UTD.htm?18/25/18843\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/84\">",
"     84",
"    </a>",
"    ]. Thereafter, indications for repeat treatment include recurrence of pruritus, presence of a typical rash, or eosinophilia. Treatment with ivermectin may be required for 10 years or more [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects following",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    administration are usually mild and are thought to occur as a result of the host immune response to released Wolbachia antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/86\">",
"     86",
"    </a>",
"    ]. Symptoms usually develop within three days of treatment and include fever, rash, dizziness, pruritus, myalgia, arthralgia, and tender lymphadenopathy. Severe reactions including systemic postural hypotension can also occur. The incidence of these symptoms correlates with burden of infection prior to treatment. Symptoms can usually be managed with analgesics and antihistamines.",
"   </p>",
"   <p>",
"    The safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    in young children (height &lt;90 cm) and pregnant women is uncertain. Ivermectin has been administered inadvertently to pregnant women during mass treatment programs, and no increased rates of congenital abnormalities were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/87\">",
"     87",
"    </a>",
"    ]. Ivermectin may be given after the first week of lactation and no adverse effects in lactating women have been documented.",
"   </p>",
"   <p>",
"    Administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    every six months results in greater reductions in microfilarial loads than annual treatment; it is possible that even more frequent treatment could provide additional benefit. In a study of 657 patients with onchocerciasis, those who received treatment every three months had fewer remaining female worms than those treated annually [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/84\">",
"     84",
"    </a>",
"    ]. In two Mexican communities, administration of treatment every three months appeared to rapidly suppress residual transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is considerable variability in reduction of microfilarial densities between individuals following treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/89\">",
"     89",
"    </a>",
"    ]. Development of ivermectin resistance has been suggested in Ghana [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/90\">",
"     90",
"    </a>",
"    ], but it remains controversial. Suboptimal responses may be attributable to host factors, including polymorphisms in host multidrug resistance (MDR1) genes. In a Ghanian study of 42 patients treated with ivermectin, a difference in MDR1 variant allele frequency was observed between suboptimal responders and responders (21 versus 12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/91\">",
"     91",
"    </a>",
"    ]. A mathematical model has been developed for analyzing drug efficacy which may be used to investigate atypical responses to ivermectin in onchocerciasis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    cannot be used for treatment of individuals in areas of ongoing transmission because new infections would require repeated courses of doxycycline; in such circumstances repeat dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    is the preferred approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H279574404\">",
"    <span class=\"h4\">",
"     Loa loa coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In areas where both onchocerciasis and Loa loa are endemic, blood should be obtained to evaluate for evidence of L. loa microfilariae prior to administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    . In the setting of coinfection with L. loa, treatment of onchocerciasis with ivermectin can facilitate entry of L. loa microfilariae into the central nervous system, leading to encephalopathy, potentially severe neurologic sequelae, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/93\">",
"     93",
"    </a>",
"    ]. The optimal approach to the treatment of onchocerciasis and loiasis coinfection is uncertain; one approach consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (200 mg orally once daily for six weeks), plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    (400 mg orally twice daily for three weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7538294\">",
"    <span class=\"h3\">",
"     Individuals outside endemic areas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of individuals outside endemic areas or in areas with relatively low levels of transmission consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    every three to six months until asymptomatic (",
"    <a class=\"graphic graphic_table graphicRef57427 \" href=\"UTD.htm?18/25/18843\">",
"     table 1",
"    </a>",
"    ). Treatment should be repeated if there is recurrence of pruritus, rash, or eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/95,96\">",
"     95,96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    is an alternative to standard therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    . The regimen is doxycycline (200 mg daily for six weeks), plus a single dose of ivermectin (150",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    administered four to six months following completion of doxycycline therapy. Doxycycline should be administered prior to ivermectin to optimize Wolbachia depletion, thereby reducing inflammatory reactions induced by ivermectin. Doxycycline is contraindicated in pregnant women and children &lt;9 years of age (",
"    <a class=\"graphic graphic_table graphicRef57427 \" href=\"UTD.htm?18/25/18843\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/97\">",
"     97",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7539050\">",
"     'Targeting Wolbachia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7537964\">",
"    <span class=\"h3\">",
"     Mass treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mass drug administration programs consist of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    administration at 6 to 12 monthly intervals for 10 to 16 years. APOC has treated hyperendemic and mesoendemic areas (hyperendemic communities have a prevalence of palpable nodules among a sample of 50 adult males of &gt;40 percent; mesoendemic communities have a prevalence of 20 to 39 percent). The Onchocerciasis Elimination Program for the Americas (OEPA) administers treatment in all areas with the goal of complete elimination.",
"   </p>",
"   <p>",
"    Mass treatment programs have had significant impact on the burden of disease due to ocular onchocerciasis, including reduction of ocular microfilarial loads and regression of early anterior segment lesions such as punctate keratitis and iridocyclitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/98-102\">",
"     98-102",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     Ivermectin",
"    </a>",
"    also has a beneficial effect on the incidence of onchocercal optic nerve disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/103\">",
"     103",
"    </a>",
"    ] and visual field loss [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/104\">",
"     104",
"    </a>",
"    ]. These improvements have been observed to occur more rapidly with mass drug treatment than with vector control alone. In one cohort study evaluating mass treatment in eight Nigerian villages, gross visual impairment decreased from 16 to 1 percent after eight years of annual ivermectin treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mass treatment has also reduced the burden of onchocercal skin disease. Reductions in the prevalence of severe itching (4 to 1 percent after five years of annual treatment) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/101,105\">",
"     101,105",
"    </a>",
"    ], nodules (59 to 18 percent after eight years of annual treatment) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/102\">",
"     102",
"    </a>",
"    ], and papular dermatitis (15 to 2 percent after eight years of treatment) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/102\">",
"     102",
"    </a>",
"    ] have been observed. A study in Nigeria noted reduction in itching (19 percent), reduction in skin rash (17 percent), and darkening of leopard skin (7 percent) following 10 years of annual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multi-country report of the community impact after five or six years of annual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    treatment noted substantial reduction in clinical symptoms and onchocercal skin disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/107\">",
"     107",
"    </a>",
"    ]. There were significant reductions in itching, nodules and depigmentation (OR 0.32, 0.37 and 0.31). In addition, there were significant reductions in acute papular onchodermatitis, chronic papular onchodermatitis and lichenified dermatitis (OR 0.28, 0.34 and 0.54).",
"   </p>",
"   <p>",
"    Elimination of onchocerciasis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    treatment in hyperendemic areas with efficient vector transmission appears to be feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/108\">",
"     108",
"    </a>",
"    ]. Data from Mali, Senegal, and Nigeria suggest 15 to 19 years of uninterrupted treatment may be required [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. Further study is needed to establish the point at which the number of parasites or parasite density falls so low that infection cannot persist [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/62,110\">",
"     62,110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     CONTROL PROGRAMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of onchocerciasis control programs have been implemented worldwide:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Onchocerciasis Control Programme (OCP, 1974-2002) &mdash; The OCP was an international partnership that used aerial larviciding of rivers for vector control in 11 West African countries. The program was highly successful in interrupting transmission and led to economic redevelopment of fertile areas previously deserted due to high rates of blindness [",
"      <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/111\">",
"       111",
"      </a>",
"      ]. The OCP also distributed",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"       ivermectin",
"      </a>",
"      to control recrudescence.",
"     </li>",
"     <li>",
"      In 1987 Merck, the manufacturer of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"       ivermectin",
"      </a>",
"      (Mectizan), pledged to donate all drugs necessary to overcome onchocerciasis and established the Mectizan Donation Program. Collaboration was established with the World Health Organization (WHO), health ministries, and non-governmental organizations to distribute ivermectin using a sustainable community-directed approach [",
"      <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/112\">",
"       112",
"      </a>",
"      ]. The unprecedented partnership for onchocerciasis control that followed this donation program inspired the formation of another global initiative, \"Vision 2020, the Right to Sight,\" which seeks to eliminate all forms of avoidable blindness by the year 2020 [",
"      <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Onchocerciasis Elimination Program in the Americas (OEPA, 1991-2012) &mdash; The OEPA consists of partnerships between the governments of the endemic countries, the Pan American Health Organization (PAHO), The Carter Center, Lions Clubs International, the Bill and Melinda Gates Foundation, and the Mectizan Donation Program. The goal is to eliminate onchocerciasis from the region via mass",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"       ivermectin",
"      </a>",
"      therapy every six months; it aims to reach at least 85 percent coverage of the eligible population. In 2008, a resolution adopted by the PAHO called for the regional elimination of ocular morbidity caused by onchocerciasis and interruption of transmission by 2012 [",
"      <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/113,114\">",
"       113,114",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Transmission has been interrupted in 7 of the 13 foci in the Americas, and OEPA is on track to eliminate onchocerciasis in the region by 2015 [",
"      <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/115\">",
"       115",
"      </a>",
"      ]. Colombia was the first country to achieve country-wide interruption of transmission, and ivermectin distribution was discontinued in 2008. Ecuador was the second country to suspend treatment, in 2010. Surveillance is required three years following cessation of treatment to achieve certification of elimination.",
"     </li>",
"     <li>",
"      The African Program for Onchocerciasis Control (APOC, 1995-2015) &mdash; APOC aims to eliminate onchocerciasis as a public health and socio-economic problem from 23 African countries by 2015, via annual",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"       ivermectin",
"      </a>",
"      treatment delivered by community distributors chosen by the communities themselves. The communities also control the timing of the intervention, taking into consideration issues like weather, religious events, and cultural events. By 2009, more than 68 million people were treated in 15 endemic countries; the average therapeutic coverage was 77 percent in countries with a stable security situation and 64 percent in post-conflict countries. The program intends to treat more than 90 million people by 2015 [",
"      <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/109\">",
"       109",
"      </a>",
"      ]. Local vector eradication has been used in combination with ivermectin treatment in a small number of APOC projects [",
"      <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/116,117\">",
"       116,117",
"      </a>",
"      ]. The APOC Trust Fund is supported by a range of partners from the public and private sectors; the program is executed through WHO, with the World Bank as the fiscal agent.",
"      <br/>",
"      <br/>",
"      The community directed intervention approach has been integrated successfully with other primary healthcare interventions, such as management of malaria, distribution of insecticide-treated bednets, and vitamin A supplementation, with the support of community-directed distributors [",
"      <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/118\">",
"       118",
"      </a>",
"      ]. African universities and nursing schools are including the community-based strategy in their curricula to broaden use of this effective technique for healthcare interventions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H279574468\">",
"    <span class=\"h2\">",
"     Loa loa coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In areas where both onchocerciasis and loiasis are endemic, the rapid assessment tool for loiasis (RAPLOA) should be employed prior to mass treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    . This tool delineates communities at high risk of loiasis using Geographical Information Systems (GIS) to identify potential vegetation areas for vector breeding together with a history of eye-worm to delineate communities at high risk of coinfection. (See",
"    <a class=\"local\" href=\"#H279574404\">",
"     'Loa loa coinfection'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36263?source=see_link\">",
"     \"Loiasis (Loa loa infection)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    may be effective for community-directed treatment in areas where both onchocerciasis and loiasis are endemic. In a Cameroon study evaluating the efficacy of community-directed treatment with doxycycline for six weeks among 104 individuals in communities co-endemic for onchocerciasis and loiasis, doxycycline alone was effective for reducing microfilaridermia and the viability of adult worms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/30/20970/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H361812554\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Onchocerciasis is caused by the filarial nematode, Onchocerca volvulus. It is also known as \"river blindness\" because the blackfly vector breeds near fast-flowing streams and rivers. The disease affects rural communities and is a major cause of blindness and skin disease in endemic areas. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Humans are infected with O. volvulus via the bite of a blackfly of the Simulium genus (",
"      <a class=\"graphic graphic_figure graphicRef66896 \" href=\"UTD.htm?42/55/43896\">",
"       figure 3",
"      </a>",
"      ). The black fly deposits infective third-stage larvae into the human skin, which mature into adult parasites (macrofilariae) over the next 6 to 12 months. The females live in subcutaneous or deeper intramuscular tissues and are surrounded by a fibrous capsule. The males migrate between nodules to fertilize females. Approximately 12 months after initial infection the adult female worms begin to produce microfilariae which migrate through subcutaneous tissues, dermal, and ocular tissues. When an infected human is bitten by another blackfly, the fly takes up dermal microfilariae. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Life cycle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations of onchocerciasis include eye involvement, subcutaneous nodules, skin involvement, and systemic manifestations. Manifestations of ocular onchocerciasis include punctate and sclerosing keratitis, uveitis, optic atrophy, and chorioretinitis. Manifestations of onchocercal skin disease include acute and chronic papular onchodermatitis, lichenified onchodermatitis, skin atrophy, hanging groin, and depigmentation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of onchocerciasis is based on a history of compatible epidemiologic exposure, clinical manifestations, and supportive laboratory evidence of infection. A skin snip biopsy is the gold standard for investigation of a patient. Slit-lamp examination can be used to look for wriggling microfilariae within the anterior chamber of the eye. Mazzotti testing should be performed only in certain clinical circumstances. Serology, antigen testing, and polymerase chain reaction are useful tools though are generally not available in endemic areas. Ultrasonography of subcutaneous nodules may be useful for identification of adult worms. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment of individuals with onchocerciasis in endemic areas with high levels of ongoing transmission with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"       ivermectin",
"      </a>",
"      (150",
"      <span class=\"nowrap\">",
"       mcg/kg)",
"      </span>",
"      administered orally as a single dose (",
"      <a class=\"graphic graphic_table graphicRef57427 \" href=\"UTD.htm?18/25/18843\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Treatment should be repeated every three to six months until the patient is asymptomatic; treatment may be required for 10 years or more. In areas where both onchocerciasis and Loa loa are endemic, blood should be obtained to evaluate for evidence of L. loa microfilariae prior to administration of ivermectin. (See",
"      <a class=\"local\" href=\"#H7537956\">",
"       'Individuals in endemic areas'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H279574404\">",
"       'Loa loa coinfection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment of individuals outside endemic areas or in areas with low levels of transmission with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"       ivermectin",
"      </a>",
"      every three to six months until asymptomatic (",
"      <a class=\"graphic graphic_table graphicRef57427 \" href=\"UTD.htm?18/25/18843\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      (200 mg daily for six weeks) is an alternative treatment, followed by a single dose of ivermectin (150",
"      <span class=\"nowrap\">",
"       mcg/kg)",
"      </span>",
"      administered four to six months following completion of doxycycline therapy. Doxycycline should be administered prior to ivermectin to optimize Wolbachia depletion, thereby reducing inflammatory reactions induced by ivermectin. (See",
"      <a class=\"local\" href=\"#H7538294\">",
"       'Individuals outside endemic areas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mass drug administration programs consist of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"       ivermectin",
"      </a>",
"      administration at 6 to 12 monthly intervals for 10 to 16 years. In areas where both onchocerciasis and loiasis may be endemic, assessment for loiasis should be made prior to mass treatment with ivermectin. (See",
"      <a class=\"local\" href=\"#H7537964\">",
"       'Mass treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/1\">",
"      Bas&aacute;&ntilde;ez MG, Pion SD, Churcher TS, et al. River blindness: a success story under threat? PLoS Med 2006; 3:e371.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Prevention of blindness and visual impairment: priority eye diseases. file://www.who.int/blindness/causes/priority/en/index3.html (Accessed on October 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/3\">",
"      Remme J, Dadzie KY, Rolland A, Thylefors B. Ocular onchocerciasis and intensity of infection in the community. I. West African savanna. Trop Med Parasitol 1989; 40:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/4\">",
"      Murdoch ME, Asuzu MC, Hagan M, et al. Onchocerciasis: the clinical and epidemiological burden of skin disease in Africa. Ann Trop Med Parasitol 2002; 96:283.",
"     </a>",
"    </li>",
"    <li>",
"     Remme JHF. The global burden of onchocerciasis in 1990. World Health Organization, Geneva 2004. file://www.who.int/healthinfo/global_burden_disease/Onchocerciasis%201990.pdf (Accessed on April 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/6\">",
"      Higazi TB, Filiano A, Katholi CR, et al. Wolbachia endosymbiont levels in severe and mild strains of Onchocerca volvulus. Mol Biochem Parasitol 2005; 141:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/7\">",
"      Norman FF, P&eacute;rez de Ayala A, P&eacute;rez-Molina JA, et al. Neglected tropical diseases outside the tropics. PLoS Negl Trop Dis 2010; 4:e762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/8\">",
"      Otranto D, Sakru N, Testini G, et al. Case report: First evidence of human zoonotic infection by Onchocerca lupi (Spirurida, Onchocercidae). Am J Trop Med Hyg 2011; 84:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/9\">",
"      Brattig NW. Pathogenesis and host responses in human onchocerciasis: impact of Onchocerca filariae and Wolbachia endobacteria. Microbes Infect 2004; 6:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/10\">",
"      Saint Andr&eacute; Av, Blackwell NM, Hall LR, et al. The role of endosymbiotic Wolbachia bacteria in the pathogenesis of river blindness. Science 2002; 295:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/11\">",
"      Brattig NW, Bazzocchi C, Kirschning CJ, et al. The major surface protein of Wolbachia endosymbionts in filarial nematodes elicits immune responses through TLR2 and TLR4. J Immunol 2004; 173:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/12\">",
"      Hise AG, Daehnel K, Gillette-Ferguson I, et al. Innate immune responses to endosymbiotic Wolbachia bacteria in Brugia malayi and Onchocerca volvulus are dependent on TLR2, TLR6, MyD88, and Mal, but not TLR4, TRIF, or TRAM. J Immunol 2007; 178:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/13\">",
"      Gillette-Ferguson I, Daehnel K, Hise AG, et al. Toll-like receptor 2 regulates CXC chemokine production and neutrophil recruitment to the cornea in Onchocerca volvulus/Wolbachia-induced keratitis. Infect Immun 2007; 75:5908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/14\">",
"      Gentil K, Pearlman E. Gamma interferon and interleukin-1 receptor 1 regulate neutrophil recruitment to the corneal stroma in a murine model of Onchocerca volvulus keratitis. Infect Immun 2009; 77:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/15\">",
"      McKechnie NM, G&uuml;rr W, Yamada H, et al. Antigenic mimicry: Onchocerca volvulus antigen-specific T cells and ocular inflammation. Invest Ophthalmol Vis Sci 2002; 43:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/16\">",
"      Timmann C, Abraha RS, Hamelmann C, et al. Cutaneous pathology in onchocerciasis associated with pronounced systemic T-helper 2-type responses to Onchocerca volvulus. Br J Dermatol 2003; 149:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/17\">",
"      Murdoch ME, Payton A, Abiose A, et al. HLA-DQ alleles associate with cutaneous features of onchocerciasis. The Kaduna-London-Manchester Collaboration for Research on Onchocerciasis. Hum Immunol 1997; 55:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/18\">",
"      Murdoch ME, Abiose A, Garate T, et al. Human onchocerciasis in Nigeria: isotypic responses and antigen recognition in individuals with defined cutaneous pathology. Am J Trop Med Hyg 1996; 54:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/19\">",
"      Ali MM, Elghazali G, Montgomery SM, et al. Fc gamma RIIa (CD32) polymorphism and onchocercal skin disease: implications for the development of severe reactive onchodermatitis (ROD). Am J Trop Med Hyg 2007; 77:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/20\">",
"      Timmann C, van der Kamp E, Kleensang A, et al. Human genetic resistance to Onchocerca volvulus: evidence for linkage to chromosome 2p from an autosome-wide scan. J Infect Dis 2008; 198:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/21\">",
"      Ali MM, Baraka OZ, AbdelRahman SI, et al. Immune responses directed against microfilariae correlate with severity of clinical onchodermatitis and treatment history. J Infect Dis 2003; 187:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/22\">",
"      Brattig NW, Lepping B, Timmann C, et al. Onchocerca volvulus-exposed persons fail to produce interferon-gamma in response to O. volvulus antigen but mount proliferative responses with interleukin-5 and IL-13 production that decrease with increasing microfilarial density. J Infect Dis 2002; 185:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/23\">",
"      Hoerauf A, Kruse S, Brattig NW, et al. The variant Arg110Gln of human IL-13 is associated with an immunologically hyper-reactive form of onchocerciasis (sowda). Microbes Infect 2002; 4:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/24\">",
"      Steel C, Nutman TB. CTLA-4 in filarial infections: implications for a role in diminished T cell reactivity. J Immunol 2003; 170:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/25\">",
"      Satoguina J, Mempel M, Larbi J, et al. Antigen-specific T regulatory-1 cells are associated with immunosuppression in a chronic helminth infection (onchocerciasis). Microbes Infect 2002; 4:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/26\">",
"      Allen JE, Adjei O, Bain O, et al. Of mice, cattle, and humans: the immunology and treatment of river blindness. PLoS Negl Trop Dis 2008; 2:e217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/27\">",
"      Satoguina JS, Adjobimey T, Arndts K, et al. Tr1 and naturally occurring regulatory T cells induce IgG4 in B cells through GITR/GITR-L interaction, IL-10 and TGF-beta. Eur J Immunol 2008; 38:3101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/28\">",
"      Adjobimey T, Hoerauf A. Induction of immunoglobulin G4 in human filariasis: an indicator of immunoregulation. Ann Trop Med Parasitol 2010; 104:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/29\">",
"      Brattig NW, Schwohl A, Rickert R, B&uuml;ttner DW. The filarial parasite Onchocerca volvulus generates the lipid mediator prostaglandin E(2). Microbes Infect 2006; 8:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/30\">",
"      Brattig NW, Schwohl A, Hoerauf A, B&uuml;ttner DW. Identification of the lipid mediator prostaglandin E2 in tissue immune cells of humans infected with the filaria Onchocerca volvulus. Acta Trop 2009; 112:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/31\">",
"      Korten S, Hoerauf A, Kaifi JT, B&uuml;ttner DW. Low levels of transforming growth factor-beta (TGF-beta) and reduced suppression of Th2-mediated inflammation in hyperreactive human onchocerciasis. Parasitology 2011; 138:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/32\">",
"      Liebau E, H&ouml;ppner J, M&uuml;hlmeister M, et al. The secretory omega-class glutathione transferase OvGST3 from the human pathogenic parasite Onchocerca volvulus. FEBS J 2008; 275:3438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/33\">",
"      Cho-Ngwa F, Liu J, Lustigman S. The Onchocerca volvulus cysteine proteinase inhibitor, Ov-CPI-2, is a target of protective antibody response that increases with age. PLoS Negl Trop Dis 2010; 4:e800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/34\">",
"      Budden FH. The natural history of ocular onchocerciasis over a period of 14--15 years and the effect on this of a single course of suramin therapy. Trans R Soc Trop Med Hyg 1976; 70:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/35\">",
"      Kluxen G, Hoerauf A. The significance of some observations on African ocular onchocerciasis described by Jean Hissette (1888-1965). Bull Soc Belge Ophtalmol 2008; :53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/36\">",
"      Apple DJ. Sir Nicholas Harold Lloyd Ridley: 10 July 1906 - 25 May 2001. Biogr Mem Fellows R Soc 2007; 53:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/37\">",
"      Murdoch ME, Hay RJ, Mackenzie CD, et al. A clinical classification and grading system of the cutaneous changes in onchocerciasis. Br J Dermatol 1993; 129:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/38\">",
"      Burnham GM. Onchocerciasis in Malawi. 2. Subjective complaints and decreased weight in persons infected with Onchocerca volvulus in the Thyolo highlands. Trans R Soc Trop Med Hyg 1991; 85:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/39\">",
"      Pion SD, Kaiser C, Boutros-Toni F, et al. Epilepsy in onchocerciasis endemic areas: systematic review and meta-analysis of population-based surveys. PLoS Negl Trop Dis 2009; 3:e461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/40\">",
"      K&ouml;nig R, Nassri A, Meindl M, et al. The role of Onchocerca volvulus in the development of epilepsy in a rural area of Tanzania. Parasitology 2010; 137:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/41\">",
"      Little MP, Breitling LP, Bas&aacute;&ntilde;ez MG, et al. Association between microfilarial load and excess mortality in onchocerciasis: an epidemiological study. Lancet 2004; 363:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/42\">",
"      Ezzedine K, Malvy D, Dhaussy I, et al. Onchocerciasis-associated limb swelling in a traveler returning from Cameroon. J Travel Med 2006; 13:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/43\">",
"      McCarthy JS, Ottesen EA, Nutman TB. Onchocerciasis in endemic and nonendemic populations: differences in clinical presentation and immunologic findings. J Infect Dis 1994; 170:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/44\">",
"      Henry NL, Law M, Nutman TB, Klion AD. Onchocerciasis in a nonendemic population: clinical and immunologic assessment before treatment and at the time of presumed cure. J Infect Dis 2001; 183:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/45\">",
"      Niamba P, Gaulier A, Ta&iuml;eb A. Hanging groin and persistent pruritus in a patient from Burkina Faso. Int J Dermatol 2007; 46:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/46\">",
"      Enk CD, Anteby I, Abramson N, et al. Onchocerciasis among Ethiopian immigrants in Israel. Isr Med Assoc J 2003; 5:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/47\">",
"      Sentongo E, Rubaale T, B&uuml;ttner DW, Brattig NW. T cell responses in coinfection with Onchocerca volvulus and the human immunodeficiency virus type 1. Parasite Immunol 1998; 20:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/48\">",
"      Tawill SA, Gallin M, Erttmann KD, et al. Impaired antibody responses and loss of reactivity to Onchocerca volvulus antigens by HIV-seropositive onchocerciasis patients. Trans R Soc Trop Med Hyg 1996; 90:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/49\">",
"      Fischer P, Kipp W, Kabwa P, Buttner DW. Onchocerciasis and human immunodeficiency virus in western Uganda: prevalences and treatment with ivermectin. Am J Trop Med Hyg 1995; 53:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/50\">",
"      Kipp W, Bamuhiiga J, Rubaale T. Simulium neavei-transmitted onchocerciasis: HIV infection increases severity of onchocercal skin disease in a small sample of patients. Trans R Soc Trop Med Hyg 2003; 97:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/51\">",
"      Kipp W, Bamhuhiiga J, Rubaale T, Kabagambe G. Adverse reactions to the ivermectin treatment of onchocerciasis patients: does infection with the human immunodeficiency virus play a role? Ann Trop Med Parasitol 2005; 99:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/52\">",
"      Evans TG. Socioeconomic consequences of blinding onchocerciasis in west Africa. Bull World Health Organ 1995; 73:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/53\">",
"      Hotez PJ, Kamath A. Neglected tropical diseases in sub-saharan Africa: review of their prevalence, distribution, and disease burden. PLoS Negl Trop Dis 2009; 3:e412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/54\">",
"      Amazigo U. Onchocerciasis and women's reproductive health: indigenous and biomedical concepts. Trop Doct 1993; 23:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/55\">",
"      Vlassoff C, Weiss M, Ovuga EB, et al. Gender and the stigma of onchocercal skin disease in Africa. Soc Sci Med 2000; 50:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/56\">",
"      Mbanefo EC, Eneanya CI, Nwaorgu OC, et al. Onchocerciasis in Anambra State, Southeast Nigeria: clinical and psychological aspects and sustainability of community directed treatment with ivermectin (CDTI). Postgrad Med J 2010; 86:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/57\">",
"      Benton B. Economic impact of onchocerciasis control through the African Programme for Onchocerciasis Control: an overview. Ann Trop Med Parasitol 1998; 92 Suppl 1:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/58\">",
"      Boatin BA, Richards FO Jr. Control of onchocerciasis. Adv Parasitol 2006; 61:349.",
"     </a>",
"    </li>",
"    <li>",
"     Skin snips for Onchocerca volvulus file://www.emro.who.int/publications/RegionalPublications/Specimen_Collection/Spcec_coll_Body_Surface_skin_Snips.htm (Accessed on October 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/60\">",
"      Ozoh G, Boussinesq M, Bissek AC, et al. Evaluation of the diethylcarbamazine patch to evaluate onchocerciasis endemicity in Central Africa. Trop Med Int Health 2007; 12:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/61\">",
"      To&egrave; L, Adjami AG, Boatin BA, et al. Topical application of diethylcarbamazine to detect onchocerciasis recrudescence in west Africa. Trans R Soc Trop Med Hyg 2000; 94:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/62\">",
"      Meeting of the national onchocerciasis task forces, September 2010. Wkly Epidemiol Rec 2010; 48:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/63\">",
"      Lipner EM, Dembele N, Souleymane S, et al. Field applicability of a rapid-format anti-Ov-16 antibody test for the assessment of onchocerciasis control measures in regions of endemicity. J Infect Dis 2006; 194:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/64\">",
"      Burbelo PD, Leahy HP, Iadarola MJ, Nutman TB. A four-antigen mixture for rapid assessment of Onchocerca volvulus infection. PLoS Negl Trop Dis 2009; 3:e438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/65\">",
"      Ayong LS, Tume CB, Wembe FE, et al. Development and evaluation of an antigen detection dipstick assay for the diagnosis of human onchocerciasis. Trop Med Int Health 2005; 10:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/66\">",
"      Park J, Dickerson TJ, Janda KD. Major sperm protein as a diagnostic antigen for onchocerciasis. Bioorg Med Chem 2008; 16:7206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/67\">",
"      Cho-Ngwa F, Zhu X, Metuge JA, et al. Identification of in vivo released products of Onchocerca with diagnostic potential, and characterization of a dominant member, the OV1CF intermediate filament. Infect Genet Evol 2011; 11:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/68\">",
"      Denery JR, Nunes AA, Hixon MS, et al. Metabolomics-based discovery of diagnostic biomarkers for onchocerciasis. PLoS Negl Trop Dis 2010; 4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/69\">",
"      Vincent JA, Lustigman S, Zhang S, Weil GJ. A comparison of newer tests for the diagnosis of onchocerciasis. Ann Trop Med Parasitol 2000; 94:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/70\">",
"      Boatin BA, To&eacute; L, Alley ES, et al. Detection of Onchocerca volvulus infection in low prevalence areas: a comparison of three diagnostic methods. Parasitology 2002; 125:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/71\">",
"      Mand S, Marfo-Debrekyei Y, Debrah A, et al. Frequent detection of worm movements in onchocercal nodules by ultrasonography. Filaria J 2005; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/72\">",
"      Duke BO. Evidence for macrofilaricidal activity of ivermectin against female Onchocerca volvulus: further analysis of a clinical trial in the Republic of Cameroon indicating two distinct killing mechanisms. Parasitology 2005; 130:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/73\">",
"      Hoerauf A, Volkmann L, Hamelmann C, et al. Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis. Lancet 2000; 355:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/74\">",
"      Johnston KL, Taylor MJ. Wolbachia in filarial parasites: targets for filarial infection and disease control. Curr Infect Dis Rep 2007; 9:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/75\">",
"      Hoerauf A, Mand S, Adjei O, et al. Depletion of wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet 2001; 357:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/76\">",
"      Hoerauf A, Specht S, B&uuml;ttner M, et al. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Med Microbiol Immunol 2008; 197:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/77\">",
"      Richards FO Jr, Amann J, Arana B, et al. No depletion of Wolbachia from Onchocerca volvulus after a short course of rifampin and/or azithromycin. Am J Trop Med Hyg 2007; 77:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/78\">",
"      Specht S, Mand S, Marfo-Debrekyei Y, et al. Efficacy of 2- and 4-week rifampicin treatment on the Wolbachia of Onchocerca volvulus. Parasitol Res 2008; 103:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/79\">",
"      Wu B, Novelli J, Foster J, et al. The heme biosynthetic pathway of the obligate Wolbachia endosymbiont of Brugia malayi as a potential anti-filarial drug target. PLoS Negl Trop Dis 2009; 3:e475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/80\">",
"      Johnston KL, Wu B, Guimar&atilde;es A, et al. Lipoprotein biosynthesis as a target for anti-Wolbachia treatment of filarial nematodes. Parasit Vectors 2010; 3:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/81\">",
"      Siva N. WHO researchers start trial on a new drug for river blindness. BMJ 2009; 339:b2755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/82\">",
"      Gloeckner C, Garner AL, Mersha F, et al. Repositioning of an existing drug for the neglected tropical disease Onchocerciasis. Proc Natl Acad Sci U S A 2010; 107:3424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/83\">",
"      Boakye DA, Fokam E, Ghansah A, et al. Cardiocladius oliffi (Diptera: Chironomidae) as a potential biological control agent against Simulium squamosum (Diptera: Simuliidae). Parasit Vectors 2009; 2:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/84\">",
"      Gardon J, Boussinesq M, Kamgno J, et al. Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial. Lancet 2002; 360:203.",
"     </a>",
"    </li>",
"    <li>",
"     Freedman D. Onchocerciasis. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 2nd, Guerrant R, Walker DH, Weller PF (Eds), Churchill Livingstone, Philadelphia 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/86\">",
"      Keiser PB, Reynolds SM, Awadzi K, et al. Bacterial endosymbionts of Onchocerca volvulus in the pathogenesis of posttreatment reactions. J Infect Dis 2002; 185:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/87\">",
"      Pacqu&eacute; M, Mu&ntilde;oz B, Poetschke G, et al. Pregnancy outcome after inadvertent ivermectin treatment during community-based distribution. Lancet 1990; 336:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/88\">",
"      Rodr&iacute;guez-P&eacute;rez MA, Lutzow-Steiner MA, Segura-Cabrera A, et al. Rapid suppression of Onchocerca volvulus transmission in two communities of the Southern Chiapas focus, Mexico, achieved by quarterly treatments with Mectizan. Am J Trop Med Hyg 2008; 79:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/89\">",
"      Pion SD, Grout L, Kamgno J, et al. Individual host factors associated with Onchocerca volvulus microfilarial densities 15, 80 and 180 days after a first dose of ivermectin. Acta Trop 2011; 120 Suppl 1:S91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/90\">",
"      Awadzi K, Boakye DA, Edwards G, et al. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 2004; 98:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/91\">",
"      Kudzi W, Dodoo AN, Mills JJ. Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans? BMC Med Genet 2010; 11:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/92\">",
"      Churcher TS, Pion SD, Osei-Atweneboana MY, et al. Identifying sub-optimal responses to ivermectin in the treatment of River Blindness. Proc Natl Acad Sci U S A 2009; 106:16716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/93\">",
"      Twum-Danso NA, Meredith SE. Variation in incidence of serious adverse events after onchocerciasis treatment with ivermectin in areas of Cameroon co-endemic for loiasis. Trop Med Int Health 2003; 8:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/94\">",
"      Klion AD, Horton J, Nutman TB. Albendazole therapy for loiasis refractory to diethylcarbamazine treatment. Clin Infect Dis 1999; 29:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/95\">",
"      Churchill DR, Godfrey-Faussett P, Birley HD, et al. A trial of a three-dose regimen of ivermectin for the treatment of patients with onchocerciasis in the UK. Trans R Soc Trop Med Hyg 1994; 88:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/96\">",
"      Godfrey-Faussett P, Dow C, Black ME, Bryceson AD. Ivermectin in the treatment of onchocerciasis in Britain. Trop Med Parasitol 1991; 42:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/97\">",
"      Hoerauf A. Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis. Curr Opin Infect Dis 2008; 21:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/98\">",
"      Dadzie KY, Remme J, De Sole G. Changes in ocular onchocerciasis after two rounds of community-based ivermectin treatment in a holo-endemic onchocerciasis focus. Trans R Soc Trop Med Hyg 1991; 85:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/99\">",
"      Whitworth JA, Gilbert CE, Mabey DM, et al. Effects of repeated doses of ivermectin on ocular onchocerciasis: community-based trial in Sierra Leone. Lancet 1991; 338:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/100\">",
"      Chippaux JP, Boussinesq M, Fobi G, et al. Effect of repeated ivermectin treatments on ocular onchocerciasis: evaluation after six to eight doses. Ophthalmic Epidemiol 1999; 6:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/101\">",
"      Kennedy MH, Bertocchi I, Hopkins AD, Meredith SE. The effect of 5 years of annual treatment with ivermectin (Mectizan) on the prevalence and morbidity of onchocerciasis in the village of Gami in the Central African Republic. Ann Trop Med Parasitol 2002; 96:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/102\">",
"      Emukah EC, Osuoha E, Miri ES, et al. A longitudinal study of impact of repeated mass ivermectin treatment on clinical manifestations of onchocerciasis in Imo State, Nigeria. Am J Trop Med Hyg 2004; 70:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/103\">",
"      Abiose A, Jones BR, Cousens SN, et al. Reduction in incidence of optic nerve disease with annual ivermectin to control onchocerciasis. Lancet 1993; 341:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/104\">",
"      Cousens SN, Cassels-Brown A, Murdoch I, et al. Impact of annual dosing with ivermectin on progression of onchocercal visual field loss. Bull World Health Organ 1997; 75:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/105\">",
"      Whitworth JA, Maude GH, Downham MD. Clinical and parasitological responses after up to 6.5 years of ivermectin treatment for onchocerciasis. Trop Med Int Health 1996; 1:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/106\">",
"      Anosike JC, Dozie IN, Ameh GI, et al. The varied beneficial effects of ivermectin (Mectizan) treatment, as observed within onchocerciasis foci in south-eastern Nigeria. Ann Trop Med Parasitol 2007; 101:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/107\">",
"      Ozoh GA, Murdoch ME, Bissek AC, et al. The African Programme for Onchocerciasis Control: impact on onchocercal skin disease. Trop Med Int Health 2011; 16:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/108\">",
"      Diawara L, Traor&eacute; MO, Badji A, et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis 2009; 3:e497.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Report of the External Mid-term Evaluation of the African Programme for Onchocerciasis Control, 2010. file://www.who.int/apoc/MidtermEvaluation_29Oct2010_final_printed.pdf (Accessed on April 28, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/110\">",
"      Duerr HP, Eichner M. Epidemiology and control of onchocerciasis: the threshold biting rate of savannah onchocerciasis in Africa. Int J Parasitol 2010; 40:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/111\">",
"      Hougard JM, Alley ES, Yam&eacute;ogo L, et al. Eliminating onchocerciasis after 14 years of vector control: a proved strategy. J Infect Dis 2001; 184:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/112\">",
"      Thylefors B. The Mectizan Donation Program (MDP). Ann Trop Med Parasitol 2008; 102 Suppl 1:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/113\">",
"      Sauerbrey M. The Onchocerciasis Elimination Program for the Americas (OEPA). Ann Trop Med Parasitol 2008; 102 Suppl 1:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/114\">",
"      Report from the 2009 InterAmerican Conference on Onchocerciasis: progress towards eliminating river blindess in the Region of the Americas. Wk Epidemiol Rec 2010; 33:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/115\">",
"      Cupp EW, Sauerbrey M, Richards F. Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan(&reg;)) monotherapy. Acta Trop 2011; 120 Suppl 1:S100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/116\">",
"      Traor&eacute; S, Wilson MD, Sima A, et al. The elimination of the onchocerciasis vector from the island of Bioko as a result of larviciding by the WHO African Programme for Onchocerciasis Control. Acta Trop 2009; 111:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/117\">",
"      Garms R, Lakwo TL, Ndyomugyenyi R, et al. The elimination of the vector Simulium neavei from the Itwara onchocerciasis focus in Uganda by ground larviciding. Acta Trop 2009; 111:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/118\">",
"      CDI Study Group. Community-directed interventions for priority health problems in Africa: results of a multicountry study. Bull World Health Organ 2010; 88:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/30/20970/abstract/119\">",
"      Turner JD, Tendongfor N, Esum M, et al. Macrofilaricidal activity after doxycycline only treatment of Onchocerca volvulus in an area of Loa loa co-endemicity: a randomized controlled trial. PLoS Negl Trop Dis 2010; 4:e660.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5683 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-FC5DC09734-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_30_20970=[""].join("\n");
var outline_f20_30_20970=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H361812554\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LIFE CYCLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H627283993\">",
"      Ocular onchocerciasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Subcutaneous nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H627284048\">",
"      Onchocercal skin disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H627284057\">",
"      Systemic manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Travelers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H627284066\">",
"      HIV coinfection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H627284074\">",
"      SOCIOECONOMIC AND PSYCHOSOCIAL ASPECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Skin snips",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Slit-lamp examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Mazzotti test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H627284083\">",
"      - Patch test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Antigen testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7538840\">",
"      Therapeutic approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7538848\">",
"      - Microfilaricidal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7539043\">",
"      Ivermectin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7538856\">",
"      - Macrofilaricidal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7539050\">",
"      Targeting Wolbachia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7539093\">",
"      Other approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7538812\">",
"      Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7537956\">",
"      - Individuals in endemic areas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H279574404\">",
"      Loa loa coinfection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7538294\">",
"      - Individuals outside endemic areas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7537964\">",
"      - Mass treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      CONTROL PROGRAMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H279574468\">",
"      Loa loa coinfection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H361812554\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5683\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5683|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/15/28915\" title=\"figure 1\">",
"      APOC countries in Africa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/16/27908\" title=\"figure 2\">",
"      Onchocerciasis distribution in the Americas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/55/43896\" title=\"figure 3\">",
"      Life cycle of Onchocerca volvulus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5683|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/19/34110\" title=\"picture 1\">",
"      Punctate keratitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/48/19206\" title=\"picture 2\">",
"      Sclerosing keratitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/19/20788\" title=\"picture 3\">",
"      Onchochorioretinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/49/786\" title=\"picture 4\">",
"      Skin snip in onchocerciasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/42/6816\" title=\"picture 5\">",
"      Onchocerca volvulus microfilariae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5683|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/25/18843\" title=\"table 1\">",
"      Treatment of onchocerciasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36263?source=related_link\">",
"      Loiasis (Loa loa infection)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_30_20971="Orbital muscle and fat CT";
var content_f20_30_20971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F59823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F59823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Increased muscle and fat in orbit in Graves' ophthalmopathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Site",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Volumes",
"(mL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Normal",
"       </td>",
"       <td class=\"subtitle2\">",
"        Graves' disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Fat",
"       </td>",
"       <td>",
"        M",
"       </td>",
"       <td>",
"        8.6-14.0",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        3.8-22.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        F",
"       </td>",
"       <td>",
"        8.2-12.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Muscle",
"       </td>",
"       <td>",
"        M",
"       </td>",
"       <td>",
"        3.1-6.8",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        3.5-21.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        F",
"       </td>",
"       <td>",
"        3.7-6.2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Orbital muscle and fat volumes as estimated from CT scans in normal men and women and patients with Graves' disease. Muscle and fat volumes are usually increased in patients with Graves' disease.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Forbes G, Gorman CA, Brennan MD, et al, Am J Neuroradiol 1986; 7:651.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_30_20971=[""].join("\n");
var outline_f20_30_20971=null;
var title_f20_30_20972="Risk factors FRs NFRs";
var content_f20_30_20972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F53298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F53298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors contributing to fatal and near-fatal anaphylactic reaction to SCIT injections",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Fatal reactions",
"       <sup>",
"        [1,2]",
"       </sup>",
"      </td>",
"      <td class=\"subtitle1\">",
"       Near-fatal reactions",
"       <sup>",
"        [3]",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       (n = 34*)",
"      </td>",
"      <td class=\"subtitle2\">",
"       (n = 68)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Uncontrolled asthma",
"      </td>",
"      <td>",
"       62 percent",
"      </td>",
"      <td>",
"       10 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Prior systemic reaction",
"      </td>",
"      <td>",
"       53 percent",
"      </td>",
"      <td>",
"       9 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Pollen season",
"      </td>",
"      <td>",
"       47 percent",
"      </td>",
"      <td>",
"       46 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Epinephrine delayed or not given",
"      </td>",
"      <td>",
"       43 percent",
"      </td>",
"      <td>",
"       6 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Reaction in allergists office",
"      </td>",
"      <td>",
"       59 percent",
"      </td>",
"      <td>",
"       93 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Dosing/administration errors (3/17 given IM)",
"      </td>",
"      <td>",
"       35 percent",
"      </td>",
"      <td>",
"       25 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. None reported",
"      </td>",
"      <td>",
"       17 percent&bull;",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       8. Inadequate waiting period",
"      </td>",
"      <td>",
"       12 percent",
"      </td>",
"      <td>",
"       3 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       9. Home administration",
"      </td>",
"      <td>",
"       9 percent",
"      </td>",
"      <td>",
"       0 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10. Beta blockers/ACE-inhibitors",
"      </td>",
"      <td>",
"       2 percent each",
"      </td>",
"      <td>",
"       3 percent/1.5 percent",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Data combined from two SCIT fatality studies",
"     <sup>",
"      [1,2]",
"     </sup>",
"     .",
"     <br>",
"      &bull; Reference [2] only.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      1. Reid MJ, et al. Survey of fatalities from skin testing and immunotherapy 1985 to 1989. J Allergy Clin Immunol 1993; 92:6.",
"      <br>",
"       2. Bernstein DI, et al. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990 to 2001. J Allergy Clin Immunol 2004; 113:1129.",
"       <br>",
"        3. Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006; 117:169.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_30_20972=[""].join("\n");
var outline_f20_30_20972=null;
var title_f20_30_20973="Patterns of inheritance";
var content_f20_30_20973=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78050&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78050&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Patterns of Mendelian and non-Mendelian inheritance",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mode of inheritance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gender preference",
"       </td>",
"       <td class=\"subtitle1\">",
"        Parental impact",
"       </td>",
"       <td class=\"subtitle1\">",
"        Probability sibling of affected individual will be affected",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Mendelian patterns of inheritance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Autosomal dominant",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        50 percent",
"       </td>",
"       <td>",
"        If affected individuals are observed in all generations, the trait is 100 percent penetrant. Autosomal dominant mutations may arise 'de novo' in an affected individual, in which case recurrence risks to siblings are very low.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Autosomal recessive",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        25 percent",
"       </td>",
"       <td>",
"        Consanguinity is common in affected individuals.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        X-linked recessive",
"       </td>",
"       <td>",
"        Males",
"       </td>",
"       <td>",
"        No father-son transmission",
"       </td>",
"       <td>",
"        <p>",
"         Brothers: 50 percent",
"        </p>",
"        <p>",
"         Sisters: 0 percent (50 percent carriers)",
"        </p>",
"       </td>",
"       <td>",
"        Disease only rarely appears in females, because two X chromosome mutations are required; this in turn requires that both parents, including an affected father, carry the mutation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        X-linked dominant",
"       </td>",
"       <td>",
"        Males more severe",
"       </td>",
"       <td>",
"        No father-son transmission",
"       </td>",
"       <td>",
"        50 percent",
"       </td>",
"       <td>",
"        Affected rate similar between males and females, but disease is typically more severe in males.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Y-linked dominant",
"       </td>",
"       <td>",
"        Males only",
"       </td>",
"       <td>",
"        Father-son",
"       </td>",
"       <td>",
"        Brothers: 100 percent",
"       </td>",
"       <td>",
"        No diseases manifest Y-dominant inheritance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Deviations from strict Mendelian inheritance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"5\">",
"        Incomplete penetrance",
"       </td>",
"       <td rowspan=\"5\">",
"        If expression is sex-limited",
"       </td>",
"       <td rowspan=\"5\">",
"        If imprinted",
"       </td>",
"       <td rowspan=\"5\">",
"        <p>",
"         For AD: 50 percent x PF",
"        </p>",
"        <p>",
"         For AR: 25 percent x PF",
"        </p>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Penetrance function (PF) is the probability of disease given the risk genotype. PF can be influenced by multiple factors, including:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1) Environmental risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2) Modifier genes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3) Gender",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4) Parent of origin effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sex-limited expression",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Gender-dependent",
"       </td>",
"       <td>",
"        Expression is either exclusive to one gender, or penetrance is substantially higher in one gender.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Imprinting",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Similar to AD, AR traits",
"       </td>",
"       <td>",
"        Penetrance is dependent on parent of origin, but allele transmission is similar from both parents.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multigenic inheritance",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        Common diseases; mutations increase disease risk modestly.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anticipation",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Disease more severe than in parents",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        Manifestations in parents and grandparents of affected offspring are typically diagnosed retrospectively.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mitochondrial inheritance",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Exclusive maternal transmission",
"       </td>",
"       <td>",
"        Very high, can approach 100 percent",
"       </td>",
"       <td>",
"        Differs from X-linked dominant in that father-daughter transmission is not observed.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AD: autosomal dominant; AR: autosomal recessive; PF: prevalence function.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_30_20973=[""].join("\n");
var outline_f20_30_20973=null;
var title_f20_30_20974="Frova introducer";
var content_f20_30_20974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Frova introducer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cook Incorporated. Copyright &copy;2008 Cook Incorporated.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_30_20974=[""].join("\n");
var outline_f20_30_20974=null;
var title_f20_30_20975="Thyroid ultrasound enlarged lymph node metastatic thyroid cancer";
var content_f20_30_20975=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F53482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F53482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thyroid ultrasound of an enlarged lymph node due to metastatic thyroid cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 185px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: Sonogram of the neck that shows an enlarged lymph node (N) due to metastatic thyroid cancer. Right panel: Doppler image that shows its intense vascularity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Manfred Blum, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_30_20975=[""].join("\n");
var outline_f20_30_20975=null;
